menu
    • menu
    [{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MT-2111","moa":"\nCD19\/DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Bio-Targeting Therapeutics","sponsor":"Xiaorong Wu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Ad-TD-nsIL12","moa":"IL-12R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Bio-Targeting Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Bio-Targeting Therapeutics \/ Xiaorong Wu","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Bio-Targeting Therapeutics \/ Xiaorong Wu"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"INCAGN01949","moa":"\nOX40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"INCAGN01949","moa":"\nOX40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Triphase Research and Development III Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Triphase Research and Development III Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Triphase Research and Development III Corp."},{"orgOrder":0,"company":"Prof Jamie Cavenagh","sponsor":"Myeloma UK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prof Jamie Cavenagh","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof Jamie Cavenagh \/ Myeloma UK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Prof Jamie Cavenagh \/ Myeloma UK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"LSU Health Sciences Center Shreveport","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LSU Health Sciences Center Shreveport","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LSU Health Sciences Center Shreveport \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"LSU Health Sciences Center Shreveport \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Spectrum Health Hospitals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spectrum Health Hospitals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Health Hospitals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Spectrum Health Hospitals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Loyola University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Loyola University \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Criterium","sponsor":"Amgen Inc | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Amgen Inc | Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Amgen Inc | Celgene Corporation"},{"orgOrder":0,"company":"Criterium","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Amgen Inc"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PrECOG","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PrECOG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrECOG \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"PrECOG \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Omar Nadeem, MD","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omar Nadeem, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omar Nadeem, MD \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Omar Nadeem, MD \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Takeda Pharmaceutical | National Cancer Institute | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Takeda Pharmaceutical | National Cancer Institute | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Takeda Pharmaceutical | National Cancer Institute | National Institutes of Health"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Takeda Pharmaceutical | Children's Hospital Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Takeda Pharmaceutical | Children's Hospital Los Angeles","highestDevelopmentStatusID":"7","companyTruncated":"TACL Consortium \/ Takeda Pharmaceutical | Children's Hospital Los Angeles"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oprozomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Vivolux AB","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VLX1570","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vivolux AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivolux AB \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Vivolux AB \/ Theradex"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Aptevo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Aptevo Therapeutics"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Eutilex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eutilex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eutilex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eutilex \/ Undisclosed"},{"orgOrder":0,"company":"Eutilex","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eutilex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eutilex \/ Samsung Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Eutilex \/ Samsung Biologics"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"YH32364","moa":"4-1BB|EFGR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BNT314","moa":"4-1BB|EpCAM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Lokon Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"Delolimogene Mupadenorepvec","moa":"4-1BBL\/CD40L","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lokon Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lokon Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lokon Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lokon Pharma","sponsor":"Precision Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"Delolimogene Mupadenorepvec","moa":"4-1BBL\/CD40L","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lokon Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lokon Pharma \/ Precision Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Lokon Pharma \/ Precision Oncology"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Oleclumab","moa":"5'-nucleotidase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Oleclumab","moa":"5'-nucleotidase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Merck & Co | PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Merck & Co | PTC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Merck & Co | PTC Therapeutics"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister Of Economy And Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Minister Of Economy And Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Minister Of Economy And Research"},{"orgOrder":0,"company":"Exscientia","sponsor":"Biotrial","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Biotrial","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Biotrial"},{"orgOrder":0,"company":"Exscientia","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Quotient Sciences"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Innolake Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ILB-2109","moa":"A2aR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innolake Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innolake Biopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innolake Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Tarus Therapeutics"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Portage Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Portage Biotech"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-10","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Teon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ Teon Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Teon Therapeutics"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TP-0184","moa":"Activin receptor-like kinase 2 (ALK-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"INCB007839","moa":"ADAM10\/ADAM17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CVL006","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"||AdNT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Miami Cancer Institute | Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Health \/ Miami Cancer Institute | Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baptist Health \/ Miami Cancer Institute | Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Miami Cancer Institute"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Bridgewest Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Public Offering","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Bridgewest Group","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Bridgewest Group"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SignPath Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SignPath Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Johnson & Johnson"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"||ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"EIS-12656","moa":"||ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ CPRIT"},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABD-3001","moa":"ALDH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced BioDesign","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanced BioDesign \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Advanced BioDesign \/ Undisclosed"},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ABD-3001","moa":"ALDH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced BioDesign","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Advanced BioDesign \/ Xerys Funds","highestDevelopmentStatusID":"7","companyTruncated":"Advanced BioDesign \/ Xerys Funds"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NMS-01940153E","moa":"ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Shouyao Holdings (Beijing) Co. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CT-707","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shouyao Holdings (Beijing) Co. LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Xcovery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xcovery \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xcovery \/ Undisclosed"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"MedImmune | Xcovery | Cancer Research Institute, New York City","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ MedImmune | Xcovery | Cancer Research Institute, New York City","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ MedImmune | Xcovery | Cancer Research Institute, New York City"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TSR-011","moa":"ALK tyrosine kinase receptor (ALK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CEND-1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Anup Kasi","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CEND-1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anup Kasi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anup Kasi \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Anup Kasi \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LSTA1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ET140202","moa":"Alpha-fetoprotein (AFP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein (AFP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Agalimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"AGI-134","moa":"Alpha-galactosidase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agalimmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agalimmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agalimmune \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AGI-134","moa":"Alpha-galactosidase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Andrei Iagaru","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"68-Ga BAY86-7548","moa":"Amyloid-beta-plaque","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Andrei Iagaru","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andrei Iagaru \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"7","companyTruncated":"Andrei Iagaru \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ValiRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ValiRx \/ Undisclosed"},{"orgOrder":0,"company":"Physiomics","sponsor":"ValiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Physiomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Physiomics \/ ValiRx","highestDevelopmentStatusID":"7","companyTruncated":"Physiomics \/ ValiRx"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Center for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Center for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Center for Cancer Research"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"APC-100","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Praful Ravi, MB BCHir, MRCP","sponsor":"Eli Lilly | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Praful Ravi, MB BCHir, MRCP","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Praful Ravi, MB BCHir, MRCP \/ Eli Lilly | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Praful Ravi, MB BCHir, MRCP \/ Eli Lilly | Bayer AG"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Novartis Pharmaceuticals Corporation | Prostate Cancer Clinical Trials Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Novartis Pharmaceuticals Corporation | Prostate Cancer Clinical Trials Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Novartis Pharmaceuticals Corporation | Prostate Cancer Clinical Trials Consortium"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"National Cancer Institute | Translational Breast Cancer Research Consortium | Conquer Cancer Foundation | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Translational Breast Cancer Research Consortium | Conquer Cancer Foundation | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Translational Breast Cancer Research Consortium | Conquer Cancer Foundation | Genentech"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ODM-204","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ODM-209","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TRC253","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRACON Pharmaceuticals \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"Innocrin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Seviteronel","moa":"Androgen Receptor | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innocrin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocrin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innocrin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Innocrin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"VT-464","moa":"Androgen Receptor | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innocrin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocrin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innocrin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Androgen Receptor | Steroid 5-alpha-reductase | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EPI-506","moa":"androgen receptor inhibitor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Tyrogenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||Platelet-derived growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Tyrogenex","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Tyrogenex"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Bristol Myers Squibb | Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Bristol Myers Squibb | Xcovery","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Bristol Myers Squibb | Xcovery"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG386","moa":"Angiopoietin-1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"JNJ-64041757","moa":"anti-inflammatory agents (acetic acid derivatives)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Enzon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"EZN-2208","moa":"antineoplastics (camptothecine derivatives); PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enzon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enzon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Glioblastoma Foundation Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Sunnybrook Research Institute | University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimonidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute | University of Toronto","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute | University of Toronto"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"antivirals","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NBTXR3","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Ascentage Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Ascentage Pharma"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Lymphoma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Lymphoma Group \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Kura Oncology"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Virginia Commonwealth University \/ AbbVie Inc"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"James P. Wilmot Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG Therapeutics \/ James P. Wilmot Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TG Therapeutics \/ James P. Wilmot Cancer Center"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Israeli Medical Association","sponsor":"Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Israeli Medical Association","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israeli Medical Association \/ Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"7","companyTruncated":"Israeli Medical Association \/ Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Thomas Jefferson University \/ AbbVie Inc"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chinook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Cancer Treatment International","sponsor":"University of Hong Kong | Chinese University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Pegylated Recombinant Human Arginase 1","moa":"Arginase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Cancer Treatment International","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Cancer Treatment International \/ University of Hong Kong | Chinese University of Hong Kong","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Cancer Treatment International \/ University of Hong Kong | Chinese University of Hong Kong"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Pegylated Human Arginase I","moa":"Arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeglea BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HX301","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"||ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Indena","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Ginseng Extract","moa":"Aryl hydrocarbon receptor; Interleukin-6; Prostaglandin G\/H synthase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Indena","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Indena"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Pegylated Recombinant Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"SNS-301","moa":"Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Apeiron Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Citigroup"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"University of Utah","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR||Serine\/threonine-protein kinase ATR (FRP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Repare Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Repare Therapeutics"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR||Serine\/threonine-protein kinase ATR (FRP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Repare Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Repare Therapeutics"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP9064","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"Institut Paoli-Calmettes","sponsor":"National Cancer Institute, France | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"M1774","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Paoli-Calmettes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Paoli-Calmettes \/ National Cancer Institute, France | Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Institut Paoli-Calmettes \/ National Cancer Institute, France | Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"M1774","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"TransThera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ TransThera Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ TransThera Biosciences"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AurKa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LY3295668","moa":"Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ AurKa Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ AurKa Pharma"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ European Investment Bank"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IOA-289","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q702","moa":"AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Merck & Co"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAK-280","moa":"B7 homolog 3 (CD276)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"177-Lu DTPA-Omburtamab","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"177-Lu DTPA-Omburtamab","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"7MW3711","moa":"||B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Xuzhou Medical University | Meditech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"B7H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech","highestDevelopmentStatusID":"7","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Xuzhou Medical University | Meditech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"B7H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech","highestDevelopmentStatusID":"7","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"B7H3-IRDye800CW","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IBI334","moa":"B7-H3 \/ EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ LegoChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ LegoChem Biosciences"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABL103","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"VE800","moa":"Bacteria microbiome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Vedanta Biosciences \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Joseph Tuscano","sponsor":"Takeda Pharmaceutical | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joseph Tuscano","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Tuscano \/ Takeda Pharmaceutical | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Joseph Tuscano \/ Takeda Pharmaceutical | Bristol Myers Squibb"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EO2463","moa":"B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"The Institute for Follicular Lymphoma Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Enterome \/ The Institute for Follicular Lymphoma Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ The Institute for Follicular Lymphoma Innovation"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asclepius Technology Company Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"BCMA CAR-NK 92 Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asclepius Technology Company Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asclepius Technology Company Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asclepius Technology Company Group \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BCMA Prime CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"AUTO2","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Car-Bcma T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing ","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing "},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-BCMA T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Shanghai AbelZeta Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"C-CAR088","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai AbelZeta Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai AbelZeta Ltd."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"New Leaf","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ New Leaf","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ New Leaf"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MEDI2228","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GeneQuantum Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"PBCAR269A","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PBCAR269A","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"REGN5459","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TeneoOne Inc.","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TeneoOne Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TeneoOne Inc. \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"TeneoOne Inc. \/ AbbVie Inc"},{"orgOrder":0,"company":"TeneoOne Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TeneoOne Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TeneoOne Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TeneoOne Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"AUTO3","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"AUTO3","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986458","moa":"BCL6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai AbelZeta Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Vivo Capital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Jefferies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Series C Financing","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ OrbiMed Advisors"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Heidelberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HDP-101","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heidelberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Heidelberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heidelberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"JCARH125","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Orvacabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CT053PTSA","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Zevor-Cel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Bifikafusp Alfa","moa":"BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Syneos Health"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI3003","moa":"BCMA\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"OCT | Data Matrix Solutions | Skolkovo Innovation Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PF-114","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ OCT | Data Matrix Solutions | Skolkovo Innovation Center","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ OCT | Data Matrix Solutions | Skolkovo Innovation Center"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-868","moa":"BD2-selective BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-868","moa":"||BD2-selective BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Steba Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Steba Biotech","highestDevelopmentStatusID":"7","companyTruncated":"University of Oxford \/ Steba Biotech"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JAB-8263","moa":"BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series E Financing","leadProduct":"FOG-001","moa":"Beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Parabilis Medicines \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FOG-001","moa":"Beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parabilis Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FOG-001","moa":"Beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parabilis Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FOG-001","moa":"Beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parabilis Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series D Financing","leadProduct":"FOG-001","moa":"Beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Parabilis Medicines \/ Arch Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ Arch Ventures"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"AIGH Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Financing","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ AIGH Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ AIGH Capital Management"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biocept Inc","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocept Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocept Inc \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Biocept Inc \/ Plus Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Private Placement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ D. Boral Capital","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ D. Boral Capital"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"AIGH Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Private Placement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ AIGH Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ AIGH Capital Management"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"K2bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Partnership","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ K2bio","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ K2bio"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Medidata","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Partnership","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Medidata"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RadioMedix \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"RadioMedix \/ Plus Therapeutics"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Expanded Collaboration","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Pharma Solutions \/ Plus Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Pharma Solutions \/ Plus Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsoTherapeutics Group \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"IsoTherapeutics Group \/ Plus Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NanoTx Therapeutics","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoTx Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"NanoTx Therapeutics \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NanoTx Therapeutics \/ Plus Therapeutics"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT1946","moa":"BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT1946","moa":"||BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT1946","moa":"BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NEO-201","moa":"||Biliary glycoprotein 1 (CEACAM1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NEO-201","moa":"||Biliary glycoprotein 1 (CEACAM1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"NEO-201","moa":"Biliary glycoprotein 1 (CEACAM1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"KTE-C19","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Kite Pharma \/ Genentech"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MEDI-551","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Merck & Co | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California, San Diego \/ Merck & Co | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Diego \/ Merck & Co | Amgen Inc"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Amgen Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Ibritumomab Tiuxetan","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Anderson Cancer Center \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Biogen"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California, San Diego \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Diego \/ Genentech"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California, San Diego \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Diego \/ Pharmacyclics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","sponsor":"Bristol Myers Squibb | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Bristol Myers Squibb | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Bristol Myers Squibb | Amgen Inc"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Peter MacCallum Cancer Centre","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peter MacCallum Cancer Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peter MacCallum Cancer Centre \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Peter MacCallum Cancer Centre \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ublituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ublituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Veltuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Queen Mary University of London \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Veltuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MT-3724","moa":"B-lymphocyte antigen CD20 | 80S Ribosome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Consonance Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"MT-3724","moa":"B-lymphocyte antigen CD20 | 80S Ribosome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Consonance Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Templates \/ Consonance Capital Management"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glofitamab","moa":"B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glofitamab","moa":"B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glofitamab","moa":"B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Glofitamab","moa":"B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-501A","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO1","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AUTO1","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"First Affiliated Hospital of Zhejiang University | RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-CD19 T Cell","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ First Affiliated Hospital of Zhejiang University | RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ First Affiliated Hospital of Zhejiang University | RenJi Hospital"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"IM19","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"MB-CART19.1","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Miltenyi Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital | Anhui Provincial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"PCAR-019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital | Anhui Provincial Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital | Anhui Provincial Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Anhui Provincial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"PCAR-019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PersonGen BioTherapeutics \/ Anhui Provincial Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ Anhui Provincial Hospital"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"TBI-1501","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takara Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takara Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ra-223 dichloride","moa":"Bone","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ra-223 dichloride","moa":"Bone","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Ra-223 dichloride","moa":"Bone","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ra-223 dichloride","moa":"Bone","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bayer AG"},{"orgOrder":0,"company":"DexTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Osteodex","moa":"Bone resorption","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"DexTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DexTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DexTech \/ Undisclosed"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RNK05047","moa":"BRD4-selective protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ranok Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RNK05047","moa":"BRD4-selective protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ranok Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RNK05047","moa":"BRD4-selective protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ranok Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alobresib","moa":"bromodomain and extra terminal motif (BET) inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GS-5829","moa":"bromodomain and extra terminal motif (BET) inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"INCB054329","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ODM-207","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BMS-986158","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BMS-986158","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"OTX015","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"OTX015","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PLX2853","moa":"Bromodomain-containing protein 4 (BRD4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opna Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Opna Bio \/ Undisclosed"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PLX2853","moa":"Bromodomain-containing protein 4 (BRD4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opna Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Opna Bio \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bleximenib","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BN102","moa":"BTK C481S","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioNova Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Kartos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Telios Pharma \/ Kartos Therapeutics"},{"orgOrder":0,"company":"STCube","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"hSTC810","moa":"BTN1A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"STCube","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"STCube \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"STCube \/ Undisclosed"},{"orgOrder":0,"company":"STCube","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Nelmastobart","moa":"BTN1A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"STCube","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"STCube \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"STCube \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"ILife Consulting | Exystat","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ ILife Consulting | Exystat","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ ILife Consulting | Exystat"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Funding","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Earlybird","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Series C Financing","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Earlybird","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Earlybird"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Bb Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"ICT01","moa":"BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Bb Pureos Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Bb Pureos Bioventures"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Telix Pharmaceuticals | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Girentuximab","moa":"CA IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Telix Pharmaceuticals | US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Telix Pharmaceuticals | US Department of Defense"},{"orgOrder":0,"company":"British Columbia Cancer Agency","sponsor":"Canadian Cancer Society | SignalChem Lifesciences Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SLC-0111","moa":"CA IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"British Columbia Cancer Agency","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"British Columbia Cancer Agency \/ Canadian Cancer Society | SignalChem Lifesciences Corporation","highestDevelopmentStatusID":"7","companyTruncated":"British Columbia Cancer Agency \/ Canadian Cancer Society | SignalChem Lifesciences Corporation"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BNT321","moa":"CA19-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"68-Ga DPI-4452","moa":"CAIX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DPI-4452","moa":"||CAIX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Binhui Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Oncolytic Type 2 Herpes Simplex Virus","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Binhui Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binhui Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Binhui Bio \/ Undisclosed"},{"orgOrder":0,"company":"Oryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Parvovirus H-1","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oryx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryx \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"GL-ONC1","moa":"Cancer cells (via oncolytic virus)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Celldex Therapeutics | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CDX-1401","moa":"Cancer\/testis antigen 1 | Lymphocyte antigen 75","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Celldex Therapeutics | Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Celldex Therapeutics | Incyte Corporation"},{"orgOrder":0,"company":"Leaf Vertical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leaf Vertical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leaf Vertical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leaf Vertical \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A2 Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A2 Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A2 Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series C Financing","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ The Column Group"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Tempus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2 Biotherapeutics \/ Tempus","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Tempus"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cea Car-T Cell","moa":"Carcinoembryonic antigen (CEA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cea-Targeted Car-T Cell","moa":"Carcinoembryonic antigen (CEA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Shanxi Bethune Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cea-Targeted Car-T Cell","moa":"Carcinoembryonic antigen (CEA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Shanxi Bethune Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Shanxi Bethune Hospital"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"First Affiliated Hospital of Wannan Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cea-Targeted Car-T Cell","moa":"Carcinoembryonic antigen (CEA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ First Affiliated Hospital of Wannan Medical College","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ First Affiliated Hospital of Wannan Medical College"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"BDC-1001","moa":"Carcinoembryonic antigen CEA (CD66e)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"IMMU-130","moa":"Carcinoembryonic antigen-related cell adhesion molecule 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pediatric Brain Tumor Consortium","sponsor":"Senhwa Biosciences | National Cancer Institute | St. Jude Children's Research Hospital | National Cancer Institute, USA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pediatric Brain Tumor Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pediatric Brain Tumor Consortium \/ Senhwa Biosciences | National Cancer Institute | St. Jude Children's Research Hospital | National Cancer Institute, USA","highestDevelopmentStatusID":"7","companyTruncated":"Pediatric Brain Tumor Consortium \/ Senhwa Biosciences | National Cancer Institute | St. Jude Children's Research Hospital | National Cancer Institute, USA"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arkadiusz Z. Dudek","sponsor":"Genentech | Midwest Melanoma Partnership | HealthPartners Institute Regions Cancer Care Center | Vanquish Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Procaspase Activating Compound-1","moa":"Caspase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arkadiusz Z. Dudek","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arkadiusz Z. Dudek \/ Genentech | Midwest Melanoma Partnership | HealthPartners Institute Regions Cancer Care Center | Vanquish Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Arkadiusz Z. Dudek \/ Genentech | Midwest Melanoma Partnership | HealthPartners Institute Regions Cancer Care Center | Vanquish Oncology"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-816","moa":"CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Teon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-816","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HST-1011","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||CBL-B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HST-1011","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prism Pharma","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prism Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prism Pharma \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Prism Pharma \/ Syneos Health"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"E7386","moa":"CBP\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Merck & Co"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"E7386","moa":"CBP\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"E7386","moa":"CBP\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Kirin \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Kirin \/ AstraZeneca"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Kirin \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-813160","moa":"C-C chemokine receptor type 5 | C-C chemokine receptor type 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BMS-813160","moa":"C-C chemokine receptor type 5 | C-C chemokine receptor type 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"NYIP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Private Placement","leadProduct":"Emapticap pegol","moa":"CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ NYIP","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ NYIP"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"C-C chemokine receptor type 4 (CCR4)||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BMS-986340","moa":"CCR8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SRF114","moa":"CCR8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Surface Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SRF114","moa":"CCR8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Yake Biotechnology Ltd. | Dongguan Taixin Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Yake Biotechnology Ltd. | Dongguan Taixin Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Yake Biotechnology Ltd. | Dongguan Taixin Hospital"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Shanxi Bethune Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD123 CAR-NK Cell","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Shanxi Bethune Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Shanxi Bethune Hospital"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD123 CAR-T Cell","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD123 CAR-T Cell","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Immunogen | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IMGN632","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Immunogen | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ Immunogen | National Cancer Institute"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"IMGN632","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT7480","moa":"CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT7480","moa":"CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BicycleTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BT7480","moa":"CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BicycleTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BicycleTx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BicycleTx \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"BT062","moa":"CD138\/Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Biotest","highestDevelopmentStatusID":"7","companyTruncated":"Biotest \/ Biotest"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Istari Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Istari Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Istari Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Istari Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Roth Capital Partners"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Agent Capital","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Agent Capital"},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"CD163","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ OncoResponse"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"OR2805","moa":"CD163","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoResponse \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Undisclosed"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||CD163","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoResponse \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Englumafusp Alfa","moa":"CD16A \/ HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Eureka Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Eureka Therapeutics"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Servier \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Precision BioSciences"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"Kincell Bio","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kincell Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kincell Bio \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Kincell Bio \/ Imugene"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.66000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-T-19 Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing University Cancer Hospital","sponsor":"Fundamenta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CAR-T-19A","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing University Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing University Cancer Hospital \/ Fundamenta Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing University Cancer Hospital \/ Fundamenta Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CC-99282","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CC-99282","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Zhujiang Hospital","sponsor":"Zhaotai Cell Bio-tech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhujiang Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhujiang Hospital \/ Zhaotai Cell Bio-tech","highestDevelopmentStatusID":"7","companyTruncated":"Zhujiang Hospital \/ Zhaotai Cell Bio-tech"},{"orgOrder":0,"company":"Xinqiao Hospital, Chongqing","sponsor":"Xuzhou Medical University | Hrain Biotechnology | Shanghai Changzheng Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xinqiao Hospital, Chongqing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinqiao Hospital, Chongqing \/ Xuzhou Medical University | Hrain Biotechnology | Shanghai Changzheng Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Xinqiao Hospital, Chongqing \/ Xuzhou Medical University | Hrain Biotechnology | Shanghai Changzheng Hospital"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Innovative Cellular Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Innovative Cellular Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Innovative Cellular Therapeutics"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruijin Hospital \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Ruijin Hospital \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd"},{"orgOrder":0,"company":"Shanxi Province Cancer Hospital","sponsor":"Shanghai Ultra-T Immune Therapeutics Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanxi Province Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanxi Province Cancer Hospital \/ Shanghai Ultra-T Immune Therapeutics Co. LTD","highestDevelopmentStatusID":"7","companyTruncated":"Shanxi Province Cancer Hospital \/ Shanghai Ultra-T Immune Therapeutics Co. LTD"},{"orgOrder":0,"company":"Shanxi Province Cancer Hospital","sponsor":"Immune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanxi Province Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanxi Province Cancer Hospital \/ Immune Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Shanxi Province Cancer Hospital \/ Immune Therapeutics"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Pell Bio-Med Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pell Bio-Med Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pell Bio-Med Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pell Bio-Med Technology \/ Undisclosed"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Second Xiangya Hospital, Central South University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioray Laboratories \/ Second Xiangya Hospital, Central South University","highestDevelopmentStatusID":"7","companyTruncated":"Bioray Laboratories \/ Second Xiangya Hospital, Central South University"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Juventas Cell Therapy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CNCT19","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Juventas Cell Therapy","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Juventas Cell Therapy"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CNCT19","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Private Placement","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"He Huang","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GC022F","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"He Huang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"He Huang \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"He Huang \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ginisortamab","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Juno","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"JCAR015","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Juno","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Juno"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TAC01-CD19","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"James Rubenstein","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"James Rubenstein","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James Rubenstein \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"James Rubenstein \/ Incyte Corporation"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TC-110 T","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCR2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Timmune Biotech Inc.","sponsor":"Hunan Provincial People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"TriCAR-T-CD19 Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Timmune Biotech Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Timmune Biotech Inc. \/ Hunan Provincial People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Timmune Biotech Inc. \/ Hunan Provincial People's Hospital"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"LYL314","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19\/CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Medical University General Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CAR2219","moa":"CD19\/CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Medical University General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Medical University General Hospital \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Medical University General Hospital \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"iOx Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMM60","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iOx Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"iOx Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ University of Oxford"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM60","moa":"||CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM60","moa":"||CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AK119","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Aleta Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ Aleta Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Aleta Biotherapeutics"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research Uk","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research Uk","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research Uk"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aleta Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Elicera Therapeutics | Uppsala University Hospital | Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CAR20(NAP)-T Cell","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Elicera Therapeutics | Uppsala University Hospital | Karolinska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Uppsala University \/ Elicera Therapeutics | Uppsala University Hospital | Karolinska University Hospital"},{"orgOrder":0,"company":"Beijing Biohealthcare Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-T 20 Cell","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Biohealthcare Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Biohealthcare Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Biohealthcare Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Longyao Biotechnology Inc., Ltd.","sponsor":"Xuzhou Medical University | Shanghai Jiaotong University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CD20 CAR-T Cell","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Longyao Biotechnology Inc., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Longyao Biotechnology Inc., Ltd. \/ Xuzhou Medical University | Shanghai Jiaotong University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Longyao Biotechnology Inc., Ltd. \/ Xuzhou Medical University | Shanghai Jiaotong University School of Medicine"},{"orgOrder":0,"company":"Shanghai Longyao Biotechnology Inc., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CD20 CAR-T Cell","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Longyao Biotechnology Inc., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Longyao Biotechnology Inc., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Longyao Biotechnology Inc., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GB261","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ ADC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"IGM Biosciences \/ ADC Therapeutics"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Mainline Biosciences (Shanghai) Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MB0151","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mainline Biosciences (Shanghai) Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mainline Biosciences (Shanghai) Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mainline Biosciences (Shanghai) Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ National Cancer Institute"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"uBriGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ uBriGene","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ uBriGene"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Prolium Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"CM355","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Injection","sponsorNew":"InnoCare Pharma \/ Prolium Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Prolium Bioscience"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMM0306","moa":"CD20\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMM0306","moa":"CD20\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMM0306","moa":"CD20\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CPO107","moa":"CD20\/SIRP-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conjupro Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Conjupro Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"90-Y Epratuzumab Tetraxetan","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Gilead Sciences"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ADCT-602","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | ADC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | ADC Therapeutics"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AZD4512","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Fortrea","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Fortrea"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AZD4512","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Kai Lin Xu; Jun Nian Zheng","sponsor":"iCarTAB BioMed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CD22 CAR-T Cell","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kai Lin Xu; Jun Nian Zheng","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kai Lin Xu; Jun Nian Zheng \/ iCarTAB BioMed","highestDevelopmentStatusID":"7","companyTruncated":"Kai Lin Xu; Jun Nian Zheng \/ iCarTAB BioMed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Inotuzumab ozogamicin","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ EIB","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ EIB"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Midcap Financial Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Midcap Financial Trust","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Midcap Financial Trust"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"YS110","moa":"CD26","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"GEN1053","moa":"CD27","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"University Hospital Southampton NHS Foundation Trust","sponsor":"University Hospital Plymouth NHS Trust | The Christie NHS Foundation Trust | Oxford University Hospitals NHS Trust | Celldex Therapeutics | Cancer Research UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Varlilumab","moa":"CD27 antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Southampton NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Southampton NHS Foundation Trust \/ University Hospital Plymouth NHS Trust | The Christie NHS Foundation Trust | Oxford University Hospitals NHS Trust | Celldex Therapeutics | Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Southampton NHS Foundation Trust \/ University Hospital Plymouth NHS Trust | The Christie NHS Foundation Trust | Oxford University Hospitals NHS Trust | Celldex Therapeutics | Cancer Research UK"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Varlilumab","moa":"CD27 antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Celldex Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Varlilumab","moa":"CD27 antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"89-Zr DFO-MSTP2109A","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"IBI129","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"GSK5764227","moa":"CD276\/Top I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Innovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Merck & Co"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"GI-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Innovation \/ Agilent Technologies","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Agilent Technologies"},{"orgOrder":0,"company":"Merck Group","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"GI-101","moa":"CD28\/CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ GI Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ GI Innovation"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GEN1047","moa":"CD3 \/ CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HY05350","moa":"CD3 | MSLN | PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Gocatamig","moa":"CD3\/BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Gocatamig","moa":"CD3\/BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BNT142","moa":"CD3\/CLDN6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LBL-034","moa":"CD3\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LBL-034","moa":"CD3\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMX-818","moa":"CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Merck & Co"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"||CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"||CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"VIR-5818","moa":"CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AMX-500","moa":"CD3\/PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"225-Ac Lintuzumab","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"225-Ac Lintuzumab","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"MSKCC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ MSKCC","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ MSKCC"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD33 CAR-T Cell","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji Hospital \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Tongji Hospital \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Evercore ISI","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Evercore ISI"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Private Placement","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"VCAR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"VCAR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"VCAR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akron Biotech \/ Vor Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Akron Biotech \/ Vor Biopharma"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MP0533","moa":"CD33\/CD123\/CD70","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GEN1055","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"GEN3014","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STI-6129","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STI-6129","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-101","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-101","moa":"||CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ISB 1442","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ISB 1442","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ISB 1442","moa":"CD-38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Modakafusp Alfa","moa":"CD38\/Type I interferon receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Modakafusp Alfa","moa":"CD38\/Type I interferon receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Modakafusp Alfa","moa":"CD38\/Type I interferon receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Modakafusp Alfa","moa":"CD38\/Type I interferon receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ University of Pennsylvania"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Theradex | BC Platforms","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Theradex | BC Platforms","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Theradex | BC Platforms"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Memgen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"rAd.CD40L","moa":"CD40L","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MD Anderson Cancer Center \/ Memgen","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Memgen"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"InSysBio \/ Genmab"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"YH003","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"YH003","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YH003","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Lokon Pharma","sponsor":"Uppsala University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LOAd703","moa":"CD40L\/4-1BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lokon Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lokon Pharma \/ Uppsala University","highestDevelopmentStatusID":"7","companyTruncated":"Lokon Pharma \/ Uppsala University"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dazostinag","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Dp303c","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IMM01","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM01","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Obrixtamig","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DSP107","moa":"CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Undisclosed"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Undisclosed"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Undisclosed"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ aMoon","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ aMoon"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Undisclosed"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Flerie Invest","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Flerie Invest"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"KAHR-102","moa":"CD47\/CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kahr Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMM2902","moa":"CD47\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMM2902","moa":"CD47\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IBC0966","moa":"CD47\/PDL1\/SIRP?","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Hebei Senlang Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD5 CAR-T Cell","moa":"CD5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking University People's Hospital \/ Hebei Senlang Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Hebei Senlang Biotechnology"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MT-101","moa":"CD5-ATAK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Myeloid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD5-ATAK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Myeloid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||CD5-ATAK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Myeloid Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"The General Hospital of Western Theater Command","sponsor":"YakeBiotech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The General Hospital of Western Theater Command","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The General Hospital of Western Theater Command \/ YakeBiotech Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"The General Hospital of Western Theater Command \/ YakeBiotech Ltd."},{"orgOrder":0,"company":"Zhengzhou University","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhengzhou University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhengzhou University \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Zhengzhou University \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CTD402","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioheng Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bioheng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EMB-06","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"Soficabtagene Geleucel","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Wugen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ Wugen","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ Wugen"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"UTC Therapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD70 CAR-T Cell","moa":"CD70","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ UTC Therapeutics Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ UTC Therapeutics Inc."},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"UTC Therapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD70 CAR-T Cell","moa":"CD70","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ UTC Therapeutics Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ UTC Therapeutics Inc."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CTX131","moa":"CD70","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTX131","moa":"CD70","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Private Placement","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Peking University Cancer Hospital & Institute | Zhejiang Cancer Hospital | Shandong Cancer Hospital and Institute | Hunan Cancer Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second Affiliated Hospital of","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HB0052","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Peking University Cancer Hospital & Institute | Zhejiang Cancer Hospital | Shandong Cancer Hospital and Institute | Hunan Cancer Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second Affiliated Hospital of","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Peking University Cancer Hospital & Institute | Zhejiang Cancer Hospital | Shandong Cancer Hospital and Institute | Hunan Cancer Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second Affiliated Hospital of"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JAB-BX102","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"JAB-BX102","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BN301","moa":"CD74\/Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNova Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AZD6750","moa":"CD8 | IL-2R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"GRT-C903","moa":"CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Undisclosed"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"SQZ-PBMC-HPV","moa":"CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ BofA Securities"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SQZ-PBMC-HPV","moa":"CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series D Financing","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"ORCA-010","moa":"CD8+ T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Therapeutics \/ CMX Research"},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ORCA-010","moa":"CD8+ T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Therapeutics \/ CMX Research"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD86\/HPV E6\/HPV E7\/IL-12\/IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD86\/HPV E6\/HPV E7\/IL-12\/IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CD86\/HPV E6\/HPV E7\/IL-12\/IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":1.3799999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3799999999999999,"dosageForm":"Injection","sponsorNew":"SQZ Biotechnologies \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SQZ-eAPC-HPV","moa":"CD86\/HPV E6\/HPV E7\/IL-12\/IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Smerud Medical Research International AS | Medical Prognosis Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"APO010","moa":"CD95","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allarity Therapeutics \/ Smerud Medical Research International AS | Medical Prognosis Institute","highestDevelopmentStatusID":"7","companyTruncated":"Allarity Therapeutics \/ Smerud Medical Research International AS | Medical Prognosis Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BMS-986442","moa":"CD96\/TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Anova Enterprises","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"5-fluorocytosine","moa":"||CDA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anova Enterprises","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anova Enterprises \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anova Enterprises \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"HY0001a","moa":"CDCP1 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CM518D1","moa":"CDH17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LM-350","moa":"CDH17 | Top I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"CDH6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"QLS5133","moa":"CDH6 | Top I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carrick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carrick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVZO-021","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BLU-222","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Undisclosed"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Undisclosed"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Undisclosed"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Undisclosed"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Boxer Capital"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Eshelman Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eshelman Ventures"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Multiple Myeloma Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AT7519M","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astex Pharmaceuticals \/ Multiple Myeloma Research Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Multiple Myeloma Research Consortium"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9||Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9||Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"||CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GDC-4198","moa":"CDK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Fudan University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dalpiciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Fudan University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Beta Pharma (Suzhou)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BPI-1178","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beta Pharma (Suzhou)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beta Pharma (Suzhou) \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beta Pharma (Suzhou) \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Birelentinib","moa":"CDK4 \/ CDK6||CDK4|CDK6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Birelentinib","moa":"CDK4 \/ CDK6||CDK4|CDK6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Birelentinib","moa":"CDK4 \/ CDK6||CDK4|CDK6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Pfizer Inc | National Center for Tumor Diseases, Heidelberg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Pfizer Inc | National Center for Tumor Diseases, Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"University of Ulm \/ Pfizer Inc | National Center for Tumor Diseases, Heidelberg"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Kansas Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Fundacion Oncosur","sponsor":"Pfizer Inc | Apices Soluciones | Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHILE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundacion Oncosur","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre"},{"orgOrder":0,"company":"GT Apeiron","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Apeiron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Apeiron \/ Exscientia","highestDevelopmentStatusID":"7","companyTruncated":"GT Apeiron \/ Exscientia"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ GT Apeiron"},{"orgOrder":0,"company":"Exscientia","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exscientia \/ Recursion Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Recursion Pharma"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ GT Apeiron"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ GT Apeiron"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GTAEXS-617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recursion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q901","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qurient \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Merck & Co"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q901","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SYHX1903","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Surgimab","sponsor":"Centre for Human Drug Research | Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Catharina Hospital Eindhoven","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SGM-101","moa":"CEA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Surgimab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surgimab \/ Centre for Human Drug Research | Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Catharina Hospital Eindhoven","highestDevelopmentStatusID":"7","companyTruncated":"Surgimab \/ Centre for Human Drug Research | Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Catharina Hospital Eindhoven"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI3004","moa":"CEA\/DR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purple Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Famewave","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Famewave","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Famewave \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Famewave \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"FameWave","sponsor":"Kitov Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FameWave","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"FameWave \/ Kitov Pharma","highestDevelopmentStatusID":"7","companyTruncated":"FameWave \/ Kitov Pharma"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"FF-10501-01","moa":"Cell differentiation (CD)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm holding \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SAR443579","moa":"Cell division cycle protein 123 (CDC123)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAR443579","moa":"Cell division cycle protein 123 (CDC123)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"AU-011","moa":"Cell membrane | Heparan Sulphate Proteoglycans","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aura Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aura Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"CicloMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fosciclopirox","moa":"Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CicloMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CicloMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CicloMed \/ Undisclosed"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Fosciclopirox","moa":"||Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"7","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MGD007","moa":"Cell surface A33 antigen (GPA33)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MGD007","moa":"Cell surface A33 antigen (GPA33)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"Immunogen","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGC936","moa":"Cellular disintegrin-related protein (ADAM9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ MacroGenics","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ MacroGenics"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Aprea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"APR-246","moa":"Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Aprea Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Aprea Therapeutics"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Aprea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"APR-246","moa":"Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Aprea Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Aprea Therapeutics"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Jules Bordet Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"APR-246","moa":"Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Jules Bordet Institute","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Jules Bordet Institute"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"James and Esther King Research Program","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"ALT-801","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ James and Esther King Research Program","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ James and Esther King Research Program"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"ALT-801","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ National Cancer Institute"},{"orgOrder":0,"company":"The Second Hospital of Shandong University","sponsor":"Shandong Sunstem Biotechnology Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Dendritic Cell Vaccine","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Second Hospital of Shandong University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Second Hospital of Shandong University \/ Shandong Sunstem Biotechnology Co.,Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"The Second Hospital of Shandong University \/ Shandong Sunstem Biotechnology Co.,Ltd."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cemsidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LY2880070","moa":"Checkpoint kinase-1 (CHK1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Esperas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Esperas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Esperas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"Shanghai Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai GeneChem \/ Shanghai Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai GeneChem \/ Shanghai Cancer Hospital"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"The First Affiliated Hospital of Guangdong Pharmaceutical University","sponsor":"Anjie Biomedical Technology | University of Technology, Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Guangdong Pharmaceutical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology | University of Technology, Sydney","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology | University of Technology, Sydney"},{"orgOrder":0,"company":"Shenzhen BinDeBio Ltd.","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen BinDeBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shenzhen BinDeBio Ltd. \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen BinDeBio Ltd. \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | The Second People's Hospital of Huai'an | Third Military Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | The Second People's Hospital of Huai'an | Third Military Medical University","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | The Second People's Hospital of Huai'an | Third Military Medical University"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"The Second People's Hospital of Huai'an | The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ The Second People's Hospital of Huai'an | The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Soochow University \/ The Second People's Hospital of Huai'an | The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd"},{"orgOrder":0,"company":"Wuhan Sian Medical Technology Co., Ltd","sponsor":"Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | People\u2019s Hospital of Yichang","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Sian Medical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Sian Medical Technology Co., Ltd \/ Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | People\u2019s Hospital of Yichang","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Sian Medical Technology Co., Ltd \/ Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | People\u2019s Hospital of Yichang"},{"orgOrder":0,"company":"Wuhan Sian Medical Technology Co., Ltd","sponsor":"Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | The First People's Hospital of Yuhang District","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Sian Medical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Sian Medical Technology Co., Ltd \/ Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | The First People's Hospital of Yuhang District","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Sian Medical Technology Co., Ltd \/ Wuhan Union Hospital | Jingzhou Central Hospital | Xiangyang Central Hospital | The First People's Hospital of Yuhang District"},{"orgOrder":0,"company":"Shenzhen BinDeBio Ltd.","sponsor":"Henan Provincial People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen BinDeBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen BinDeBio Ltd. \/ Henan Provincial People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen BinDeBio Ltd. \/ Henan Provincial People's Hospital"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Mustang Bio"},{"orgOrder":0,"company":"Kai Lin Xu; Jun Nian Zheng","sponsor":"iCarTAB BioMed | Huaian first people's hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kai Lin Xu; Jun Nian Zheng","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kai Lin Xu; Jun Nian Zheng \/ iCarTAB BioMed | Huaian first people's hospital","highestDevelopmentStatusID":"7","companyTruncated":"Kai Lin Xu; Jun Nian Zheng \/ iCarTAB BioMed | Huaian first people's hospital"},{"orgOrder":0,"company":"Kecellitics Biotech","sponsor":"Hebei Yanda Ludaopei Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kecellitics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kecellitics Biotech \/ Hebei Yanda Ludaopei Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Kecellitics Biotech \/ Hebei Yanda Ludaopei Hospital"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Undisclosed"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Undisclosed"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SRA737","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SRA737","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SRA737","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Alcedis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SCO-101","moa":"Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scandion Oncology \/ Alcedis","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Alcedis"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel unspecific (ClC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"Chloride channel unspecific (ClC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel unspecific (ClC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n."},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Birinapant","moa":"||cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"||cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Merck & Co"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"7","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"OKI-179","moa":"Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ASKB589","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKB589","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HLX43","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HLX43","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"RC118","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"RC118","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"RC118","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TST001","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TST001","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"CLDN1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CLDN18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Transcenta Holding","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Transcenta Holding"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BNT141","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CT041","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Leap Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"FL-301","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Leap Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ Leap Therapeutics"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FL-301","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leap Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAC01-CLDN18.2","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Undisclosed"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"XNW27011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"XNW27011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":1.54,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.54,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Astellas Pharma"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"BNT211","moa":"||CLDN-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Business Finland","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Business Finland"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Faron Pharmaceuticals"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTX-712","moa":"CLK kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chordia Therapeutics \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Chordia Therapeutics \/ Theradex"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LM-061","moa":"c-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LM-061","moa":"c-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Octimet Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"OMO-1","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Octimet Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octimet Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Octimet Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PLB1004","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VERT-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EP0089-101","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Loxo-292","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Loxo Oncology Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Loxo-292","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Loxo Oncology Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Perlmutter NYU Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NYU Langone Health \/ Perlmutter NYU Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Perlmutter NYU Cancer Center"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adg106","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National University Hospital, Singapore \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"7","companyTruncated":"National University Hospital, Singapore \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Adg106","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adg106","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adg106","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Series D Financing","leadProduct":"Adg106","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ General Atlantic"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National University Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Adg106","moa":"||Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ National University Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ National University Cancer Institute"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Agenus | Lustgarten Foundation | Oncovir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AGEN2373","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Agenus | Lustgarten Foundation | Oncovir","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Agenus | Lustgarten Foundation | Oncovir"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LVGN6051","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lyvgen \/ Undisclosed"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NM21-1480","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Numab Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Donafenib","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Jiangsu Alphamab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Jiangsu Alphamab","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Natalie Galanina","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Golcadomide","moa":"CRBN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Natalie Galanina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natalie Galanina \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Natalie Galanina \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Pathos","sponsor":"Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathos \/ Duke University","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Duke University"},{"orgOrder":0,"company":"Pathos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"||CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Undisclosed"},{"orgOrder":0,"company":"Pathos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"Pocenbrodib","moa":"||CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0.37,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Undisclosed","sponsorNew":"Pathos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Undisclosed"},{"orgOrder":0,"company":"CellCentric","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Inobrodib","moa":"CREB-binding protein (CREBBP)||CREBBP|EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Undisclosed"},{"orgOrder":0,"company":"CellCentric","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Inobrodib","moa":"CREB-binding protein (CREBBP)||CREBBP|EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Undisclosed"},{"orgOrder":0,"company":"CellCentric","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Inobrodib","moa":"||CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Undisclosed"},{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Inobrodib","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Morningside Ventures","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Morningside Ventures"},{"orgOrder":0,"company":"CellCentric","sponsor":"BrightEdge","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Inobrodib","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellCentric \/ BrightEdge","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ BrightEdge"},{"orgOrder":0,"company":"Prostate Cancer Clinical Trial Consortium","sponsor":"CellCentric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Inobrodib","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prostate Cancer Clinical Trial Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prostate Cancer Clinical Trial Consortium \/ CellCentric","highestDevelopmentStatusID":"7","companyTruncated":"Prostate Cancer Clinical Trial Consortium \/ CellCentric"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Bristol Myers Squibb | coMMit Myeloma Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iberdomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Bristol Myers Squibb | coMMit Myeloma Trials","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Bristol Myers Squibb | coMMit Myeloma Trials"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Celgene Corporation"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Lille \/ Celgene Corporation"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Celgene Corporation"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ARCAGY GINECO GROUP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ARCAGY GINECO GROUP","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCAGY GINECO GROUP \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ARCAGY GINECO GROUP \/ Undisclosed"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMC Utrecht \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"UMC Utrecht \/ Celgene Corporation"},{"orgOrder":0,"company":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","sponsor":"Celgene Corporation | Dynamic Science | Thermo Fisher Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Celgene Corporation | Dynamic Science | Thermo Fisher Scientific","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Celgene Corporation | Dynamic Science | Thermo Fisher Scientific"},{"orgOrder":0,"company":"University Hospital, Essen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Essen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Essen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Essen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Medical University Innsbruck","sponsor":"Celgene Corporation | Innsbruck - Tyrolean Working Group of Experimental Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University Innsbruck","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University Innsbruck \/ Celgene Corporation | Innsbruck - Tyrolean Working Group of Experimental Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Medical University Innsbruck \/ Celgene Corporation | Innsbruck - Tyrolean Working Group of Experimental Oncology"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Celgene Corporation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Celgene Corporation | GSK","highestDevelopmentStatusID":"7","companyTruncated":"University of Nebraska \/ Celgene Corporation | GSK"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Merck & Co | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Fox Chase Cancer Center \/ Merck & Co | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Fox Chase Cancer Center \/ Merck & Co | Bristol Myers Squibb"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Celgene Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb | Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Celgene Corporation"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Healthwell Acquisition Corp. I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Termination","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Healthwell Acquisition Corp. I","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Healthwell Acquisition Corp. I"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Celgene Corporation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Celgene Corporation"},{"orgOrder":0,"company":"David Bond","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"David Bond","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Bond \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"David Bond \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mikkael Sekeres, MD","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mikkael Sekeres, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mikkael Sekeres, MD \/ Bristol Myers Squibb | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Mikkael Sekeres, MD \/ Bristol Myers Squibb | Bristol Myers Squibb"},{"orgOrder":0,"company":"Alliance for Clinical Trials in Oncology","sponsor":"National Cancer Institute | Celgene Corporation | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alliance for Clinical Trials in Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Celgene Corporation | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Celgene Corporation | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Multiple Myeloma Research Consortium","sponsor":"Bristol Myers Squibb | Gabrail Cancer Center Research | Washington University School of Medicine | Beth Israel Deaconess Medical Center | Dana-Farber Cancer Institute | Wake Forest University Health Sciences | Memorial Sloan Kettering Cancer Center | Icah","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Multiple Myeloma Research Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiple Myeloma Research Consortium \/ Bristol Myers Squibb | Gabrail Cancer Center Research | Washington University School of Medicine | Beth Israel Deaconess Medical Center | Dana-Farber Cancer Institute | Wake Forest University Health Sciences | Memorial Sloan Kettering Cancer Center | Icah","highestDevelopmentStatusID":"7","companyTruncated":"Multiple Myeloma Research Consortium \/ Bristol Myers Squibb | Gabrail Cancer Center Research | Washington University School of Medicine | Beth Israel Deaconess Medical Center | Dana-Farber Cancer Institute | Wake Forest University Health Sciences | Memorial Sloan Kettering Cancer Center | Icah"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BLZ945","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MCS110","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ZielBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZielBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ Undisclosed"},{"orgOrder":0,"company":"ZielBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZielBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ Undisclosed"},{"orgOrder":0,"company":"ZielBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ZielBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BMS-986218","moa":"CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ BioNTech"},{"orgOrder":0,"company":"Xilio Development, Inc.","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vilastobart","moa":"CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Development, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Development, Inc. \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Development, Inc. \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Xilio Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Xilio Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Xilio Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CTLA4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ADG126","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADG126","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Sheba Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Sheba Medical Center"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Yale Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Yale Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Yale Cancer Center"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BA3071","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Evalstotug","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ BeiGene"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Evalstotug","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HX044","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HX044","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI310","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ PPD","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ PPD"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"PFM Health Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series D Financing","leadProduct":"RIVAL-01","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Turnstone Biologics \/ PFM Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone Biologics \/ PFM Health Sciences"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"AMP945","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"FAK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amplia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amplia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CWP232291","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CWP232291","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cytovation","sponsor":"Norwegian Cancer Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"CY-101","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Norwegian Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Norwegian Cancer Society"},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Merck & Co"},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Merck & Co"},{"orgOrder":0,"company":"Cytovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Undisclosed"},{"orgOrder":0,"company":"Cytovation","sponsor":"Recurrent Respiratory Papillomatosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2023","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Cytovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Undisclosed"},{"orgOrder":0,"company":"Cytovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Undisclosed"},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Merck & Co"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2025","type":"Financing","leadProduct":"CyPep-1","moa":"CTNNB\/Wnt","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MEDSIR \/ Undisclosed"},{"orgOrder":0,"company":"Polyphor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Balixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyphor \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Polyphor \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BMS-936564","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abbisko Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Genentech"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MD Anderson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ulocuplumab","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"USL311","moa":"C-X-C chemokine receptor type 4 (CXCR4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"Astellas Pharma | AstraZeneca | Prostate Cancer UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AZD5069","moa":"CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Institute of Cancer Research, United Kingdom \/ Astellas Pharma | AstraZeneca | Prostate Cancer UK","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ Astellas Pharma | AstraZeneca | Prostate Cancer UK"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"90-Y PentixaTher","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"||Cyclic ADP-ribose hydrolase 1 (CD38)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven Pharmaceuticals \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"BeyondBio Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BEY1107","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeyondBio Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeyondBio Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeyondBio Inc \/ Undisclosed"},{"orgOrder":0,"company":"BeyondBio Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BEY1107","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeyondBio Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeyondBio Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeyondBio Inc \/ Undisclosed"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lerociclib","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lerociclib","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Deimos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"||cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Deimos Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Deimos Biosciences"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PF-06873600","moa":"cyclin dependent kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Merger","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0.82999999999999996,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Panacea Biotec Limited","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Panacea Biotec Limited"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0.84999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Panacea Acquisition","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Panacea Acquisition"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"Cyclin-dependent kinase 2 (CDK2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Multiple Myeloma Research Consortium","sponsor":"AbbVie Inc | Celgene Corporation | Eli Lilly | Genentech | Johnson & Johnson Innovative Medicine | Takeda Pharmaceutical | GSK | Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Multiple Myeloma Research Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiple Myeloma Research Consortium \/ AbbVie Inc | Celgene Corporation | Eli Lilly | Genentech | Johnson & Johnson Innovative Medicine | Takeda Pharmaceutical | GSK | Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Multiple Myeloma Research Consortium \/ AbbVie Inc | Celgene Corporation | Eli Lilly | Genentech | Johnson & Johnson Innovative Medicine | Takeda Pharmaceutical | GSK | Karyopharm Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eli Lilly | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly | Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly | Exelixis"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Criterium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Undisclosed"},{"orgOrder":0,"company":"Vadim S Koshkin","sponsor":"Prostate Cancer Foundation | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vadim S Koshkin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vadim S Koshkin \/ Prostate Cancer Foundation | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Vadim S Koshkin \/ Prostate Cancer Foundation | Eli Lilly"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Pfizer Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Pfizer Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Pfizer Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Novartis Pharmaceuticals Corporation | UT Southwestern Medical Center | Cedars-Sinai | Virginia Mason Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Novartis Pharmaceuticals Corporation | UT Southwestern Medical Center | Cedars-Sinai | Virginia Mason Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Novartis Pharmaceuticals Corporation | UT Southwestern Medical Center | Cedars-Sinai | Virginia Mason Medical Center"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kari Wisinski","sponsor":"Novartis Pharmaceuticals Corporation | Big Ten Cancer Research Consortium | University of Wisconsin, Madison","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kari Wisinski","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kari Wisinski \/ Novartis Pharmaceuticals Corporation | Big Ten Cancer Research Consortium | University of Wisconsin, Madison","highestDevelopmentStatusID":"7","companyTruncated":"Kari Wisinski \/ Novartis Pharmaceuticals Corporation | Big Ten Cancer Research Consortium | University of Wisconsin, Madison"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"CDK7||Cyclin-dependent kinase 7 (CDK7)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Alvocidib","moa":"Cyclin-dependent kinase 7 | Cyclin-dependent kinase 4 | Cyclin-dependent kinase 1 | Cyclin-dependent kinase 6 | Cyclin-dependent kinase 2 | Cyclin-dependent kinase 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alvocidib","moa":"||Cyclin-dependent kinase 7 | Cyclin-dependent kinase 4 | Cyclin-dependent kinase 1 | Cyclin-dependent kinase 6 | Cyclin-dependent kinase 2 | Cyclin-dependent kinase 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD4573","moa":"Cyclin-dependent kinase 9 (CDK9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AZD4573","moa":"Cyclin-dependent kinase 9 (CDK9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Panacela Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Panacela Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacela Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Panacela Labs \/ Undisclosed"},{"orgOrder":0,"company":"Panacela Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Panacela Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacela Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Panacela Labs \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Aim ImmunoTech","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Aim ImmunoTech"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Targovax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Apricoxib","moa":"Cyclooxygenase-2||Cyclooxygenase-2||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Oslo University Hospital \/ Targovax","highestDevelopmentStatusID":"7","companyTruncated":"Oslo University Hospital \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Apricoxib","moa":"Cyclooxygenase-2||Cyclooxygenase-2||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Apricoxib","moa":"||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Innovation Norway"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INV-9956","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionova Life Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionova Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Astex Pharmaceuticals | Forma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Astex Pharmaceuticals | Forma Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Astex Pharmaceuticals | Forma Therapeutics"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Institute of Cancer Research, United Kingdom \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Herbert Irving Comprehensive Cancer Center | Weill Medical College of Cornell University | NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Anastrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Herbert Irving Comprehensive Cancer Center | Weill Medical College of Cornell University | NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Herbert Irving Comprehensive Cancer Center | Weill Medical College of Cornell University | NYU Langone Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Novartis Pharmaceuticals Corporation | TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Novartis Pharmaceuticals Corporation | TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Novartis Pharmaceuticals Corporation | TRACON Pharmaceuticals"},{"orgOrder":0,"company":"Emmanuel Antonarakis, MD","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Emmanuel Antonarakis, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emmanuel Antonarakis, MD \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Emmanuel Antonarakis, MD \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO4010","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EO4010","moa":"||Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"NEC Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ NEC Corporation","highestDevelopmentStatusID":"7","companyTruncated":"NEC Corporation \/ NEC Corporation"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"NEC Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ NEC Corporation","highestDevelopmentStatusID":"7","companyTruncated":"NEC Corporation \/ NEC Corporation"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":"7","companyTruncated":"NEC Corporation \/ AGC Biologics"},{"orgOrder":0,"company":"Beijing Doing Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Cytokine Induced Killer Cell","moa":"Cytotoxic T-cell\/NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Doing Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Doing Biomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Doing Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Chuan An Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Cytokine Induced Killer Cell","moa":"Cytotoxic T-cell\/NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chuan An Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chuan An Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chuan An Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sabz Biomedicals","sponsor":"Ministry of Health and Medical Education | Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Cytokine Induced Killer Cell","moa":"Cytotoxic T-cell\/NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sabz Biomedicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sabz Biomedicals \/ Ministry of Health and Medical Education | Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"7","companyTruncated":"Sabz Biomedicals \/ Ministry of Health and Medical Education | Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"Capital Medical University","sponsor":"Duke University | Geneplus-Beijing Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"DC-CIK","moa":"Cytotoxic T-cell\/NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Capital Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capital Medical University \/ Duke University | Geneplus-Beijing Co. Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Capital Medical University \/ Duke University | Geneplus-Beijing Co. Ltd."},{"orgOrder":0,"company":"Agenus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AGEN1884","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Undisclosed"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs \/ Oslo University Hospital"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bristol Myers Squibb | Northwestern University | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Northwestern University | Oregon Health and Science University","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Northwestern University | Oregon Health and Science University"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Bristol Myers Squibb | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Bristol Myers Squibb | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Bristol Myers Squibb | Gilead Sciences"},{"orgOrder":0,"company":"Rabih Said","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rabih Said","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabih Said \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"Rabih Said \/ Agenus"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Quavonlimab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Yoon Jun Kim","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yoon Jun Kim","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Yoon Jun Kim \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Yoon Jun Kim \/ AstraZeneca"},{"orgOrder":0,"company":"Agenus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Zalifrelimab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ADG116","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADG116","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADG116","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ADG116","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ADG116","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BMS-986249","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BMS-986288","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BMS-986288","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"OncoC4","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Onc-392","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ National Cancer Institute"},{"orgOrder":0,"company":"OncoC4","sponsor":"Prostate Cancer Clinical Trials Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Onc-392","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ Prostate Cancer Clinical Trials Consortium","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ Prostate Cancer Clinical Trials Consortium"},{"orgOrder":0,"company":"Biocytogen","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocytogen \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Biocytogen \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YH001","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"||Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Sunshine Lake Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Sunshine Lake Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Sunshine Lake Pharma"},{"orgOrder":0,"company":"Lawrence Feldman, MD","sponsor":"Merck & Co | HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lawrence Feldman, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lawrence Feldman, MD \/ Merck & Co | HiberCell","highestDevelopmentStatusID":"7","companyTruncated":"Lawrence Feldman, MD \/ Merck & Co | HiberCell"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDC-3042","moa":"Dectin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDC-3042","moa":"||Dectin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HPN328","moa":"Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HPN328","moa":"Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HPN328","moa":"Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"Atezolizumab","moa":"||Delta-like protein 3 (DLL3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Stemcentrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Rovalpituzumab Tesirine","moa":"Delta-like protein 3 | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemcentrx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemcentrx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemcentrx \/ Undisclosed"},{"orgOrder":0,"company":"Stemcentrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Rovalpituzumab Tesirine","moa":"Delta-like protein 3 | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemcentrx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemcentrx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemcentrx \/ Undisclosed"},{"orgOrder":0,"company":"Stemcentrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Rovalpituzumab Tesirine","moa":"Delta-like protein 3 | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemcentrx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemcentrx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemcentrx \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Rovalpituzumab Tesirine","moa":"Delta-like protein 3 | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Auto-Dendritic Adjuvant Therapy","moa":"Dendritic cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PT Prodia StemCell Indonesia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PT Prodia StemCell Indonesia \/ Undisclosed"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Activated Dendritic Cell","moa":"Dendritic cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwest Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwest Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"DCVAC","moa":"Dendritic cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Medical Biotechnology | CyTIX","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Dendritic Cell","moa":"Dendritic cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Medical Biotechnology | CyTIX","highestDevelopmentStatusID":"7","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Medical Biotechnology | CyTIX"},{"orgOrder":0,"company":"University Hospital Antwerp","sponsor":"Algemeen Ziekenhuis Maria Middelares | Vitaz | Kom Op Tegen Kanker | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Dendritic Cell Vacce","moa":"Dendritic cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Antwerp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital Antwerp \/ Algemeen Ziekenhuis Maria Middelares | Vitaz | Kom Op Tegen Kanker | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Antwerp \/ Algemeen Ziekenhuis Maria Middelares | Vitaz | Kom Op Tegen Kanker | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMS-986408","moa":"DGKA\/DGK-zeta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brequinar","moa":"DHODH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Creek Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clear Creek Bio \/ Undisclosed"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RP7214","moa":"DHODH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATX-559","moa":"DHX9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATX-559","moa":"DHX9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASP1570","moa":"Diacylglycerol kinase zeta (DGKZ)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Leap Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"DKN-01","moa":"Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johannes Gutenberg University Mainz \/ Leap Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Johannes Gutenberg University Mainz \/ Leap Therapeutics"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Leap Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"DKN-01","moa":"Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NYU Langone Health \/ Leap Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Leap Therapeutics"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Sirexatamab","moa":"||Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"West China Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"Dihydrofolate reductase | Thymidylate synthase | GAR transformylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"West China Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"West China Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"West China Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"Dihydrofolate reductase | Thymidylate synthase | GAR transformylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Clinical Trials Centre Cologne | Klinik f\u00fcr H\u00e4matologie Aachen | Medizinische Klinik W\u00fcrzburg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F2G Limited \/ Clinical Trials Centre Cologne | Klinik f\u00fcr H\u00e4matologie Aachen | Medizinische Klinik W\u00fcrzburg","highestDevelopmentStatusID":"7","companyTruncated":"F2G Limited \/ Clinical Trials Centre Cologne | Klinik f\u00fcr H\u00e4matologie Aachen | Medizinische Klinik W\u00fcrzburg"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BXCL701","moa":"Dipeptidyl peptidase 8 (DPP-8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BIW-8962","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"National Cancer Institute | Bristol Myers Squibb | AnYxis Immuno-Oncology | Provenance Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"hu14.18-IL2","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ National Cancer Institute | Bristol Myers Squibb | AnYxis Immuno-Oncology | Provenance Biopharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University of Wisconsin, Madison \/ National Cancer Institute | Bristol Myers Squibb | AnYxis Immuno-Oncology | Provenance Biopharmaceuticals"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GC4711","moa":"||Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Momotaro-Gene","sponsor":"The Pacific Link Consulting Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ad5-SGE-REIC\/Dkk3","moa":"DKK-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Momotaro-Gene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momotaro-Gene \/ The Pacific Link Consulting Co","highestDevelopmentStatusID":"7","companyTruncated":"Momotaro-Gene \/ The Pacific Link Consulting Co"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Arizona \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Arizona \/ Amgen Inc"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"||DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Compass Therapeutics | ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CTX-009","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Compass Therapeutics | ABL Bio","highestDevelopmentStatusID":"7","companyTruncated":"HANDOK \/ Compass Therapeutics | ABL Bio"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ES104","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"ARCE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ARD103","moa":"DMD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ARCE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARCE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ARCE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SpectraCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpectraCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpectraCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpectraCure \/ Undisclosed"},{"orgOrder":0,"company":"SpectraCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpectraCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpectraCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpectraCure \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4t M\u00fcnster","sponsor":"photonamic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Universit\u00e4t M\u00fcnster","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4t M\u00fcnster \/ photonamic","highestDevelopmentStatusID":"7","companyTruncated":"Universit\u00e4t M\u00fcnster \/ photonamic"},{"orgOrder":0,"company":"Hemerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hemerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hemerion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allarity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allarity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai International Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai International Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai International Medical Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai International Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai International Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai International Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai International Medical Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai International Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Cancer Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ningbo Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ningbo Cancer Hospital \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ningbo Cancer Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Cancer Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ningbo Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ningbo Cancer Hospital \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ningbo Cancer Hospital \/ Undisclosed"},{"orgOrder":0,"company":"University College, London","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University College, London \/ Merck & Co"},{"orgOrder":0,"company":"InhaTarget Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InhaTarget Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InhaTarget Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InhaTarget Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Aim ImmunoTech | National Cancer Institute | The University of Pittsburgh School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roswell Park Cancer Institute \/ Aim ImmunoTech | National Cancer Institute | The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Aim ImmunoTech | National Cancer Institute | The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"National Cancer Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Genentech"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ National Cancer Institute"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Privo Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Privo Technologies \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Julie E. Bauman","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Julie E. Bauman","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Julie E. Bauman \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Julie E. Bauman \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Medical Dermatology Specialists","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical Dermatology Specialists","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medical Dermatology Specialists \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Medical Dermatology Specialists \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Medical Devices Co., Ltd. Japan","sponsor":"JIMRO Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Medical Devices Co., Ltd. Japan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Medical Devices Co., Ltd. Japan \/ JIMRO Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Medical Devices Co., Ltd. Japan \/ JIMRO Co., Ltd."},{"orgOrder":0,"company":"medac","sponsor":"IKP","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ IKP","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ IKP"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SonALAsense \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Undisclosed"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ascentawits Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AST-3424","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentawits Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentawits Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentawits Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Loyola University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Loyola University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Cristina Gasparetto","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cristina Gasparetto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristina Gasparetto \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Cristina Gasparetto \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sherif Farag, MB, BS","sponsor":"Hoosier Cancer Research Network | Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sherif Farag, MB, BS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sherif Farag, MB, BS \/ Hoosier Cancer Research Network | Teva Pharmaceutical Industries","highestDevelopmentStatusID":"7","companyTruncated":"Sherif Farag, MB, BS \/ Hoosier Cancer Research Network | Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Bristol Myers Squibb | National Cancer Institute | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Bristol Myers Squibb | National Cancer Institute | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Bristol Myers Squibb | National Cancer Institute | National Institutes of Health"},{"orgOrder":0,"company":"Vaishalee Kenkre","sponsor":"Epizyme | University of Wisconsin, Madison","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaishalee Kenkre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaishalee Kenkre \/ Epizyme | University of Wisconsin, Madison","highestDevelopmentStatusID":"7","companyTruncated":"Vaishalee Kenkre \/ Epizyme | University of Wisconsin, Madison"},{"orgOrder":0,"company":"GERCOR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GERCOR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GERCOR \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GERCOR \/ Undisclosed"},{"orgOrder":0,"company":"Hellenic Oncology Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Oncology Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Oncology Research Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Oncology Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione Policlinico Universitario Agostino Gemelli","sponsor":"Istituto Mario Negri | Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fondazione Policlinico Universitario Agostino Gemelli","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Policlinico Universitario Agostino Gemelli \/ Istituto Mario Negri | Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Fondazione Policlinico Universitario Agostino Gemelli \/ Istituto Mario Negri | Foundation Medicine"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Spanish Breast Cancer Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Spanish Breast Cancer Research Group","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Spanish Breast Cancer Research Group"},{"orgOrder":0,"company":"Insightec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Undisclosed"},{"orgOrder":0,"company":"Insightec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Undisclosed"},{"orgOrder":0,"company":"Hoosier Cancer Research Network","sponsor":"University of Sydney | Australia New Zealand Gynaecological Oncology Group | Neuphoria Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hoosier Cancer Research Network","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoosier Cancer Research Network \/ University of Sydney | Australia New Zealand Gynaecological Oncology Group | Neuphoria Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hoosier Cancer Research Network \/ University of Sydney | Australia New Zealand Gynaecological Oncology Group | Neuphoria Therapeutics"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"National Cancer Institute | Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Varian Medical Systems","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Varian Medical Systems"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | AstraZeneca"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | Merck & Co"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nisha Mohindra, MD","sponsor":"Hoosier Cancer Research Network | Merck & Co | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nisha Mohindra, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nisha Mohindra, MD \/ Hoosier Cancer Research Network | Merck & Co | Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Nisha Mohindra, MD \/ Hoosier Cancer Research Network | Merck & Co | Celgene Corporation"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | Bayer AG"},{"orgOrder":0,"company":"University of Washington","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ AbbVie Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CPX-351","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Jazz Pharmaceuticals | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CPX-351","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ Jazz Pharmaceuticals | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Jazz Pharmaceuticals | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Guenther Koehne","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CPX-351","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guenther Koehne","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guenther Koehne \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Guenther Koehne \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Cancer Hospital \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Henan Cancer Hospital \/ Pregene"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Cancer Hospital \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Henan Cancer Hospital \/ Pregene"},{"orgOrder":0,"company":"Jichi Medical University","sponsor":"Takara Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jichi Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jichi Medical University \/ Takara Bio","highestDevelopmentStatusID":"7","companyTruncated":"Jichi Medical University \/ Takara Bio"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"National Cancer Institute, France | Fondation ARC | Merck & Co | Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ National Cancer Institute, France | Fondation ARC | Merck & Co | Transgene","highestDevelopmentStatusID":"7","companyTruncated":"Institut Bergoni\u00e9 \/ National Cancer Institute, France | Fondation ARC | Merck & Co | Transgene"},{"orgOrder":0,"company":"The Christie NHS Foundation Trust","sponsor":"Merck & Co | University of Liverpool | University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Christie NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Christie NHS Foundation Trust \/ Merck & Co | University of Liverpool | University of Manchester","highestDevelopmentStatusID":"7","companyTruncated":"The Christie NHS Foundation Trust \/ Merck & Co | University of Liverpool | University of Manchester"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"National Cancer Institute | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ National Cancer Institute | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ National Cancer Institute | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Bellicum Pharmaceuticals | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals | National Cancer Institute"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Genentech | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Genentech | Oregon Health and Science University","highestDevelopmentStatusID":"7","companyTruncated":"OHSU Knight Cancer Institute \/ Genentech | Oregon Health and Science University"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"KSQ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ KSQ Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ KSQ Therapeutics"},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"Masonic Cancer Center, University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intima Bioscience \/ Masonic Cancer Center, University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bioscience \/ Masonic Cancer Center, University of Minnesota"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instil Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Instil Bio \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"PromiCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ PromiCell Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ PromiCell Therapeutics"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prescient Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Fernando Cabanillas","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fernando Cabanillas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fernando Cabanillas \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Fernando Cabanillas \/ Sanofi"},{"orgOrder":0,"company":"University of Regensburg","sponsor":"ClinAssess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dacarbazine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Regensburg","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Regensburg \/ ClinAssess","highestDevelopmentStatusID":"7","companyTruncated":"University of Regensburg \/ ClinAssess"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kintara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kintara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Templates \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Agenus"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Hallberg Management AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Hallberg Management AB","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Hallberg Management AB"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Quotient Sciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Parexel | National Cheng-Kung University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Parexel | National Cheng-Kung University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Parexel | National Cheng-Kung University Hospital"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Pfizer Inc | EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promontory Therapeutics \/ Pfizer Inc | EMD Serono","highestDevelopmentStatusID":"7","companyTruncated":"Promontory Therapeutics \/ Pfizer Inc | EMD Serono"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phosplatin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Promontory Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phosplatin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phosplatin Therapeutics \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Merck & Co | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"INT230-6","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ Merck & Co | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Merck & Co | Bristol Myers Squibb"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Francisco \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Jazz Pharmaceuticals | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Jazz Pharmaceuticals | Stand Up To Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital of Philadelphia \/ Jazz Pharmaceuticals | Stand Up To Cancer"},{"orgOrder":0,"company":"Antonio Calles Blanco","sponsor":"MEDSIR | PharmaMar | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antonio Calles Blanco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Antonio Calles Blanco \/ MEDSIR | PharmaMar | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Antonio Calles Blanco \/ MEDSIR | PharmaMar | Merck & Co"},{"orgOrder":0,"company":"Poveda, Andr\u00e9s, M.D.","sponsor":"AstraZeneca | PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Poveda, Andr\u00e9s, M.D.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poveda, Andr\u00e9s, M.D. \/ AstraZeneca | PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Poveda, Andr\u00e9s, M.D. \/ AstraZeneca | PharmaMar"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONCOtherapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"ONCOtherapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NEO212","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeOnc Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeOnc Technologies \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"NOVE-HiDAC","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"OBI-3424","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AllVascular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AllVascular","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AllVascular \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AllVascular \/ Undisclosed"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PEN-866 Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Tarveda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Pinnacle Biologics | Simphotek Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Photofrin Porfimer Sodium","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Pinnacle Biologics | Simphotek Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Pinnacle Biologics | Simphotek Inc."},{"orgOrder":0,"company":"Spirogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SG2000","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spirogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spirogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spirogen \/ Undisclosed"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SONALA-001","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SonALAsense \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Undisclosed"},{"orgOrder":0,"company":"Armando Santoro","sponsor":"Humanitas Research Hospital | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Armando Santoro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armando Santoro \/ Humanitas Research Hospital | GSK","highestDevelopmentStatusID":"7","companyTruncated":"Armando Santoro \/ Humanitas Research Hospital | GSK"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Ningbo Yinzhou People\u2019s Hospital | Huizhou Municipal Central Hospital | BoYuan RunSheng Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Ningbo Yinzhou People\u2019s Hospital | Huizhou Municipal Central Hospital | BoYuan RunSheng Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Ningbo Yinzhou People\u2019s Hospital | Huizhou Municipal Central Hospital | BoYuan RunSheng Pharma"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Reliable Cancer Therapies | Anticancer Fund, Belgium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Reliable Cancer Therapies | Anticancer Fund, Belgium","highestDevelopmentStatusID":"7","companyTruncated":"University of Ulm \/ Reliable Cancer Therapies | Anticancer Fund, Belgium"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Robert H. Lurie Cancer Center | National Comprehensive Cancer Network | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Robert H. Lurie Cancer Center | National Comprehensive Cancer Network | GSK","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ Robert H. Lurie Cancer Center | National Comprehensive Cancer Network | GSK"},{"orgOrder":0,"company":"Radiation Therapy Oncology Group","sponsor":"National Cancer Institute | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radiation Therapy Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology"},{"orgOrder":0,"company":"NeuGATE Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeuGATE Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuGATE Theranostics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeuGATE Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Institut Bergoni\u00e9 \/ PharmaMar"},{"orgOrder":0,"company":"Grupo Espanol de Investigacion en Sarcomas","sponsor":"Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espanol de Investigacion en Sarcomas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Investigacion en Sarcomas \/ Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espanol de Investigacion en Sarcomas \/ Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group"},{"orgOrder":0,"company":"Sarcoma Oncology Research Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Oncology Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Oncology Research Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Oncology Research Center \/ Undisclosed"},{"orgOrder":0,"company":"Sarcoma Alliance for Research through Collaboration","sponsor":"Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Alliance for Research through Collaboration","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Alliance for Research through Collaboration \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Alliance for Research through Collaboration \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Clinical Trial Center North | Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Clinical Trial Center North | Servier","highestDevelopmentStatusID":"7","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Clinical Trial Center North | Servier"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Trifluridine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Taiho Oncology"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Modulight, Inc. | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Verteporfin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Modulight, Inc. | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Modulight, Inc. | National Cancer Institute"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Universitair Ziekenhuis Brussel","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Universitair Ziekenhuis Brussel","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Universitair Ziekenhuis Brussel \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Universitair Ziekenhuis Brussel \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"National Comprehensive Cancer Network | Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ National Comprehensive Cancer Network | Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ National Comprehensive Cancer Network | Taiho Oncology"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Pfizer Inc | Van Andel Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Pfizer Inc | Van Andel Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"University of Maryland, Baltimore \/ Pfizer Inc | Van Andel Research Institute"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Astex Pharmaceuticals | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Astex Pharmaceuticals | Genentech"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmascience Inc. \/ Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier","highestDevelopmentStatusID":"7","companyTruncated":"Pharmascience Inc. \/ Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"AstraZeneca | Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ AstraZeneca | Astex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ AstraZeneca | Astex Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Taiho Oncology"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Novartis Pharmaceuticals Corporation | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation | Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation | Eisai Inc"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TACL Consortium \/ Undisclosed"},{"orgOrder":0,"company":"Epibone","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EB-CMF","moa":"DNA \/ Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epibone","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epibone \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epibone \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"ASTX727","moa":"DNA [cytosine-5]-methyltransferase (DNMT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Michael Savona","sponsor":"Incyte Corporation | Theradex | Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"ASTX727","moa":"DNA [cytosine-5]-methyltransferase (DNMT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Michael Savona","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Savona \/ Incyte Corporation | Theradex | Astex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Michael Savona \/ Incyte Corporation | Theradex | Astex Pharmaceuticals"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"Golden Biotechnology \/ Covance"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"||DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Bristol Myers Squibb | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Bristol Myers Squibb | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Bristol Myers Squibb | Merck & Co"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jonathan Brammer","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonathan Brammer","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonathan Brammer \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Jonathan Brammer \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"GSK | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lamivudine","moa":"DNA | DNA polymerase\/reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ GSK | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ GSK | Gilead Sciences"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baptist Health \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Baptist Health \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Peter MacCallum Cancer Centre","sponsor":"Movember Foundation | Medical Research Future Fund | Advanced Accelerator Applications | E.J. Whitten Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peter MacCallum Cancer Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peter MacCallum Cancer Centre \/ Movember Foundation | Medical Research Future Fund | Advanced Accelerator Applications | E.J. Whitten Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Peter MacCallum Cancer Centre \/ Movember Foundation | Medical Research Future Fund | Advanced Accelerator Applications | E.J. Whitten Foundation"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Van Andel Research Institute | Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Guadecitabine Sodium","moa":"DNA methyltransferase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Van Andel Research Institute | Astex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Van Andel Research Institute | Astex Pharmaceuticals"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Undisclosed"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Illinois, Chicago \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"7","companyTruncated":"University of Illinois, Chicago \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"PrECOG","sponsor":"GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PrECOG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrECOG \/ GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PrECOG \/ GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Targazyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targazyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targazyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targazyme \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Second People's Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Second People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Second People's Hospital \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Second People's Hospital \/ Pregene"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Cancer Hospital \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Henan Cancer Hospital \/ Pregene"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intima Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"DNA repair protein RAD51 homolog 1 (RAD51)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F FLT","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"FF-10502-01","moa":"DNA synthesis (DNA synth)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm holding \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Pfizer Inc | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Pfizer Inc | Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ Pfizer Inc | Ipsen"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8010","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8010","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8010","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"University of Southern California \/ National Cancer Institute | Ipsen"},{"orgOrder":0,"company":"Brown University","sponsor":"Merrimack Pharmaceuticals | Rhode Island Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Merrimack Pharmaceuticals | Rhode Island Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Merrimack Pharmaceuticals | Rhode Island Hospital"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Taiho Oncology | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Taiho Oncology | Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Taiho Oncology | Ipsen"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Undisclosed"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Edison Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Undisclosed"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Cerulean Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Cerulean Pharma","highestDevelopmentStatusID":"7","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Cerulean Pharma"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I | Tumor-associated calcium signal transducer 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gustave Roussy \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gustave Roussy \/ AstraZeneca"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Worldwide Clinical Trials | National Center for Research and Development, Poland","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WPD Pharmaceuticals \/ Worldwide Clinical Trials | National Center for Research and Development, Poland","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Worldwide Clinical Trials | National Center for Research and Development, Poland"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WPD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EnGeneIC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Herbert Irving Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center"},{"orgOrder":0,"company":"NanoCarrier Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"NC 6300","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoCarrier Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoCarrier Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanoCarrier Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SQ3370","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Doxorubicin","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Expanded Collaboration","leadProduct":"Doxorubicin","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Shasqi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Arcus Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Arcus Biosciences"},{"orgOrder":0,"company":"Shasqi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Undisclosed"},{"orgOrder":0,"company":"Shasqi","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ National Cancer Institute"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vosaroxin","moa":"DNA topoisomerase II | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vosaroxin","moa":"DNA topoisomerase II | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Michaela Liedtke","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amrubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Michaela Liedtke","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michaela Liedtke \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Michaela Liedtke \/ Celgene Corporation"},{"orgOrder":0,"company":"Peking Union Medical College","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Insightec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Undisclosed"},{"orgOrder":0,"company":"Insightec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Sunstate Biosciences LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Sunstate Biosciences LLC","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Irvine \/ Sunstate Biosciences LLC"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bristol Myers Squibb | Barbara Ann Karmanos Cancer Institute | British Columbia Cancer Agency","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Barbara Ann Karmanos Cancer Institute | British Columbia Cancer Agency","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Barbara Ann Karmanos Cancer Institute | British Columbia Cancer Agency"},{"orgOrder":0,"company":"Huijing Wu","sponsor":"Beijing Xisike Clinical Oncology Research Foundation | CSPC Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Huijing Wu","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huijing Wu \/ Beijing Xisike Clinical Oncology Research Foundation | CSPC Pharmaceutical Group","highestDevelopmentStatusID":"7","companyTruncated":"Huijing Wu \/ Beijing Xisike Clinical Oncology Research Foundation | CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Hui Zeng","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hui Zeng","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hui Zeng \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Hui Zeng \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD7648","moa":"DNA-dependent protein kinase catalytic (PRKDC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HLX208","moa":"DPP-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||DPP8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Brown University","sponsor":"Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Rhode Island Hospital | Bristol Myers Squibb | Oncoceutics Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"Dopamine D2 receptor (D2R)||DRD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Oncoceutics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Chimerix \/ Oncoceutics Inc"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BAY86-9766","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Heidelberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"WX-554","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heidelberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heidelberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heidelberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Spirita Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"E6201","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Mitogen-activated protein kinase kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spirita Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spirita Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spirita Oncology \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Verastem Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Chicago \/ Verastem Oncology"},{"orgOrder":0,"company":"Adrienne G. Waks","sponsor":"Verastem Oncology | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adrienne G. Waks","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adrienne G. Waks \/ Verastem Oncology | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Adrienne G. Waks \/ Verastem Oncology | Eli Lilly"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Institute of Cancer Research, United Kingdom \/ Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cobimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cobimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Columbia University \/ Genentech"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpringWorks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pimasertib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"Sheffield Teaching Hospitals NHS Foundation Trust","sponsor":"University of Birmingham | AstraZeneca | Thermo Fisher Scientific | Cancer Research UK | University of Sheffield","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sheffield Teaching Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sheffield Teaching Hospitals NHS Foundation Trust \/ University of Birmingham | AstraZeneca | Thermo Fisher Scientific | Cancer Research UK | University of Sheffield","highestDevelopmentStatusID":"7","companyTruncated":"Sheffield Teaching Hospitals NHS Foundation Trust \/ University of Birmingham | AstraZeneca | Thermo Fisher Scientific | Cancer Research UK | University of Sheffield"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Cancer Research UK | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Cancer Research UK | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"University of Birmingham \/ Cancer Research UK | AstraZeneca"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Chest Hospital \/ BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ GSK"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Celldex Therapeutics"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TACL Consortium \/ Undisclosed"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Stand Up To Cancer | Canadian Breast Cancer Foundation | Ontario Institute for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CFI-402257","moa":"Dual specificity protein kinase TTK (MPS1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Stand Up To Cancer | Canadian Breast Cancer Foundation | Ontario Institute for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Canadian Cancer Trials Group \/ Stand Up To Cancer | Canadian Breast Cancer Foundation | Ontario Institute for Cancer Research"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Dual specificity protein kinase TTK (MPS1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Dual specificity protein kinase TTK (MPS1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFI-402257","moa":"Dual specificity protein kinase TTK (MPS1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CV6 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"VK-2019","moa":"EBNA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Eutilex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"EBViNT Cell","moa":"EBV antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eutilex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eutilex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eutilex \/ Undisclosed"},{"orgOrder":0,"company":"Xinqiao Hospital, Chongqing","sponsor":"TCRCure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"EBV-specific TCR-T cell","moa":"EBV antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xinqiao Hospital, Chongqing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma"},{"orgOrder":0,"company":"Xinqiao Hospital, Chongqing","sponsor":"TCRCure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"EBV-specific TCR-T cell","moa":"EBV antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xinqiao Hospital, Chongqing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma"},{"orgOrder":0,"company":"Shanghai Blueray Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BR1733","moa":"EED","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Blueray Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Blueray Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Blueray Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Tianjin Medical University Cancer Institute and Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Anti-EGFR Antibody","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Tianjin Medical University Cancer Institute and Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Tianjin Medical University Cancer Institute and Hospital"},{"orgOrder":0,"company":"Formation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AVID100","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Formation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Formation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BBT-176","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"BLU-945","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0.62,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Zai Lab"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BLU-945","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clifutinib Besylate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clifutinib Besylate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DF9001","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"DF9001","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedCloud Bio \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"RedCloud Bio \/ Parexel"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedCloud Bio \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"7","companyTruncated":"RedCloud Bio \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedCloud Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RedCloud Bio \/ Undisclosed"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedCloud Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RedCloud Bio \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10376","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"In3Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Undisclosed"},{"orgOrder":0,"company":"In3Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Undisclosed"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Undisclosed"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Undisclosed"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Undisclosed"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Undisclosed"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"JS212","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"JS212","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.53000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ORIC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ORIC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ORIC Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"ORIC Pharmaceuticals \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"ORIC Pharmaceuticals \/ Nextech"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ORIC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ORIC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Simmitinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Antares Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antares Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antares Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0.62,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VelaVigo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"VBC101","moa":"EGFR | C-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VelaVigo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VelaVigo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VelaVigo \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Biotheus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BNT3212","moa":"EGFR | HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Biotheus","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Biotheus"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-361175","moa":"EGFR C797S\/EGFR T790M\/EGFR exon 19 deletion","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xcovery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-361175","moa":"EGFR C797S\/EGFR T790M\/EGFR exon 19 deletion","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xcovery \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xcovery \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"STX-241","moa":"EGFR exon 21 mutation\/EGFR-Ex19del","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"STX-241","moa":"EGFR exon 21 mutation\/EGFR-Ex19del","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pierre Fabre \/ Scorpion Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Scorpion Therapeutics"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR Exon20ins mutant (EGFR Exon20ins)||EGFR*","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"REGN7075","moa":"EGFR\/CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||EGFR\/CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"West China Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pyrotinib Maleate","moa":"EGFR\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"West China Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"West China Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"West China Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BMS-986507","moa":"EGFR\/HER3\/Topoisomerase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Red Tree Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicara Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Bicara Therapeutics \/ Red Tree Venture Capital","highestDevelopmentStatusID":"7","companyTruncated":"Bicara Therapeutics \/ Red Tree Venture Capital"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"Ficerafusp Alpha","moa":"EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicara Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicara Therapeutics \/ Biocon","highestDevelopmentStatusID":"7","companyTruncated":"Bicara Therapeutics \/ Biocon"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR|HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MRG003","moa":"\nEGFR\/Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MRG003","moa":"\nEGFR\/Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ISIS EIF4E Rx","moa":"EIF4E","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ISIS EIF4E Rx","moa":"EIF4E","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"||Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Denileukin Diftitox","moa":"||Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Isoray","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cesium-131","moa":"Emitter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Cincinnati \/ Isoray","highestDevelopmentStatusID":"7","companyTruncated":"University of Cincinnati \/ Isoray"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"Rhenium","moa":"Emitter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"Rhenium","moa":"Emitter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Roswell Park Cancer Institute | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRACON Pharmaceuticals \/ Roswell Park Cancer Institute | US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Roswell Park Cancer Institute | US Department of Defense"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Orinove","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"ORIN1001","moa":"Endoplasmic reticulum to nucleus signaling 1 (ERN1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orinove","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orinove \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orinove \/ Undisclosed"},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ENB003","moa":"Endothelin B receptor (EDNRB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENB Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ENB003","moa":"||Endothelin B receptor (EDNRB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENB Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ENB003","moa":"||Endothelin B receptor (EDNRB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENB Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CPI-1205","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Constellation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Constellation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SHR2554","moa":"Enhancer of zeste homolog 2 (EZH2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DRP-104","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dracen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"INCB001158","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"INCB001158","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"INCB001158","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"INCB001158","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB001158","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calithera Biosciences \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"National Pediatric Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Oregon Health & Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Oregon Health & Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Oregon Health & Sciences"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"VolitionRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ VolitionRx","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ VolitionRx"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"National Pediatric Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"enzyme inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salarius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LY3039478","moa":"enzyme inhibitors: gamma secretase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"4SC AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"4SC-202","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SC AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4SC AG \/ Undisclosed"},{"orgOrder":0,"company":"GNT Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GNT Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GNT Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GNT Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viracta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viracta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Resminostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YAKULT HONSHA CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"4SC AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Resminostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SC AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4SC AG \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Chroma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tefinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ Chroma Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Queen Mary University of London \/ Chroma Therapeutics"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"VRx-3996","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viracta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Cancer Research Uk","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Cancer Research Uk","highestDevelopmentStatusID":"7","companyTruncated":"Sosei Heptares \/ Cancer Research Uk"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HTL0039732","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cancer Research UK \/ Nxera Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Nxera Pharma"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"KB004","moa":"EphA3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MBRC-101","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MBrace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BicycleTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"BT5528","moa":"Ephrin type-A receptor 2 (EPHA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BicycleTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BicycleTx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BicycleTx \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ National OncoVenture","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ National OncoVenture"},{"orgOrder":0,"company":"ProActa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tarloxotinib","moa":"Epidermal growth factor receptor||Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProActa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProActa \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProActa \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"Affimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NKGen Biotech \/ Affimed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Affimed"},{"orgOrder":0,"company":"Shenzhen Second People's Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"EGFR CART","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Second People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Second People's Hospital \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Second People's Hospital \/ Pregene"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MCLA-158","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MM-151","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"MM-151","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merrimack Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merrimack Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Symphogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Sym013","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Symphogen \/ Undisclosed"},{"orgOrder":0,"company":"Symphogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Sym015","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Symphogen \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAK-186","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"ABT-414","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Dept. of Radiation Oncology, Heidelberg | University Hospital Heidelberg | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heidelberg University \/ Dept. of Radiation Oncology, Heidelberg | University Hospital Heidelberg | Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Heidelberg University \/ Dept. of Radiation Oncology, Heidelberg | University Hospital Heidelberg | Merck Group"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Merck Group | Leiden University Medical Center | Academisch Ziekenhuis Maastricht | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medisch Spectrum Twente | Medical Center Haaglanden | Elisabeth-T","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Merck Group | Leiden University Medical Center | Academisch Ziekenhuis Maastricht | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medisch Spectrum Twente | Medical Center Haaglanden | Elisabeth-T","highestDevelopmentStatusID":"7","companyTruncated":"Radboud University Medical Center \/ Merck Group | Leiden University Medical Center | Academisch Ziekenhuis Maastricht | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medisch Spectrum Twente | Medical Center Haaglanden | Elisabeth-T"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Erlotinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Groupe Francophone des Myelodysplasies \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NCIC Clinical Trials Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Erlotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NCIC Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NCIC Clinical Trials Group \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"NCIC Clinical Trials Group \/ GSK"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Beijing CSCO-Allist Cancer Research Foundation | Shanghai Allist Pharmaceuticals Co.,Ltd. | Guangzhou Burning Rock Medical Examination Institute Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Beijing CSCO-Allist Cancer Research Foundation | Shanghai Allist Pharmaceuticals Co.,Ltd. | Guangzhou Burning Rock Medical Examination Institute Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Beijing CSCO-Allist Cancer Research Foundation | Shanghai Allist Pharmaceuticals Co.,Ltd. | Guangzhou Burning Rock Medical Examination Institute Co., Ltd."},{"orgOrder":0,"company":"Spanish Lung Cancer Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spanish Lung Cancer Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Lung Cancer Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spanish Lung Cancer Group \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"HLX07","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HLX07","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HLX07","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib Succinate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Eli Lilly | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Necitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Eli Lilly | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Eli Lilly | Genentech"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amsterdam UMC, VUmc \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Amsterdam UMC, VUmc \/ Amgen Inc"},{"orgOrder":0,"company":"The Queen Elizabeth Hospital","sponsor":"Amgen Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Queen Elizabeth Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Queen Elizabeth Hospital \/ Amgen Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"The Queen Elizabeth Hospital \/ Amgen Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Georgetown University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Panitumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Wisconsin, Madison \/ Amgen Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PF-06747775","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"RM-1929","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Undisclosed"},{"orgOrder":0,"company":"Symphogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sym004","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Symphogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Symphogen \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Zalutumumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"LYZZ Alpha Holding","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LYZZ Alpha Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LYZZ Alpha Holding \/ Tigermed","highestDevelopmentStatusID":"7","companyTruncated":"LYZZ Alpha Holding \/ Tigermed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Covance"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ LabCorp"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"||Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"China Merchants Bank International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ China Merchants Bank International","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ China Merchants Bank International"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpimAb Biotherapeutics \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ LabCorp"},{"orgOrder":0,"company":"QIMR Berghofer Medical Research Institute","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QIMR Berghofer Medical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics"},{"orgOrder":0,"company":"Centre Georges Fran\u00e7ois Leclerc","sponsor":"GSK | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lapatinib Ditosylate","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Georges Fran\u00e7ois Leclerc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Georges Fran\u00e7ois Leclerc \/ GSK | Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Centre Georges Fran\u00e7ois Leclerc \/ GSK | Sanofi"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lapatinib Ditosylate","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ GSK"},{"orgOrder":0,"company":"Qingdao Zhixin Health Technology","sponsor":"The Affiliated Hospital of Qingdao University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pyrotinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qingdao Zhixin Health Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qingdao Zhixin Health Technology \/ The Affiliated Hospital of Qingdao University","highestDevelopmentStatusID":"7","companyTruncated":"Qingdao Zhixin Health Technology \/ The Affiliated Hospital of Qingdao University"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-4 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-4 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Pfizer Inc"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-4 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Pfizer Inc"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Acea Bio | ACEA Pharmaceutical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abivertinib","moa":"Epidermal growth factor receptor erbB1 | Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Acea Bio | ACEA Pharmaceutical Research","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Acea Bio | ACEA Pharmaceutical Research"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GRWD5769","moa":"ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"ICG\u2019s Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"GRWD5769","moa":"ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab-conjugated IRDye 700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"ERBB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zongertinib","moa":"ERBB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MRG002","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MRG002","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MRG002","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Klus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"A166","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Klus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klus Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Klus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fudan University","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"GQ1001","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"7","companyTruncated":"Fudan University \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ISB 1302","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"SBT6050","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silverback Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Silverback Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series B Financing","leadProduct":"SBT6050","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silverback Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Silverback Therapeutics \/ Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Silverback Therapeutics \/ Venture Partners"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Beroterkib","moa":"ERK||Extracellular signal-regulated kinase 1 (ERK1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Mosaic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Beroterkib","moa":"ERK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Mosaic Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Mosaic Therapeutics"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Erasca"},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Pierre Fabre"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IPN01194","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"HH2710","moa":"ERK1\/ERK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Axcentua Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AXP107-11","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Axcentua Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Axcentua Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Axcentua Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pantarhei Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pantarhei Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pantarhei Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pantarhei Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Debiopharm","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Debiopharm"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EnhancedBio","sponsor":"Zenopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"ZB716","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnhancedBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnhancedBio \/ Zenopharm","highestDevelopmentStatusID":"7","companyTruncated":"EnhancedBio \/ Zenopharm"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"H3B-6545","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"H3B-6545","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H3 Biomedicine Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H3 Biomedicine Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"H3 Biomedicine Inc \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OP-1250","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OP-1250","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Zeno Alpha Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zeno Alpha Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeno Alpha Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zeno Alpha Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zeno Alpha Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zeno Alpha Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeno Alpha Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zeno Alpha Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zeno Alpha Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zeno Alpha Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeno Alpha Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zeno Alpha Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Tybourne Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"ZN-c5","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Tybourne Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Tybourne Capital Management"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Context Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Context Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Neoantigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chlorotrianisene","moa":"Estrogen receptor beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Neoantigen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Neoantigen Therapeutics"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Royal DSM \/ Humanetics","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"Sofya Pintova","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sofya Pintova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofya Pintova \/ Royal DSM","highestDevelopmentStatusID":"7","companyTruncated":"Sofya Pintova \/ Royal DSM"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eltanexor","moa":"exportin 1 inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eltanexor","moa":"exportin 1 inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eltanexor","moa":"exportin 1 inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eltanexor","moa":"exportin 1 inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Fudan University | Antengene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Fudan University | Antengene","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Fudan University | Antengene"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Karyopharm Therapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Karyopharm Therapeutics | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Karyopharm Therapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Xia Zhongjun","sponsor":"Antengene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xia Zhongjun","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xia Zhongjun \/ Antengene","highestDevelopmentStatusID":"7","companyTruncated":"Xia Zhongjun \/ Antengene"},{"orgOrder":0,"company":"Martin Gutierrez","sponsor":"Hackensack Meridian Health | Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Martin Gutierrez","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martin Gutierrez \/ Hackensack Meridian Health | Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Martin Gutierrez \/ Hackensack Meridian Health | Karyopharm Therapeutics"},{"orgOrder":0,"company":"Tong Chen, MD","sponsor":"Antengene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tong Chen, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tong Chen, MD \/ Antengene","highestDevelopmentStatusID":"7","companyTruncated":"Tong Chen, MD \/ Antengene"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Funding","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HH2853","moa":"EZH1\/EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HH2853","moa":"EZH1\/EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA Greater Los Angeles Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA Greater Los Angeles Healthcare System","highestDevelopmentStatusID":"7","companyTruncated":"VA Office of Research and Development \/ VA Greater Los Angeles Healthcare System"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"XNW5004","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evopoint Biosciences \/ Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd."},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"XNW5004","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XNW5004","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Incuron | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CBL0137","moa":"Facilitates chromatin transcription complex (FACT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Incuron | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ Incuron | National Cancer Institute"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"68-Ga FAP-2286","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novita Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NP-G2-044","moa":"Fascin (FSCN1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novita Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novita Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novita Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novita Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NP-G2-044","moa":"Fascin (FSCN1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novita Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novita Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novita Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"BioInvent | Bloodwise","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BI-1206","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ BioInvent | Bloodwise","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ BioInvent | Bloodwise"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Cancer Research"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BI-1206","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ BioInvent"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Kaixin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Divestment","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Kaixin Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Kaixin Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BI-1607","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BI-1607","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Tianjin Tasly Group","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"LondonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LondonPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"LondonPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LondonPharma \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"||FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Allink Biotherapeutics","sponsor":"Lanchi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"ALK201","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Allink Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Shanghai Allink Biotherapeutics \/ Lanchi Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Allink Biotherapeutics \/ Lanchi Ventures"},{"orgOrder":0,"company":"Shanghai Allink Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ALK201","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Allink Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Allink Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Allink Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Carlsbad Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Carlsbad Technology","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Carlsbad Technology"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DZD6008","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DZD6008","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DZD6008","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DZD6008","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"EverNov Medicines","sponsor":"Medidata Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EVER4010001","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EverNov Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EverNov Medicines \/ Medidata Solutions","highestDevelopmentStatusID":"7","companyTruncated":"EverNov Medicines \/ Medidata Solutions"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Shanghai Yingli Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"YL-13027","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Shanghai Yingli Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Shanghai Yingli Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"YL-13027","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"YL-13027","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YL-13027","moa":"FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"University of Heidelberg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ University of Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ University of Heidelberg"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotopia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Isotopia","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotopia"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Novartis Innovative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Divestment","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Novartis Innovative Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Novartis Innovative Therapies"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"3B Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ 3B Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ 3B Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"AZD4547","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Cancer Research UK | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"AZD4547","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Cancer Research UK | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Cancer Research UK | AstraZeneca"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Derazantinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Merck & Co"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Derazantinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ LabCorp"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ BeOne Medicines"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Elevar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"Fibroblast growth factor receptor 2 (FGFR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"Fibroblast growth factor receptor 3 | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation | Genentech"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"Fibroblast growth factor receptor 3 | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roblitinib","moa":"Fibroblast growth factor receptor 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roblitinib","moa":"||Fibroblast growth factor receptor 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"L19IL2","moa":"Fibronectin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Eudax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"131-I F16SIP","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Eudax","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Eudax"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"131-I L19SIP","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Micvotabart Pelidotin","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Deep Track Capital"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Auristatin","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ The University of Chicago"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Arix Bioscience Plc","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Arix Bioscience Plc"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Pfizer Inc"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Termination","leadProduct":"Pembrolizumab","moa":"||FIt3 ligand","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":1.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Injection","sponsorNew":"Turnstone Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"National Institutes of Health | National Institute of Neurological Disorders and Stroke | Office of Rare Diseases | National Center for Advancing Translational Sciences | Novartis Pharmaceuticals Corporation | PTEN Research | Gansu Provincial Maternal and","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boston Children's Hospital \/ National Institutes of Health | National Institute of Neurological Disorders and Stroke | Office of Rare Diseases | National Center for Advancing Translational Sciences | Novartis Pharmaceuticals Corporation | PTEN Research | Gansu Provincial Maternal and","highestDevelopmentStatusID":"7","companyTruncated":"Boston Children's Hospital \/ National Institutes of Health | National Institute of Neurological Disorders and Stroke | Office of Rare Diseases | National Center for Advancing Translational Sciences | Novartis Pharmaceuticals Corporation | PTEN Research | Gansu Provincial Maternal and"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Utah","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Guangdong Provincial People's Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangdong Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Guangdong Provincial People's Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Guangdong Provincial People's Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation | New York University | University of Hawaii","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation | New York University | University of Hawaii","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation | New York University | University of Hawaii"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Southern Europe New Drug Organization","sponsor":"Novartis Pharmaceuticals Corporation | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Southern Europe New Drug Organization","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Southern Europe New Drug Organization \/ Novartis Pharmaceuticals Corporation | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Southern Europe New Drug Organization \/ Novartis Pharmaceuticals Corporation | Bayer AG"},{"orgOrder":0,"company":"Southern Europe New Drug Organization","sponsor":"Novartis Pharmaceuticals Corporation | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Southern Europe New Drug Organization","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Southern Europe New Drug Organization \/ Novartis Pharmaceuticals Corporation | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Southern Europe New Drug Organization \/ Novartis Pharmaceuticals Corporation | Merck & Co"},{"orgOrder":0,"company":"Hans J. van der Vliet, MD, PhD","sponsor":"Dutch Cancer Society | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hans J. van der Vliet, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hans J. van der Vliet, MD, PhD \/ Dutch Cancer Society | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Hans J. van der Vliet, MD, PhD \/ Dutch Cancer Society | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"MaineHealth","sponsor":"Desmoid Tumor Research Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaineHealth","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc"},{"orgOrder":0,"company":"University of Washington","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Aadi Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Aadi Bioscience"},{"orgOrder":0,"company":"Sherif S. Farag","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sherif S. Farag","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sherif S. Farag \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sherif S. Farag \/ Celgene Corporation"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Pfizer Inc | Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Pfizer Inc | Mundipharma","highestDevelopmentStatusID":"7","companyTruncated":"Charite University, Berlin, Germany \/ Pfizer Inc | Mundipharma"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Puma Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Puma Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Georg Hess","sponsor":"Pfizer Inc | Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georg Hess","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georg Hess \/ Pfizer Inc | Mundipharma","highestDevelopmentStatusID":"7","companyTruncated":"Georg Hess \/ Pfizer Inc | Mundipharma"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NMS-03592088","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Aptose Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tuspetinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Aptose Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Aptose Biosciences"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GB3226","moa":"FLT3 | MLLT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Ellipses Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Institute of Cancer Research \/ Ellipses Pharma","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Ellipses Pharma"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"RX-5902","moa":"fluoroquinolone derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Undisclosed"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Folate","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isofol Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Isofol Medical \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Sutro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"STRO-002","moa":"Folate receptor alpha (FOLR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Sutro Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Sutro Biopharma"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Children's Oncology Group | Innovative Therapies for Children with Cancer Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Children's Oncology Group | Innovative Therapies for Children with Cancer Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Children's Oncology Group | Innovative Therapies for Children with Cancer Consortium"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Ally Bridge Group","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Ally Bridge Group"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Acapatamab","moa":"FOLH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Acapatamab","moa":"FOLH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Eribulin","moa":"||FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.1000000000000001,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Sequoia China","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Sequoia China","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Sequoia China"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Synaffix"},{"orgOrder":0,"company":"Kancera","sponsor":"NSGO-CTU","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kancera \/ NSGO-CTU","highestDevelopmentStatusID":"7","companyTruncated":"Kancera \/ NSGO-CTU"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Cancer Institute | Henry Ford Health System | Medical College of Wisconsin | University of Maryland, Baltimore | Milwaukee VA Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BIO300","moa":"Free radical","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ National Cancer Institute | Henry Ford Health System | Medical College of Wisconsin | University of Maryland, Baltimore | Milwaukee VA Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ National Cancer Institute | Henry Ford Health System | Medical College of Wisconsin | University of Maryland, Baltimore | Milwaukee VA Medical Center"},{"orgOrder":0,"company":"Philogen","sponsor":"Innopharma Inc | Eudax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"L19TNF","moa":"fusion proteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Innopharma Inc | Eudax","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Innopharma Inc | Eudax"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"L19TNF","moa":"fusion proteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Onfekafusp Alfa","moa":"fusion proteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Linical | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Linical | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Linical | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"PureTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PureTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PureTech \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Galectin-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"Replimune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"RP1","moa":"GALV-GP R-protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Replimune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Replimune \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Expanded Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0.63,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Seagen"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"AlaMab Therapeutics","sponsor":"CSPC ZhongQi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ALMB-0168","moa":"Gap junction alpha-1 protein (GJA1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AlaMab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlaMab Therapeutics \/ CSPC ZhongQi","highestDevelopmentStatusID":"7","companyTruncated":"AlaMab Therapeutics \/ CSPC ZhongQi"},{"orgOrder":0,"company":"CatalYm","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Series D Financing","leadProduct":"Nivolumab","moa":"||GDF15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CatalYm \/ Canaan Partners","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ Canaan Partners"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BMS-986156","moa":"GIT receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"OBI-888","moa":"Globohexaosylceramide (Globo H)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"OBI-888","moa":"Globohexaosylceramide (Globo H)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"OBI-999","moa":"Globohexaosylceramide (Globo H)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"OBI-999","moa":"Globohexaosylceramide (Globo H)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"OBI-999","moa":"Globohexaosylceramide (Globo H)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GlyPharma Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"FE 203799","moa":"Glucagon-like peptide 2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GlyPharma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlyPharma Therapeutics \/ VectivBio","highestDevelopmentStatusID":"7","companyTruncated":"GlyPharma Therapeutics \/ VectivBio"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Medpace, Inc"},{"orgOrder":0,"company":"Enceladus Pharmaceuticals","sponsor":"University Hospital Aachen | Accelovance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enceladus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enceladus Pharmaceuticals \/ University Hospital Aachen | Accelovance","highestDevelopmentStatusID":"7","companyTruncated":"Enceladus Pharmaceuticals \/ University Hospital Aachen | Accelovance"},{"orgOrder":0,"company":"Tanja Andrea Gruber","sponsor":"Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tanja Andrea Gruber","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CORT125281","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"HPN424","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HPN424","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HPN424","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LAVA-1207","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"REGN4336","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"REGN5678","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc"},{"orgOrder":0,"company":"Yuan Yuan","sponsor":"Agenus | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yuan Yuan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuan Yuan \/ Agenus | Gateway for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Yuan Yuan \/ Agenus | Gateway for Cancer Research"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"National Cancer Institute | Calithera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Calithera Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ National Cancer Institute | Calithera Biosciences"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Telaglenestat","moa":"Glutaminase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ascentawits Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AST-001","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentawits Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentawits Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentawits Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Jarrow Formulas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Jarrow Formulas","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Irvine \/ Jarrow Formulas"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actuate Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"LY2090314","moa":"Glycogen synthase kinase-3 beta | Glycogen synthase kinase-3 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Mayo Clinic"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"E-602","moa":"Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Sotio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Sotio","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Sotio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SAR444200","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Targovax \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ AstraZeneca"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Theradex Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex Oncology"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"ONCOS-102","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"Cancer Research Institute, New York City | MedImmune | Targovax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"ONCOS-102","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ludwig Institute for Cancer Research \/ Cancer Research Institute, New York City | MedImmune | Targovax","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ Cancer Research Institute, New York City | MedImmune | Targovax"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"US Department of Defense | Regeneron Pharmaceuticals | Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Degarelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ US Department of Defense | Regeneron Pharmaceuticals | Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"University of Wisconsin, Madison \/ US Department of Defense | Regeneron Pharmaceuticals | Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"David H. Koch Charitable Foundation | BioSante Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Degarelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ David H. Koch Charitable Foundation | BioSante Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ David H. Koch Charitable Foundation | BioSante Pharmaceuticals"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Aeterna Zentaris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Zoptarelin Doxorubicin","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Aeterna Zentaris","highestDevelopmentStatusID":"7","companyTruncated":"University of Southern California \/ National Cancer Institute | Aeterna Zentaris"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Miami | Miami VA Healthcare System | University of Miami Sylvester Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Zoptarelin Doxorubicin","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aeterna Zentaris \/ University of Miami | Miami VA Healthcare System | University of Miami Sylvester Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Aeterna Zentaris \/ University of Miami | Miami VA Healthcare System | University of Miami Sylvester Comprehensive Cancer Center"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VERU-100","moa":"Gonadotropin-releasing hormone receptor (GNRHR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TAI-GPC3-CAR-T","moa":"GPC3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai GeneChem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai GeneChem \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MRG006A","moa":"GPC3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C-CAR031","moa":"GPC3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai AbelZeta Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linnaeus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PTT-4256","moa":"GPR65","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pathios Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PTT-4256","moa":"GPR65","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pathios Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"PTT-4256","moa":"GPR65","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathios Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pathios Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Forimtamig","moa":"GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Forimtamig","moa":"GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"JX-594","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Transgene"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"BP1001","moa":"GRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Tipiracil HCl","moa":"||Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cancer Research \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Aravive | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Aravive | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Aravive | AstraZeneca"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Dalantercept","moa":"Growth\/differentiation factor 2 | Bone morphogenetic protein 10","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hana Pharm","sponsor":"Bold Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hana Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hana Pharm \/ Bold Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hana Pharm \/ Bold Therapeutics"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bold Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bold Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"177-Lu NeoB","moa":"GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR Bombesin","moa":"||GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"68-Ga NeoB","moa":"GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga NeoB","moa":"GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"68-Ga RM2","moa":"GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Criterium","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Amgen Inc"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Rain Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Rain Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of South Carolina \/ Rain Oncology"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Devalingam Mahalingam","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Devalingam Mahalingam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Devalingam Mahalingam \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Devalingam Mahalingam \/ Amgen Inc"},{"orgOrder":0,"company":"Anova Pharma","sponsor":"NeOnc Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Perillyl Alcohol","moa":"GTPase NRas (NRAS)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anova Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anova Pharma \/ Neonc Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Anova Pharma \/ Neonc Technologies"},{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Perillyl Alcohol","moa":"GTPase NRas (NRAS)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeOnc Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeOnc Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Frontier Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Frontier Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Frontier Medicine \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Deep Track Capital"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Frontier Medicine \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Deerfield Management"},{"orgOrder":0,"company":"Sabine Mueller, MD, PhD","sponsor":"The V Foundation for Cancer Research | Pacific Pediatric Neuro-Oncology Consortium | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"H3.3K27M","moa":"H3F3A (H3.3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sabine Mueller, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sabine Mueller, MD, PhD \/ The V Foundation for Cancer Research | Pacific Pediatric Neuro-Oncology Consortium | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sabine Mueller, MD, PhD \/ The V Foundation for Cancer Research | Pacific Pediatric Neuro-Oncology Consortium | Bristol Myers Squibb"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BlueSphere Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Undisclosed"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BlueSphere Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Undisclosed"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BlueSphere Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Undisclosed"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BlueSphere Bio \/ Celularity","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Celularity"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"HA-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SCG101","moa":"HBsAg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCG Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG101","moa":"HBsAg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCG Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SCG101","moa":"HBsAg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCG Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HB-302","moa":"HBV PreS1\/PreS2\/S antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CG200745","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CrystalGenomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Undisclosed"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CG200745","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CrystalGenomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Undisclosed"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CG200745","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CrystalGenomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Undisclosed"},{"orgOrder":0,"company":"Celleron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CXD101","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celleron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celleron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celleron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CG200745","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CrystalGenomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Purinostat Mesylate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Purinostat Mesylate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Novelwise Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NBM-BMX","moa":"HDAC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novelwise Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novelwise Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novelwise Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Novelwise Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBM-BMX","moa":"HDAC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novelwise Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novelwise Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novelwise Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HDM2005","moa":"HDM allergens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"KW-2478","moa":"Heat shock protein 90 alpha (HSP90A)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Kirin \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Sarcoma Alliance for Research through Collaboration","sponsor":"Madrigal Pharmaceuticals | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Alliance for Research through Collaboration","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Alliance for Research through Collaboration \/ Madrigal Pharmaceuticals | US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Alliance for Research through Collaboration \/ Madrigal Pharmaceuticals | US Department of Defense"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Luminespib","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Onalespib","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Onalespib","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CTX110","moa":"Hemoglobin (HB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CTX110","moa":"Hemoglobin (HB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cobolimab","moa":"Hepatitis A virus cellular receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MBG453","moa":"Hepatitis A virus cellular receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Australasian Leukaemia & Lymphoma Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MBG-453","moa":"Hepatitis A virus cellular receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Australasian Leukaemia & Lymphoma Group","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Australasian Leukaemia & Lymphoma Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sabatolimab","moa":"Hepatitis A virus cellular receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AZD7789","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MP0250","moa":"Hepatocyte growth factor (HGF)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MP0250","moa":"Hepatocyte growth factor (HGF)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Cooperative Oncology Group","sponsor":"National Cancer Institute | ECOG-ACRIN Cancer Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AMG 337","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eastern Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Cooperative Oncology Group \/ National Cancer Institute | ECOG-ACRIN Cancer Research Group","highestDevelopmentStatusID":"7","companyTruncated":"Eastern Cooperative Oncology Group \/ National Cancer Institute | ECOG-ACRIN Cancer Research Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Capmatinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Emibetuzumab","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Onartuzumab","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Criterium","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tepotinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ EMD Serono","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ EMD Serono"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"SCRI Development Innovations, LLC \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"Hepatocyte growth factor receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Insert","sponsorNew":"University of Colorado, Denver \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"Hepatocyte growth factor receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Partnership","leadProduct":"131-I Conjugated Anti-HER2 sdAb 2Rs15d","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen Theragnostics \/ Precirix"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-1966","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biomedical Radiation Sciences","sponsor":"Swedish Cancer Society | Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"68-Ga ABY-025","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biomedical Radiation Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedical Radiation Sciences \/ Swedish Cancer Society | Affibody","highestDevelopmentStatusID":"7","companyTruncated":"Biomedical Radiation Sciences \/ Swedish Cancer Society | Affibody"},{"orgOrder":0,"company":"Precirix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precirix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Undisclosed"},{"orgOrder":0,"company":"Precirix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precirix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Undisclosed"},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ INKEF Capital"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DB-1202","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DB-1310","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HER2 BATs","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Virginia \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Virginia \/ Merck & Co"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"JSKN033","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"JSKN033","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"RC48","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"RC48-ADC","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Undisclosed"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TAC01-HER2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Merck & Co"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Undisclosed"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"ATEM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Series A Financing","leadProduct":"Cyclophosphamide","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ ATEM Capital","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ ATEM Capital"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai International Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HerinCAR-PD1","moa":"HER2\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai International Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai International Medical Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai International Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Cancer Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HerinCAR-PD1","moa":"HER2\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ningbo Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ningbo Cancer Hospital \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ningbo Cancer Hospital \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Biotheus | MediLink Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BNT326","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Biotheus | MediLink Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Biotheus | MediLink Therapeutics"},{"orgOrder":0,"company":"BioNTech","sponsor":"Biotheus | MediLink Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BNT326","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Biotheus | MediLink Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Biotheus | MediLink Therapeutics"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cancer Research UK \/ Hummingbird Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"George Clinical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ George Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ George Clinical"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Merck Group"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"IBI133","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Ahmad Tarhini","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AMG102","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ahmad Tarhini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ahmad Tarhini \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ahmad Tarhini \/ Amgen Inc"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NiKang Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Huntsman Cancer Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Huntsman Cancer Institute | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Huntsman Cancer Institute | National Cancer Institute"},{"orgOrder":0,"company":"Tianhong Li","sponsor":"National Cancer Institute | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianhong Li","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianhong Li \/ National Cancer Institute | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Tianhong Li \/ National Cancer Institute | Merck & Co"},{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xynomic Pharmaceuticals \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Xynomic Pharmaceuticals \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Herlev Hospital","sponsor":"Copenhagen University Hospital at Herlev | Bispebjerg Hospital | Valerio Therapeutics | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Herlev Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herlev Hospital \/ Copenhagen University Hospital at Herlev | Bispebjerg Hospital | Valerio Therapeutics | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Herlev Hospital \/ Copenhagen University Hospital at Herlev | Bispebjerg Hospital | Valerio Therapeutics | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Valerio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Valerio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Acrotech Biopharma \/ Valerio Therapeutics"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Entinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Entinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Merck Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Entinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Merck Group | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Merck Group | Pfizer Inc"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Entinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Onyx Therapeutics | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Onyx Therapeutics | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"SCRI Development Innovations, LLC \/ Onyx Therapeutics | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ronald Hoffman","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ronald Hoffman","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ronald Hoffman \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Ronald Hoffman \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sabine Mueller, MD, PhD","sponsor":"Midatech Pharma | Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sabine Mueller, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sabine Mueller, MD, PhD \/ Midatech Pharma | Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Sabine Mueller, MD, PhD \/ Midatech Pharma | Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Midatech Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Midatech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Bloodwise | Bristol Myers Squibb | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Birmingham \/ Bloodwise | Bristol Myers Squibb | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Birmingham \/ Bloodwise | Bristol Myers Squibb | Amgen Inc"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"Bristol Myers Squibb | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GWT-TUD \/ Bristol Myers Squibb | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"GWT-TUD \/ Bristol Myers Squibb | AstraZeneca"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Celgene Corporation"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Celgene Corporation"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"St. Francis Hospital & Medical Center | Weill Medical College of Cornell University | University of Nebraska | Celgene Corporation | Biologics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ St. Francis Hospital & Medical Center | Weill Medical College of Cornell University | University of Nebraska | Celgene Corporation | Biologics, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ St. Francis Hospital & Medical Center | Weill Medical College of Cornell University | University of Nebraska | Celgene Corporation | Biologics, Inc."},{"orgOrder":0,"company":"Columbia University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Columbia University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Priyanka Sharma","sponsor":"Celgene Corporation | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Priyanka Sharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priyanka Sharma \/ Celgene Corporation | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Priyanka Sharma \/ Celgene Corporation | Bristol Myers Squibb"},{"orgOrder":0,"company":"Ryan Wilcox","sponsor":"University of Michigan Rogel Cancer Center | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryan Wilcox","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryan Wilcox \/ University of Michigan Rogel Cancer Center | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Ryan Wilcox \/ University of Michigan Rogel Cancer Center | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mocetinostat","moa":"Histone deacetylase 2 | Histone deacetylase 1 | Histone deacetylase 11 | Histone deacetylase 3 | Histone deacetylase 8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mocetinostat","moa":"Histone deacetylase 2 | Histone deacetylase 1 | Histone deacetylase 11 | Histone deacetylase 3 | Histone deacetylase 8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"MethylGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mocetinostat","moa":"Histone deacetylase 2 | Histone deacetylase 1 | Histone deacetylase 11 | Histone deacetylase 3 | Histone deacetylase 8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ MethylGene","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ MethylGene"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"MethylGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mocetinostat","moa":"Histone deacetylase 2 | Histone deacetylase 1 | Histone deacetylase 11 | Histone deacetylase 3 | Histone deacetylase 8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ MethylGene","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ MethylGene"},{"orgOrder":0,"company":"National Center for Tumor Diseases, Heidelberg","sponsor":"University Hospital Heidelberg | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1||Histone deacetylase 3 | Histone deacetylase 2 | Histone deacetylase 1 | Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Center for Tumor Diseases, Heidelberg","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for Tumor Diseases, Heidelberg \/ University Hospital Heidelberg | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"National Center for Tumor Diseases, Heidelberg \/ University Hospital Heidelberg | Merck & Co"},{"orgOrder":0,"company":"University Hospital Freiburg","sponsor":"Merck & Co | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Freiburg","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Freiburg \/ Merck & Co | Janssen-Cilag","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Freiburg \/ Merck & Co | Janssen-Cilag"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Hackensack Meridian Health \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Merck & Co"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Merck & Co | Phoenix Children's Hospital | Hershey Medical Center | Johns Hopkins University | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins | Children's Hospital Colorado | University of Florida | Alberta Children's Hospital | MD Anderson Canc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Merck & Co | Phoenix Children's Hospital | Hershey Medical Center | Johns Hopkins University | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins | Children's Hospital Colorado | University of Florida | Alberta Children's Hospital | MD Anderson Canc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Merck & Co | Phoenix Children's Hospital | Hershey Medical Center | Johns Hopkins University | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins | Children's Hospital Colorado | University of Florida | Alberta Children's Hospital | MD Anderson Canc"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vorinostat","moa":"Histone deacetylase 2 | Histone deacetylase 3 | Histone deacetylase 6 | Histone deacetylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bristol Myers Squibb \/ Leukemia and Lymphoma Society","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Jennifer Amengual","sponsor":"Acetylon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jennifer Amengual","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jennifer Amengual \/ Acetylon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Jennifer Amengual \/ Acetylon Pharmaceuticals"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lymphoma Academic Research Organisation \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Susan Chi, MD","sponsor":"Bristol Myers Squibb | Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Susan Chi, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Susan Chi, MD \/ Bristol Myers Squibb | Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Susan Chi, MD \/ Bristol Myers Squibb | Epizyme"},{"orgOrder":0,"company":"Jacob Soumerai","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacob Soumerai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacob Soumerai \/ MEI Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Jacob Soumerai \/ MEI Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Milatuzumab","moa":"HLA-DR antigens-associated invariant chain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Milatuzumab","moa":"HLA-DR antigens-associated invariant chain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Invectys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ Undisclosed"},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ CTMA","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ CTMA"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ CTMC","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ CTMC"},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Invectys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MD Anderson Cancer Center \/ Invectys","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Invectys"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"National Cancer Institute | GE Healthcare | Siemens Medical Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Perfluorobutane","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)||Homeostasis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ National Cancer Institute | GE Healthcare | Siemens Medical Solutions","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ National Cancer Institute | GE Healthcare | Siemens Medical Solutions"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BGB-A425","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NDI-101150","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Saturn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Saturn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Saturn \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Saturn \/ Undisclosed"},{"orgOrder":0,"company":"Cellid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BVAC-E6E7","moa":"HPV E6\/HPV E7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellid","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellid \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellid \/ Undisclosed"},{"orgOrder":0,"company":"Oryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"P16_37-63","moa":"HPV E7 oncoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryx \/ Undisclosed"},{"orgOrder":0,"company":"Oryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"P16_37-63","moa":"HPV E7 oncoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryx \/ Undisclosed"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Dutch Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ISA101","moa":"HPV16 E6\/E7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Dutch Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Dutch Cancer Society"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MEDI0457","moa":"HPV16 E6\/E7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tarveda Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Locnartecan","moa":"||HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tarveda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Locnartecan","moa":"HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tarveda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Alocelyvir","moa":"HSV-1 DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain \/ Apices Soluciones","highestDevelopmentStatusID":"7","companyTruncated":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain \/ Apices Soluciones"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rznomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Undisclosed"},{"orgOrder":0,"company":"SWOG Cancer Research Network","sponsor":"National Cancer Institute | Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pegvorhyaluronidase Alfa","moa":"Hyaluronic acid","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SWOG Cancer Research Network","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SWOG Cancer Research Network \/ National Cancer Institute | Halozyme Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"SWOG Cancer Research Network \/ National Cancer Institute | Halozyme Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BMS-986226","moa":"ICOS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986242","moa":"IDO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"IFNA2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Alira Health | Arithmos | Ospedale San Raffaele","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Alira Health | Arithmos | Ospedale San Raffaele","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Alira Health | Arithmos | Ospedale San Raffaele"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"ENEA Tech and Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ ENEA Tech and Biomedical","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ ENEA Tech and Biomedical"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"IRCCS San Raffaele","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ IRCCS San Raffaele","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ IRCCS San Raffaele"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Genenta Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Genenta Science","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Genenta Science"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Financing","leadProduct":"111-In FPI-1547","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Oxford Finance","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Oxford Finance"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"BWX Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2023","type":"Agreement","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ BWX Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ BWX Technologies"},{"orgOrder":0,"company":"IGF Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"765IGF-MTX","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGF Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGF Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IGF Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ADRX-0405","moa":"IgG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adcentrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADRX-0405","moa":"IgG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adcentrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ADRX-0405","moa":"IgG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adcentrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Wugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986369","moa":"IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/IKZF3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986449","moa":"IKZF2\/IKZF4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Bio-Targeting Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"BioTTT001","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Bio-Targeting Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Bio-Targeting Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Bio-Targeting Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DF6002","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDS Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RPTR-168","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Repertoire Immune Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RPTR-168","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Repertoire Immune Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-224","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-224","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Healthcare","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Healthcare"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Capital Markets","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Capital Markets"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"STX-001","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strand Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Strand Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strand Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Strand Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Strand Therapeutics \/ Kinnevik AB","highestDevelopmentStatusID":"7","companyTruncated":"Strand Therapeutics \/ Kinnevik AB"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"ImmVira","sponsor":"China Merchants China Direct Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ China Merchants China Direct Investments","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ China Merchants China Direct Investments"},{"orgOrder":0,"company":"ImmVira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Undisclosed"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Werewolf Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Werewolf Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Development, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efarindodekin Alfa","moa":"IL-12R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Development, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Development, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Development, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Efarindodekin Alfa","moa":"IL-12R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"Xilio Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OBX-115","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series C Financing","leadProduct":"OBX-115","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Wellington Management","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Wellington Management"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RPTR-147","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RPTR-147","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Merck & Co"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AdHER2DC","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IAP0971","moa":"IL15R\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IAP0971","moa":"IL15R\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IAP0971","moa":"IL15R\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IAP0971","moa":"IL15R\/PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST-067","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simcha Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Simcha Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series B Financing","leadProduct":"Vevoctadekin","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Simcha Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"Vevoctadekin","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Simcha Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Vevoctadekin","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"XB2001","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BNT151","moa":"IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ALKS 4230","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mural Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mural Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"ALKS 4230","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mural Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mural Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Forbion"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANV419","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenge Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Undisclosed"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenge Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Undisclosed"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenge Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Undisclosed"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenge Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BNZ132-1-40","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"IOV-3001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Sentinel BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"SENT-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Made Scientific \/ Sentinel BioTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Made Scientific \/ Sentinel BioTherapeutics"},{"orgOrder":0,"company":"Selecxine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SLC-3010","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecxine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Selecxine \/ Undisclosed"},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SLC-3010","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"7","companyTruncated":"Selecxine \/ GenScript ProBio"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TransCon IL-2 Beta\/Gamma","moa":"IL-2 receptor beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AU-007","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series A Financing","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Aulos \/ Apple Tree Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Apple Tree Partners"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Merck Group"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AU-007","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alkermes Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Alkermes Plc","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Alkermes Plc"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SAR444245","moa":"||IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"THOR-707","moa":"IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Synthorx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"THOR-707","moa":"||IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImCheck Therapeutics \/ Synthorx","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Synthorx"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"THOR-707","moa":"IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alfa","moa":"IL2RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mural Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mural Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Termination","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":1.46,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Magrolimab","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Undisclosed"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genexine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Undisclosed"},{"orgOrder":0,"company":"Genexine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ NeoImmuneTech"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Ubix Therapeutics","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ubix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ubix Therapeutics \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Ubix Therapeutics \/ NeoImmuneTech"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"Genexine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"GX-I7","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Merck & Co"},{"orgOrder":0,"company":"Medikine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medikine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medikine \/ Undisclosed"},{"orgOrder":0,"company":"Medikine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medikine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medikine \/ Undisclosed"},{"orgOrder":0,"company":"Medikine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medikine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medikine \/ Undisclosed"},{"orgOrder":0,"company":"Medikine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medikine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medikine \/ Undisclosed"},{"orgOrder":0,"company":"Medikine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medikine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medikine \/ Undisclosed"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Deep Insight","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Deep Insight"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"BND-22","moa":"ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Termination","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"TJ Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TJ107","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TJ Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TJ Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TJ Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin Vaccine","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BNT112","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Cellid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Bvac-C","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellid","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellid \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellid \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"EpiCept","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ EpiCept","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ EpiCept"},{"orgOrder":0,"company":"Vastra Gotaland Region","sponsor":"Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Amino Acid","year":"2017","type":"Inapplicable","leadProduct":"Histamine Dihydrochloride","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vastra Gotaland Region","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vastra Gotaland Region \/ Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Vastra Gotaland Region \/ Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Oncovir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Polyinosinic Acid","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Oncovir","highestDevelopmentStatusID":"7","companyTruncated":"VA Office of Research and Development \/ Oncovir"},{"orgOrder":0,"company":"Immunitor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"V3-P","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunitor \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitor \/ Undisclosed"},{"orgOrder":0,"company":"Vyriad","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Vsv-Ifn-Beta-Nis","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyriad \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Vyriad \/ Mayo Clinic"},{"orgOrder":0,"company":"Vyriad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Vsv-Ifn-Beta-Nis","moa":"Immune","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyriad \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vyriad \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"AZD8205","moa":"Immune costimulatory protein B7H4 (VTCN1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"GTB-3550","moa":"Immunoglobulin gamma Fc receptor III (FCGR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.95999999999999996,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"||immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Exicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||immunomodulators: toll-like receptor agonist","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exicure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Undisclosed"},{"orgOrder":0,"company":"Exicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||immunomodulators: toll-like receptor agonist","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exicure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Undisclosed"},{"orgOrder":0,"company":"Swiss Group for Clinical Cancer Research","sponsor":"Immunophotonics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dexfenfluramine","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Swiss Group for Clinical Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Group for Clinical Cancer Research \/ Immunophotonics","highestDevelopmentStatusID":"7","companyTruncated":"Swiss Group for Clinical Cancer Research \/ Immunophotonics"},{"orgOrder":0,"company":"Immunophotonics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexfenfluramine","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunophotonics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunophotonics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunophotonics \/ Undisclosed"},{"orgOrder":0,"company":"M.R. Meijerink","sponsor":"Immunophotonics | AngioDynamics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexfenfluramine","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"M.R. Meijerink","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"M.R. Meijerink \/ Immunophotonics | AngioDynamics","highestDevelopmentStatusID":"7","companyTruncated":"M.R. Meijerink \/ Immunophotonics | AngioDynamics"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1503","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Enteric Coated","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"GEN-009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genocea \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-201","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunophotonics","sponsor":"Swiss Group for Clinical Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"N-dihydrogalactochitosan","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunophotonics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunophotonics \/ Swiss Group for Clinical Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Immunophotonics \/ Swiss Group for Clinical Cancer Research"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986205","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BMS-986205","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986205","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986205","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Edward Kim","sponsor":"Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BMS-986205","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edward Kim","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edward Kim \/ Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Edward Kim \/ Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation | National Cancer Institute"},{"orgOrder":0,"company":"James J. Lee","sponsor":"Incyte Corporation | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"James J. Lee","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James J. Lee \/ Incyte Corporation | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"James J. Lee \/ Incyte Corporation | Merck & Co"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"JTX-2011","moa":"Inducible T-cell costimulator","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"Inhibitor of apoptosis protein (hIAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"Inhibitor of apoptosis protein (hIAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"APG-1387","moa":"Inhibitor of apoptosis protein (hIAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||Inhibitor of apoptosis protein (hIAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TyrNovo Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TyrNovo Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TyrNovo Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TyrNovo Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Purple Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NT219","moa":"Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Purple Biotech","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Purple Biotech"},{"orgOrder":0,"company":"Rush University Medical Center","sponsor":"Axelar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AXL1717","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rush University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rush University Medical Center \/ Axelar","highestDevelopmentStatusID":"7","companyTruncated":"Rush University Medical Center \/ Axelar"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ganitumab","moa":"Insulin-like growth factor I receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PharmaBio Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"E7820","moa":"Integrin alpha-2 (ITGA2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ PharmaBio Development","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ PharmaBio Development"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"GB1275","moa":"Integrin alpha-M (ITGAM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Merck & Co"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB1275","moa":"||Integrin alpha-M (ITGAM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB1275","moa":"||Integrin alpha-M (ITGAM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Frontage Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Frontage Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Frontage Clinical Services"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"ProDa BioTech","sponsor":"Gabrail Cancer Center Research | Georgia State University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Proagio","moa":"Integrin-alpha-5\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProDa BioTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProDa BioTech \/ Gabrail Cancer Center Research | Georgia State University","highestDevelopmentStatusID":"7","companyTruncated":"ProDa BioTech \/ Gabrail Cancer Center Research | Georgia State University"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BI-505","moa":"Intercellular adhesion molecule-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Faron Pharmaceuticals"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Taiwan University Hospital \/ PharmaEssentia","highestDevelopmentStatusID":"7","companyTruncated":"National Taiwan University Hospital \/ PharmaEssentia"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CAN04","moa":"Interleukin 1 receptor accessory protein (IL1RAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CAN04","moa":"Interleukin 1 receptor accessory protein (IL1RAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"||Interleukin 15 receptor alpha (IL15RA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Cellular Biomedicine Group"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NKTR-255","moa":"Interleukin 15 receptor alpha (IL15RA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SAR440234","moa":"Interleukin 3 receptor alpha (IL3RA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Buzzard Pharmaceuticals","sponsor":"Baylor Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Isunakinra","moa":"interleukin-1 (IL-1) receptor antagonists","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Buzzard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buzzard Pharmaceuticals \/ Baylor Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Buzzard Pharmaceuticals \/ Baylor Research Institute"},{"orgOrder":0,"company":"3PBiovian","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Isunakinra","moa":"interleukin-1 (IL-1) receptor antagonists","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3PBiovian \/ Buzzard Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"3PBiovian \/ Buzzard Pharmaceuticals"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"EGEN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"EGEN-001","moa":"Interleukin-12 beta (IL12B)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EGEN","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EGEN \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EGEN \/ Undisclosed"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"Interleukin-15 (IL15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Almirall","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Almirall"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"Interleukin-15 (IL15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"Interleukin-15 (IL15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SAR445877","moa":"Interleukin-15 (IL15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Megan Daly, MD","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Megan Daly, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Megan Daly, MD \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Megan Daly, MD \/ Merck & Co"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"SL-401","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stanford University \/ Stemline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Stanford University \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Leukemia and Lymphoma Society","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Novartis Pharmaceuticals Corporation | EUSA Pharma | National Cancer Institute | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation | EUSA Pharma | National Cancer Institute | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Gabrail Cancer Center Research \/ Novartis Pharmaceuticals Corporation | EUSA Pharma | National Cancer Institute | National Institutes of Health"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BMS-986253","moa":"Interleukin-8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"This trial was conducted previously by Cormorant","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BMS-986253","moa":"Interleukin-8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ This trial was conducted previously by Cormorant","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ This trial was conducted previously by Cormorant"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SX-682","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"Prostate Cancer UK | Janssen Pharmaceutica | Oncology Institute of Southern Switzerland | Syntrix Pharmaceuticals | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Belfast Health and Social Care Trust | Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1|CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Institute of Cancer Research, United Kingdom \/ Prostate Cancer UK | Janssen Pharmaceutica | Oncology Institute of Southern Switzerland | Syntrix Pharmaceuticals | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Belfast Health and Social Care Trust | Institute","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ Prostate Cancer UK | Janssen Pharmaceutica | Oncology Institute of Southern Switzerland | Syntrix Pharmaceuticals | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Belfast Health and Social Care Trust | Institute"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb | Syntrix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1\/CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb | Syntrix Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb | Syntrix Pharmaceuticals"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Moffitt Cancer Center | National Heart, Lung, and Blood Institute | AdventHealth | Gabrail Cancer Center Research | University of Miami | Mayo Clinic | Montefiore Medical Center | National Cancer Institute | Sidney Kimmel Comprehensive Cancer Center, John","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1\/CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Moffitt Cancer Center | National Heart, Lung, and Blood Institute | AdventHealth | Gabrail Cancer Center Research | University of Miami | Mayo Clinic | Montefiore Medical Center | National Cancer Institute | Sidney Kimmel Comprehensive Cancer Center, John","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Pharmaceuticals \/ Moffitt Cancer Center | National Heart, Lung, and Blood Institute | AdventHealth | Gabrail Cancer Center Research | University of Miami | Mayo Clinic | Montefiore Medical Center | National Cancer Institute | Sidney Kimmel Comprehensive Cancer Center, John"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1\/CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1\/CXCR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Imunon \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Imunon \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"ALT-803","moa":"interleukins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of South Carolina \/ ImmunityBio"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"ALT-803","moa":"interleukins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Nykode Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Nykode Therapeutics"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Nektar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"||interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"NKTR-214","moa":"interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"NKTR-214","moa":"interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"NKTR-214","moa":"interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Merck & Co"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Immune Oncology Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Immune Oncology Network","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Immune Oncology Network"},{"orgOrder":0,"company":"Abivax","sponsor":"C3 Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ABX196","moa":"Invariant natural killer T-cells","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abivax \/ C3 Research Associates","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ C3 Research Associates"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ABX196","moa":"||Invariant natural killer T-cells","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Undisclosed"},{"orgOrder":0,"company":"AdvanCell","sponsor":"SV Health Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Series C Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ SV Health Investors","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ SV Health Investors"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Funding","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Medical Research Future Fund","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Medical Research Future Fund"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Collaboration","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Point Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Point Biopharma"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Series B Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Morningside Ventures","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Morningside Ventures"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Agreement","leadProduct":"64-Cu SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"RBN-2397","moa":"||ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-2397","moa":"||ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"R289","moa":"IRAK1\/IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Curis \/ Cantor Fitzgerald","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Curis \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Laidlaw & Company"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Forma Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Bristol Myers Squibb | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Bristol Myers Squibb | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Bristol Myers Squibb | AbbVie Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Stanford University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Stanford University \/ Celgene Corporation"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OPC-415","moa":"ITGB7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biotroy Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BT02","moa":"ITPRIPL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotroy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotroy Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biotroy Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ATX-295","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Volastra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Function Oncology","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Function Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Function Oncology \/ Volastra Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Function Oncology \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Volastra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Volastra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Volastra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lirilumab","moa":"Killer cell immunoglobulin-like receptor 2DL2 | Killer cell immunoglobulin-like receptor 2DL1 | Killer cell immunoglobulin-like receptor 2DL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lirilumab","moa":"Killer cell immunoglobulin-like receptor 2DL2 | Killer cell immunoglobulin-like receptor 2DL1 | Killer cell immunoglobulin-like receptor 2DL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Lirilumab","moa":"Killer cell immunoglobulin-like receptor 2DL2 | Killer cell immunoglobulin-like receptor 2DL1 | Killer cell immunoglobulin-like receptor 2DL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"PETHEMA Foundation","sponsor":"Pfizer Inc | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Filanesib","moa":"Kinesin-like protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PETHEMA Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PETHEMA Foundation \/ Pfizer Inc | Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PETHEMA Foundation \/ Pfizer Inc | Celgene Corporation"},{"orgOrder":0,"company":"NKMax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"NKMax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Undisclosed"},{"orgOrder":0,"company":"NKMax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Undisclosed"},{"orgOrder":0,"company":"NKMax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Undisclosed"},{"orgOrder":0,"company":"NKMax","sponsor":"NKGen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ NKGen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ NKGen Biotech"},{"orgOrder":0,"company":"Merck Group","sponsor":"NKMax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ NKMax","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ NKMax"},{"orgOrder":0,"company":"Kiq","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Bezuclastinib","moa":"||KIT*","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiq","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kiq \/ Unum Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kiq \/ Unum Therapeutics"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abcuro, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Natera Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Natera Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Natera Inc."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Jones","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Jones","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Jones"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GKCC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ GKCC","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ GKCC"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AMP CpG","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"AMP CpG","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JAB-23E73","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JAB-23E73","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InxMed","sponsor":"InventisBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"D1553","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ InventisBio","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ InventisBio"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"D3S-001","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Medicxi"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"D3S-001","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Garsorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"InventisBio \/ Merck & Co"},{"orgOrder":0,"company":"InventisBio","sponsor":"InxMed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Garsorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ InxMed","highestDevelopmentStatusID":"7","companyTruncated":"InventisBio \/ InxMed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Garsorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Garsorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Merck Group"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0.31,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Allist Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JAB 21822","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allist Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allist Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allist Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allist Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JAB-21822","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allist Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allist Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allist Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JAB-21822","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY3499446","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JDQ443","moa":"KRAS G12C mutant (KRAS G12C)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JDQ443","moa":"KRAS G12C mutant (KRAS G12C)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"ARV-806","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GFH375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GFH375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Verastem Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"VS-7375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"VS-7375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"Tablet","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"VS-7375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0.63,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"Tablet","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VS-7375","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Anocca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ANOC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anocca \/ Undisclosed"},{"orgOrder":0,"company":"Anocca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ANOC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anocca \/ Undisclosed"},{"orgOrder":0,"company":"Anocca","sponsor":"Mellby Gard","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"ANOC-001","moa":"||KRAS G12V","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anocca","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Anocca \/ Mellby Gard","highestDevelopmentStatusID":"7","companyTruncated":"Anocca \/ Mellby Gard"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"APTO-253","moa":"Kruppel like factor 4 (KLF4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APTO-253","moa":"Kruppel like factor 4 (KLF4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APTO-253","moa":"Kruppel like factor 4 (KLF4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"INCAGN02385","moa":"LAG3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Leads Biolabs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Chime Biologics \/ Leads Biolabs"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.77000000000000002,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ BeiGene"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BMS-986213","moa":"LAG-3|PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase||L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeglea BioTherapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"||LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"TRU-016","moa":"Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"TRU-016","moa":"Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TRU-016","moa":"Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"GEN3009","moa":"Leukocyte antigen CD37 (CD37)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Nelson Chao","sponsor":"Mereo BioPharma Group | National Center for Advancing Translational Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nelson Chao","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nelson Chao \/ Mereo BioPharma Group | National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Nelson Chao \/ Mereo BioPharma Group | National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"NGM707","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"NGM707","moa":"||Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ The Column Group"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM707","moa":"Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NGM707","moa":"Leukocyte immunoglobulin-like receptor B2 (LILRB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAR444881","moa":"Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Magrolimab","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Leukemia and Lymphoma Society","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AO-176","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arch Oncology \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arch Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Arch Oncology \/ Eventide Asset Management","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Eventide Asset Management"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Arch Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Arch Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Arch Oncology"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI188","moa":"Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"MB-CART20.1","moa":"Leukocyte surface antigen Leu-16 (CD20)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Miltenyi Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"PBCAR20A","moa":"Leukocyte surface antigen Leu-16 (CD20)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Leukocyte surface antigen Leu-16 (CD20)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"||Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Merck & Co"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCure \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Merck & Co"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NC410","moa":"Leukocyte-associated Ig-like receptor 1 (LAIR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OR502","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Undisclosed"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Undisclosed"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Undisclosed"},{"orgOrder":0,"company":"OncoResponse","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"OR502","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ CPRIT"},{"orgOrder":0,"company":"OncoResponse","sponsor":"RiverVest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"OR502","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ RiverVest Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ RiverVest Venture Partners"},{"orgOrder":0,"company":"Rgenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rgenix \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BMS-986016","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Favezelimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IMP701","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Relatlimab","moa":"Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F-star Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F-star Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Invox Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"F-star Therapeutics \/ Invox Pharma","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Invox Pharma"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F-star Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Invox Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"F-star Therapeutics \/ Invox Pharma","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Invox Pharma"},{"orgOrder":0,"company":"Invox Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FS118","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invox Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invox Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Invox Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Johnson & Johnson Innovative Medicine | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance Foundation Trials \/ Johnson & Johnson Innovative Medicine | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Alliance Foundation Trials \/ Johnson & Johnson Innovative Medicine | Bristol Myers Squibb"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"MOR202","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | Imago BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | Imago BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | Imago BioSciences"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imago BioSciences \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Washington University School of Medicine"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2879552","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 820","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ AmMax Bio","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ AmMax Bio"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"AMG820","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AmMax Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"AmMax Bio \/ Merck & Co"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ARRY-382","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Incyte Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Uma Borate","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Uma Borate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uma Borate \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Uma Borate \/ Incyte Corporation"},{"orgOrder":0,"company":"Centre Antoine Lacassagne","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Antoine Lacassagne","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Antoine Lacassagne \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Centre Antoine Lacassagne \/ GSK"},{"orgOrder":0,"company":"Centre L\u00e9on B\u00e9rard","sponsor":"Novartis Pharmaceuticals Corporation | National Cancer Institute, France","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre L\u00e9on B\u00e9rard","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre L\u00e9on B\u00e9rard \/ Novartis Pharmaceuticals Corporation | National Cancer Institute, France","highestDevelopmentStatusID":"7","companyTruncated":"Centre L\u00e9on B\u00e9rard \/ Novartis Pharmaceuticals Corporation | National Cancer Institute, France"},{"orgOrder":0,"company":"Hellenic Oncology Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Oncology Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Oncology Research Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Oncology Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Oncology Genito-Urinary Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spanish Oncology Genito-Urinary Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Oncology Genito-Urinary Group \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Spanish Oncology Genito-Urinary Group \/ GSK"},{"orgOrder":0,"company":"The Christie NHS Foundation Trust","sponsor":"Novartis Pharmaceuticals Corporation | Mateon Therapeutics | East and North Hertfordshire NHS Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Christie NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Christie NHS Foundation Trust \/ Novartis Pharmaceuticals Corporation | Mateon Therapeutics | East and North Hertfordshire NHS Trust","highestDevelopmentStatusID":"7","companyTruncated":"The Christie NHS Foundation Trust \/ Novartis Pharmaceuticals Corporation | Mateon Therapeutics | East and North Hertfordshire NHS Trust"},{"orgOrder":0,"company":"Jalid Sehouli (likely, if this is a typo)","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jalid Sehouli (likely, if this is a typo)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jalid Sehouli (likely, if this is a typo) \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Jalid Sehouli (likely, if this is a typo) \/ GSK"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Plexxikon | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Plexxikon | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Plexxikon | Merck & Co"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Plexxikon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Plexxikon","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Plexxikon"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Plexxikon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Plexxikon","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Plexxikon"},{"orgOrder":0,"company":"Hope Rugo","sponsor":"Susan G. Komen for the Cure | Plexxikon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hope Rugo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hope Rugo \/ Susan G. Komen for the Cure | Plexxikon","highestDevelopmentStatusID":"7","companyTruncated":"Hope Rugo \/ Susan G. Komen for the Cure | Plexxikon"},{"orgOrder":0,"company":"Gulam Manji","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gulam Manji","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gulam Manji \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Gulam Manji \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"BAX69","moa":"Macrophage migration inhibitory factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxalta Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baxalta Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ad-MAGEA3","moa":"MAGE-A3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Turnstone Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1-MAGEA3-NYESO","moa":"MAGEA3\/NY-ESO-1 antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IMC-C103C","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMC-C103C","moa":"||MAGE-A4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Genentech"},{"orgOrder":0,"company":"BioMed Valley Discoveries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioMed Valley Discoveries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMed Valley Discoveries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioMed Valley Discoveries \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"BioMed Valley Discoveries | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ BioMed Valley Discoveries | Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ BioMed Valley Discoveries | Incyte Corporation"},{"orgOrder":0,"company":"xCures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"xCures","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"xCures \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"xCures \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"LY2228820","moa":"MAP kinase p38 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"MAP kinase-interacting serine\/threonine-protein kinase 1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Effector Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Effector Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Atebimetinib","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Atebimetinib","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Eli Lilly"},{"orgOrder":0,"company":"Immunering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunering","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunering \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunering \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Jefferies"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Cemiplimab","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IDE-397","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Bicycle Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BT1718","moa":"Matrix metalloproteinase-14 (MMP-14)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ Bicycle Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Bicycle Therapeutics"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BT1718","moa":"Matrix metalloproteinase-14 (MMP-14)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"PEN-221","moa":"maytansinoid derivatives; peptides: inhibition of growth hormone release","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarveda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Isoray","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Merger","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Isoray","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint Molecular Targeting \/ Isoray"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint Molecular Targeting \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"Cellular tumor antigen p53 (TP53)||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Ascentage Pharma"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"TIO Discovery Engine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CFI-402411","moa":"MEK kinase kinase 1 (MAP4K1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treadwell Therapeutics \/ TIO Discovery Engine","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ TIO Discovery Engine"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CFI-402411","moa":"||MEK kinase kinase 1 (MAP4K1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CFI-402411","moa":"MEK kinase kinase 1 (MAP4K1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Iowa","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Iowa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Iowa \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Iowa \/ Amgen Inc"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"CareFusion | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ CareFusion | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ CareFusion | Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Merck & Co"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moffitt Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"OncoTherapy Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"OTS167","moa":"MELK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoTherapy Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoTherapy Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoTherapy Science \/ Undisclosed"},{"orgOrder":0,"company":"Fortis Therapeutics","sponsor":"FibroGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"FOR46","moa":"Membrane cofactor protein (CD46)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fortis Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Fortis Therapeutics \/ FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"Fortis Therapeutics \/ FibroGen"},{"orgOrder":0,"company":"Fortis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"FOR46","moa":"Membrane cofactor protein (CD46)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fortis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fortis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fortis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rahul Aggarwal","sponsor":"Fortis Therapeutics | FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"FOR46","moa":"Membrane cofactor protein (CD46)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rahul Aggarwal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rahul Aggarwal \/ Fortis Therapeutics | FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"Rahul Aggarwal \/ Fortis Therapeutics | FibroGen"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BN104","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNova Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chen Suning","sponsor":"BioNova Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BN104","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chen Suning","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chen Suning \/ BioNova Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Chen Suning \/ BioNova Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals | Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MD Anderson Cancer Center \/ Astex Pharmaceuticals | Syndax Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Astex Pharmaceuticals | Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MRX2843","moa":"MERTK\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aduro Biotech","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"CRS-207","moa":"Mesothelin (MSLN)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aduro Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aduro Biotech \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Aduro Biotech \/ Incyte Corporation"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TC-510","moa":"Mesothelin (MSLN)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCR2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"REGN5093-M114","moa":"MET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CELLABMED","sponsor":"YooYoung Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"YYB101","moa":"MET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CELLABMED","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CELLABMED \/ YooYoung Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"CELLABMED \/ YooYoung Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ BeiGene"},{"orgOrder":0,"company":"SynDevRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Evexomostat","moa":"METAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SynDevRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynDevRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SynDevRx \/ Undisclosed"},{"orgOrder":0,"company":"SynDevRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"||METAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SynDevRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynDevRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SynDevRx \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TAK-448","moa":"Metastasis-suppressor KiSS-1 (KISS1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"STC-15","moa":"METTL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Storm Therapeutics \/ Coherus Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Storm Therapeutics \/ Coherus Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Storm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"STC-15","moa":"||METTL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Coherus Biosciences \/ Storm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Biosciences \/ Storm Therapeutics"},{"orgOrder":0,"company":"Mirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MRX34","moa":"microRNA hsa-miR-34 (MIR34)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CAS 253128-41-5","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CAS 253128-41-5","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"SCRI Development Innovations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"ME-344","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MEI Pharma \/ SCRI Development Innovations, LLC","highestDevelopmentStatusID":"7","companyTruncated":"MEI Pharma \/ SCRI Development Innovations, LLC"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"SCRI Development Innovations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ME-344","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MEI Pharma \/ SCRI Development Innovations, LLC","highestDevelopmentStatusID":"7","companyTruncated":"MEI Pharma \/ SCRI Development Innovations, LLC"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Sumitomo Pharma America","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enzomenib","moa":"||MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Rad51-IN-2","moa":"Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vadastuximab Talirine","moa":"monoclonal antibodies: chimeric","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OncXerna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TJ004309","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TJ Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TJ Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TJ Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TJ011133","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TJ Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TJ Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TJ Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Alomfilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BGB-A333","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Uliledlimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Uliledlimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Tetulomab Tetraxetan Lu-177","moa":"monoclonal antibodies: mouse","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Icon Plc"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Tetulomab Tetraxetan Lu-177","moa":"monoclonal antibodies: mouse","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Tetulomab Tetraxetan Lu-177","moa":"monoclonal antibodies: mouse","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Icon Plc"},{"orgOrder":0,"company":"Rainier Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"B-701","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rainier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rainier Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rainier Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cevostamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cevostamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cevostamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Hu3F8-BsAb","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivatrotamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"REGN4018","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rainier Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Vofatamab","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rainier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rainier Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rainier Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"XmAb18087","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Xencor \/ Icon Plc"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"Iomab-B","moa":"monoclonal antibodies: tumors; iodine-containing contrast media","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Actinium pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Actinium pharmaceuticals"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Tempus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"A2B694","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2 Biotherapeutics \/ Tempus","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Tempus"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"A2B694","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2 Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"BMS-986148","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"BMS-986148","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Df1001","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ElevateBio \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Gavocabtagene Autoleucel","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Gavocabtagene Autoleucel","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCR2 Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RC88","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RC88","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RC88","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"UTC Therapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Pan-T Booster Co-Expressing Msln Car T Cell Therapy","moa":"MSLN\/T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese PLA General Hospital \/ UTC Therapeutics Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ UTC Therapeutics Inc."},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CRLX301","moa":"mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sarcoma Oncology Research Center","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Nab-Rapamycin","moa":"mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Oncology Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Oncology Research Center \/ Aadi Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Oncology Research Center \/ Aadi Bioscience"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"German Cancer Aid","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methadone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ German Cancer Aid","highestDevelopmentStatusID":"7","companyTruncated":"AIO-Studien-gGmbH \/ German Cancer Aid"},{"orgOrder":0,"company":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","sponsor":"Anjie Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AJMUC1","moa":"MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University \/ Anjie Biomedical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University \/ Anjie Biomedical Technology"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LBL-033","moa":"MUC16\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LBL-033","moa":"MUC16\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Immucin","moa":"Mucin-1 (MUC1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxil Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaxil Bio \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Centre, Singapore","sponsor":"OncoQuest | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Centre, Singapore \/ OncoQuest | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Centre, Singapore \/ OncoQuest | Bristol Myers Squibb"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OMO-103","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptomyc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/ Undisclosed"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omomyc","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptomyc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"DCR-MYC","moa":"MYCBP messenger RNA (MYCBP mRNA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dicerna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"||MyD88\/CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"||NACHT, LRR and PYD domains-containing protein 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olatec Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Olatec Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"April Salama","sponsor":"Merck & Co | Olatec Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NACHT, LRR and PYD domains-containing protein 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"April Salama","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"April Salama \/ Merck & Co | Olatec Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"April Salama \/ Merck & Co | Olatec Therapeutics"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Astellas Pharma | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Astellas Pharma | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Francisco \/ Astellas Pharma | Merck & Co"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-103","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Centre L\u00e9on B\u00e9rard","sponsor":"NETRIS Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NP137","moa":"Netrin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre L\u00e9on B\u00e9rard","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centre L\u00e9on B\u00e9rard \/ NETRIS Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Centre L\u00e9on B\u00e9rard \/ NETRIS Pharma"},{"orgOrder":0,"company":"Immunogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"IMGN901","moa":"Neural cell adhesion molecule (NCAM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Undisclosed"},{"orgOrder":0,"company":"OncoMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"OMP-59R5","moa":"Neurogenic locus notch homolog protein 3 | Neurogenic locus notch homolog protein 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoMed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OncoMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"OMP-59R5","moa":"Neurogenic locus notch homolog protein 3 | Neurogenic locus notch homolog protein 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoMed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NBE Therapeutics","sponsor":"Cmed Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"NBE-002","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NBE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NBE Therapeutics \/ Cmed Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"NBE Therapeutics \/ Cmed Clinical Services"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Zilovertamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ozuriftamab Vedotin","moa":"Neurotrophic tyrosine kinase ROR2 (ROR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"Nova Pharmaceuticals","sponsor":"Galera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Targinine","moa":"Nitric oxide synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nova Pharmaceuticals \/ Galera Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nova Pharmaceuticals \/ Galera Therapeutics"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"CNDO-109 AANK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coronado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coronado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986315","moa":"NKG2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IPH2201","moa":"NKG2-A\/NKG2-B type II integral membrane protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Monalizumab","moa":"NKG2-A\/NKG2-B type II integral membrane protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jules Bordet Institute \/ Innate Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Jules Bordet Institute \/ Innate Pharma"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Monalizumab","moa":"NKG2-A\/NKG2-B type II integral membrane protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Monalizumab","moa":"NKG2-A\/NKG2-B type II integral membrane protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CYAD-01","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Leucid Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leucid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leucid Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leucid Bio \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IPH6401","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"Tactile Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tactile Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tactile Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tactile Medical \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Olympus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Olympus","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Olympus"},{"orgOrder":0,"company":"Cellestia Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CB-103","moa":"Notch receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellestia Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cellestia Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellestia Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Glenn J. Hanna","sponsor":"Adenoid Cystic Carcinoma Research Foundation | Cellestia Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CB-103","moa":"Notch receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glenn J. Hanna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenn J. Hanna \/ Adenoid Cystic Carcinoma Research Foundation | Cellestia Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Glenn J. Hanna \/ Adenoid Cystic Carcinoma Research Foundation | Cellestia Biotech"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MB-dNPM1-TCR.1","moa":"NPM1 mutant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Miltenyi Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"Androgen receptor (AR)||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Bavdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Foundation Medicine"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TPX-0005","moa":"NT-3 growth factor receptor | Nerve growth factor receptor Trk-A | ROS1-SDC4 | Neurotrophic tyrosine kinase receptor type 2 | Proto-oncogene tyrosine-protein kinase ROS | CD74-ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TPX-0005","moa":"NT-3 growth factor receptor | Nerve growth factor receptor Trk-A | ROS1-SDC4 | Neurotrophic tyrosine kinase receptor type 2 | Proto-oncogene tyrosine-protein kinase ROS | CD74-ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK||Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK||Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK||Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"NTRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Lycera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"LYC-55716","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lycera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lycera \/ Undisclosed"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Bristol Myers Squibb | Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Guadecitabine","moa":"nucleoside antiviral or antineoplastic agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Bristol Myers Squibb | Astex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University of Southern California \/ National Cancer Institute | Bristol Myers Squibb | Astex Pharmaceuticals"},{"orgOrder":0,"company":"Ajjai Alva","sponsor":"AstraZeneca | Big Ten Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Guadecitabine","moa":"nucleoside antiviral or antineoplastic agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ajjai Alva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajjai Alva \/ AstraZeneca | Big Ten Cancer Research Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Ajjai Alva \/ AstraZeneca | Big Ten Cancer Research Consortium"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"RX-3117","moa":"nucleoside antiviral or antineoplastic agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RX-3117","moa":"nucleoside antiviral or antineoplastic agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire Vaudois","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NY-ESO-1","moa":"NY-ESO-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier Universitaire Vaudois","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire Vaudois \/ Immutep","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier Universitaire Vaudois \/ Immutep"},{"orgOrder":0,"company":"Nina Bhardwaj","sponsor":"Ludwig Institute for Cancer Research | Oncovir | Cancer Research Institute, New York City","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NY-ESO-1 Protein","moa":"NY-ESO-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nina Bhardwaj","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nina Bhardwaj \/ Ludwig Institute for Cancer Research | Oncovir | Cancer Research Institute, New York City","highestDevelopmentStatusID":"7","companyTruncated":"Nina Bhardwaj \/ Ludwig Institute for Cancer Research | Oncovir | Cancer Research Institute, New York City"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Imcnyeso","moa":"NY-ESO-1 \/ CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BH-30643","moa":"OMNI-EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlossomHill Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BlossomHill Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlossomHill Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BH-30643","moa":"OMNI-EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlossomHill Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BlossomHill Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlossomHill Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"GEN1044","moa":"Oncotrophoblast glycoprotein 5T4 (TPBG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"Aminex Therapeutics | Penn State University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"Ornithine decarboxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hershey Medical Center \/ Aminex Therapeutics | Penn State University","highestDevelopmentStatusID":"7","companyTruncated":"Hershey Medical Center \/ Aminex Therapeutics | Penn State University"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"REGN5668","moa":"Ovarian carcinoma antigen CA125 (MUC16)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beat AML, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||OX-2 membrane glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beat AML, LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Beat AML","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Samalizumab","moa":"OX-2 membrane glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beat AML \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML \/ Undisclosed"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"AgonOx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"CD134 mab","moa":"OX40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ AgonOx","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ AgonOx"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INBRX-106","moa":"OX40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inhibrx \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Inhibrx \/ Merck & Co"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BGB-A445","moa":"OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"State Key Laboratory of Respiratory Disease","sponsor":"CAS Lamvac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"P. Vivax-Infected Red Blood Cell","moa":"P. vivax antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"State Key Laboratory of Respiratory Disease","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"State Key Laboratory of Respiratory Disease \/ CAS Lamvac Biotech","highestDevelopmentStatusID":"7","companyTruncated":"State Key Laboratory of Respiratory Disease \/ CAS Lamvac Biotech"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JAB-30355","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nutshell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTS071","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nutshell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutshell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nutshell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nutshell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTS071","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nutshell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutshell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nutshell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"ALRN-6924","moa":"p53-binding protein Mdm4 (MDM4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AP402","moa":"p95HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AP402","moa":"p95HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"EO1001","moa":"Pan-ErbB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edison Oncology \/ Apollomics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Apollomics Inc"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syntara Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syntara Limited \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"||Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ University of Rochester Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Parexel Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ Parexel Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Parexel Biotech"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Undisclosed"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THE-630","moa":"Pan-variant KIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"THE-630","moa":"Pan-variant KIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"THE-630","moa":"Pan-variant KIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THE-630","moa":"Pan-variant KIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"THE-630","moa":"Pan-variant KIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Foresite Capital","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Foresite Capital"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"XNW29016","moa":"PARG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Idience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"IDX-1197","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idience \/ Undisclosed"},{"orgOrder":0,"company":"Idience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IDX-1197","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idience \/ Undisclosed"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RP12146","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RP12146","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Seoul National University Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Swedish Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Swedish Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"Zofia Piotrowska","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zofia Piotrowska","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zofia Piotrowska \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Zofia Piotrowska \/ AstraZeneca"},{"orgOrder":0,"company":"Colette Shen","sponsor":"AstraZeneca | University of North Carolina, Chapel Hill","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Colette Shen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colette Shen \/ AstraZeneca | University of North Carolina, Chapel Hill","highestDevelopmentStatusID":"7","companyTruncated":"Colette Shen \/ AstraZeneca | University of North Carolina, Chapel Hill"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Chicago \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Kansas Medical Center \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Kansas Medical Center \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"Brown University","sponsor":"Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology"},{"orgOrder":0,"company":"Vejle Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Veliparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vejle Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vejle Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Vejle Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Vejle Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Veliparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vejle Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vejle Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Vejle Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Veliparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Abbott Laboratories"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Veliparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HRS-1167","moa":"PARP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Saruparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IMP1734","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc"},{"orgOrder":0,"company":"Oryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"H-1 parvovirus","moa":"Parvovirus H-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oryx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryx \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PBP1510","moa":"PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Anaveon","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Merck & Co"},{"orgOrder":0,"company":"Anaveon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"||PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"GSK | Lixte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ GSK | Lixte","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ GSK | Lixte"},{"orgOrder":0,"company":"TTCC","sponsor":"GSK | MFAR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TTCC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTCC \/ GSK | MFAR","highestDevelopmentStatusID":"7","companyTruncated":"TTCC \/ GSK | MFAR"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"EMB-02","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EMB-02","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Capital Medical University","sponsor":"Duke University | Geneplus-Beijing Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Capital Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capital Medical University \/ Duke University | Geneplus-Beijing Co. Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Capital Medical University \/ Duke University | Geneplus-Beijing Co. Ltd."},{"orgOrder":0,"company":"Keio University","sponsor":"Merck & Co | Ohara Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Keio University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keio University \/ Merck & Co | Ohara Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Keio University \/ Merck & Co | Ohara Pharmaceutical"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Adagene Suzhou Limited | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National University Hospital, Singapore \/ Adagene Suzhou Limited | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"National University Hospital, Singapore \/ Adagene Suzhou Limited | Merck & Co"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National University Hospital, Singapore \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"National University Hospital, Singapore \/ Merck & Co"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"National Taiwan University Hospital \/ Merck & Co"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ETOP IBCSG Partners Foundation \/ Breast International Group","highestDevelopmentStatusID":"7","companyTruncated":"ETOP IBCSG Partners Foundation \/ Breast International Group"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Merck & Co"},{"orgOrder":0,"company":"University College, London","sponsor":"Celleron Therapeutics | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Celleron Therapeutics | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University College, London \/ Celleron Therapeutics | Merck & Co"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Oxford \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Oxford \/ Merck & Co"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Imperial College London \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Merck & Co"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Colorado, Denver \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Merck & Co"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al | MERCK CANADA INC | Bristol Myers Squibb | Jewish General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al | MERCK CANADA INC | Bristol Myers Squibb | Jewish General Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al | MERCK CANADA INC | Bristol Myers Squibb | Jewish General Hospital"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Merck & Co | Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Merck & Co | Lantheus Medical Imaging","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Merck & Co | Lantheus Medical Imaging"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Merck & Co | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Merck & Co | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Merck & Co | Clovis Oncology"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Merck & Co | Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Merck & Co | Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Merck & Co | Celldex Therapeutics"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fox Chase Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Fox Chase Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Brown University","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Novocure","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Novocure"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Merck & Co | Earle A. Chiles Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Merck & Co | Earle A. Chiles Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Providence Health & Services \/ Merck & Co | Earle A. Chiles Research Institute"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Prostate Cancer Foundation | Madison Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Prostate Cancer Foundation | Madison Vaccines","highestDevelopmentStatusID":"7","companyTruncated":"University of Wisconsin, Madison \/ Prostate Cancer Foundation | Madison Vaccines"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Johnson & Johnson Innovative Medicine | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Johnson & Johnson Innovative Medicine | Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Merck & Co"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ashraf Badros","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ashraf Badros","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ashraf Badros \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Ashraf Badros \/ Merck & Co"},{"orgOrder":0,"company":"Asha Nayak","sponsor":"Oncovir | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asha Nayak","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Nayak \/ Oncovir | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Asha Nayak \/ Oncovir | Merck & Co"},{"orgOrder":0,"company":"Asha Nayak","sponsor":"Merck & Co | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asha Nayak","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Nayak \/ Merck & Co | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Asha Nayak \/ Merck & Co | Gilead Sciences"},{"orgOrder":0,"company":"Chirag G. Patil","sponsor":"Merck & Co | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chirag G. Patil","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chirag G. Patil \/ Merck & Co | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Chirag G. Patil \/ Merck & Co | National Cancer Institute"},{"orgOrder":0,"company":"Arkadiusz Z. Dudek","sponsor":"Merck & Co | Big Ten Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arkadiusz Z. Dudek","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arkadiusz Z. Dudek \/ Merck & Co | Big Ten Cancer Research Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Arkadiusz Z. Dudek \/ Merck & Co | Big Ten Cancer Research Consortium"},{"orgOrder":0,"company":"Jason R. Brown","sponsor":"Hoosier Cancer Research Network | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jason R. Brown","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jason R. Brown \/ Hoosier Cancer Research Network | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jason R. Brown \/ Hoosier Cancer Research Network | Merck & Co"},{"orgOrder":0,"company":"Anne Chang","sponsor":"Merck & Co | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anne Chang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anne Chang \/ Merck & Co | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Anne Chang \/ Merck & Co | National Cancer Institute"},{"orgOrder":0,"company":"Vinita Takiar","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vinita Takiar","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vinita Takiar \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Vinita Takiar \/ Merck & Co"},{"orgOrder":0,"company":"Mamta Parikh","sponsor":"Karyopharm Therapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mamta Parikh","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mamta Parikh \/ Karyopharm Therapeutics | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Mamta Parikh \/ Karyopharm Therapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Alexander B Olawaiye","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alexander B Olawaiye","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexander B Olawaiye \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Alexander B Olawaiye \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sasanlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sintilimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Sintilimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Peking University","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking University \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Peking University \/ Innovent Biologics"},{"orgOrder":0,"company":"Shanghai Gynecologic Oncology Group","sponsor":"Shanghai Zhongshan Hospital | Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Gynecologic Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Gynecologic Oncology Group \/ Shanghai Zhongshan Hospital | Tongji Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Gynecologic Oncology Group \/ Shanghai Zhongshan Hospital | Tongji Hospital"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Innovent Biologics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"James Cleary","sponsor":"Arcus Biosciences | Lustgarten Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"James Cleary","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James Cleary \/ Arcus Biosciences | Lustgarten Foundation","highestDevelopmentStatusID":"7","companyTruncated":"James Cleary \/ Arcus Biosciences | Lustgarten Foundation"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GB263T","moa":"PD-1 \/ LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genor Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genor Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"OSE-279","moa":"PD-1\/IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OSE Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OSE Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Alpha-PD-1-mesoCAR-T Cell","moa":"PD-1\/Mesothelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AZD2936","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MHB039A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MHB039A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK112","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK112","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK112","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK112","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK112","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PDCD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"Alpha-ketoglutarate dehydrogenase (OGDH)||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Sara\u2019s Cure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adebrelimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adebrelimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Institut Curie","sponsor":"Replimune | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Curie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Curie \/ Replimune | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Institut Curie \/ Replimune | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adagene Suzhou Limited | Tempest Therapeutics | NiKang Therapeutics | Immune-Onc Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Adagene Suzhou Limited | Tempest Therapeutics | NiKang Therapeutics | Immune-Onc Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Adagene Suzhou Limited | Tempest Therapeutics | NiKang Therapeutics | Immune-Onc Therapeutics"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Translational Research in Oncology | Tesaro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Translational Research in Oncology | Tesaro","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Translational Research in Oncology | Tesaro"},{"orgOrder":0,"company":"University of Florida","sponsor":"Genentech | Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Genentech | Aveo Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Genentech | Aveo Oncology"},{"orgOrder":0,"company":"Duke University","sponsor":"Johns Hopkins University | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Johns Hopkins University | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Duke University \/ Johns Hopkins University | Genentech"},{"orgOrder":0,"company":"Abramson Cancer Center at Penn Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abramson Cancer Center at Penn Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abramson Cancer Center at Penn Medicine \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Abramson Cancer Center at Penn Medicine \/ Genentech"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Genentech | Foundation Medicine | Pfizer Inc | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance Foundation Trials \/ Genentech | Foundation Medicine | Pfizer Inc | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Alliance Foundation Trials \/ Genentech | Foundation Medicine | Pfizer Inc | Eli Lilly"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Genentech | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Genentech | Stand Up To Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Genentech | Stand Up To Cancer"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Genentech"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"SignalOne Bio, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ SignalOne Bio, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ SignalOne Bio, Inc."},{"orgOrder":0,"company":"Instituto Oncol\u00f3gico Dr. Rosell","sponsor":"F. Hoffmann-La Roche | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Instituto Oncol\u00f3gico Dr. Rosell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto Oncol\u00f3gico Dr. Rosell \/ F. Hoffmann-La Roche | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","highestDevelopmentStatusID":"7","companyTruncated":"Instituto Oncol\u00f3gico Dr. Rosell \/ F. Hoffmann-La Roche | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica"},{"orgOrder":0,"company":"Roberto Pili","sponsor":"Genentech | Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roberto Pili","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roberto Pili \/ Genentech | Syndax Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Roberto Pili \/ Genentech | Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Hospices Civils de Lyon","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospices Civils de Lyon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hospices Civils de Lyon \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Hospices Civils de Lyon \/ Merck Group"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Merck Group"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oklahoma \/ EMD Serono","highestDevelopmentStatusID":"7","companyTruncated":"University of Oklahoma \/ EMD Serono"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Vaccinex","sponsor":"University of Rochester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ University of Rochester","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ University of Rochester"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Baylor College of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | EMD Serono","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | EMD Serono"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Andrew Sharabi","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Andrew Sharabi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Andrew Sharabi \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Andrew Sharabi \/ Pfizer Inc"},{"orgOrder":0,"company":"Worldwide Innovative Network Association","sponsor":"ARC Foundation for Cancer Research | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Innovative Network Association","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Innovative Network Association \/ ARC Foundation for Cancer Research | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Innovative Network Association \/ ARC Foundation for Cancer Research | Pfizer Inc"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"GT90001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Jiangsu Alphamab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"GT90001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Jiangsu Alphamab","highestDevelopmentStatusID":"7","companyTruncated":"Kintor Pharmaceutical \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"GT90001","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Veterans General Hospital","sponsor":"FBD Biologics | National Taiwan University Hospital | Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HCB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taipei Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Veterans General Hospital \/ FBD Biologics | National Taiwan University Hospital | Chang Gung Memorial Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Taipei Veterans General Hospital \/ FBD Biologics | National Taiwan University Hospital | Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"FBD Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HCB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FBD Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FBD Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FBD Biologics \/ Undisclosed"},{"orgOrder":0,"company":"FBD Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HCB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FBD Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FBD Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FBD Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HLX301","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HLX301","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HLX301","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"LockBody Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ LockBody Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ LockBody Therapeutics"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LY3022855","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDC*line Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDC*line Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"PDC*line Pharma \/ Korea Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korea Investment Partners"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korean Investment Partners"},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qure Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qure Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qure Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TQB2450","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TQB2450","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PRS-344","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HB0036","moa":"PD-L1\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHR-1701","moa":"PD-L1\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Zhejiang Cancer Hospital | Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM2510","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Zhejiang Cancer Hospital | Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Zhejiang Cancer Hospital | Fudan University"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"IMM2510","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Instil Bio"},{"orgOrder":0,"company":"Huabo Biopharm","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HB0025","moa":"PD-L1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Huabo Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huabo Biopharm \/ Shanghai Huaota Biopharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Huabo Biopharm \/ Shanghai Huaota Biopharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI3014","moa":"PDL1|Top 1|Trop-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PM8002","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"PM8002","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nab-Paclitaxel","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Lumicell","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LUM015","moa":"PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lumicell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumicell \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Lumicell \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Institutes of Health Clinical Center | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluciclatide","moa":"peptides","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Institutes of Health Clinical Center | GE Healthcare","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Institutes of Health Clinical Center | GE Healthcare"},{"orgOrder":0,"company":"University of Washington","sponsor":"Blaze Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tozuleristide","moa":"peptides","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Blaze Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Blaze Bioscience"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ariceum Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Ariceum Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"7","companyTruncated":"Ariceum Therapeutics \/ Healthcaps India"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rimiducid","moa":"Peptidyl-prolyl cis-trans isomerase FKBP1A; Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"RSO-021","moa":"Peroxiredoxin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RS Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RS Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RS Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Cleveland Clinic"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Ibrilatazar","moa":"||Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ CTI Life Sciences"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy"},{"orgOrder":0,"company":"AGC Pharma Chemicals Europe","sponsor":"Ability Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Pharma Chemicals Europe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Pharma Chemicals Europe \/ Ability Pharma","highestDevelopmentStatusID":"7","companyTruncated":"AGC Pharma Chemicals Europe \/ Ability Pharma"},{"orgOrder":0,"company":"Shanghai JMT-Bio Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai JMT-Bio Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai JMT-Bio Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai JMT-Bio Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene \/ Undisclosed"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","highestDevelopmentStatusID":"7","companyTruncated":"PIQUR Therapeutics \/ Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Ionctura | AbbVie Inc | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Ionctura | AbbVie Inc | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Ionctura | AbbVie Inc | Bristol Myers Squibb"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ahon Pharmaceutical","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"FCN-411","moa":"PI3K?","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ahon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ahon Pharmaceutical \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ahon Pharmaceutical \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ETX-636","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ensem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ensem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tersolisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tersolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tersolisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Tersolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":2.5,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tersolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Willett Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Tersolisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Willett Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Willett Advisors"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tersolisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I||PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Canadian Cancer Trials Group \/ Pfizer Inc"},{"orgOrder":0,"company":"Australian & New Zealand Children's Haematology\/Oncology Group","sponsor":"Children's Cancer Institute Australia | The Hospital for Sick Children | Medical Research Future Fund | Kazia Therapeutics | C17 Council","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Australian & New Zealand Children's Haematology\/Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australian & New Zealand Children's Haematology\/Oncology Group \/ Children's Cancer Institute Australia | The Hospital for Sick Children | Medical Research Future Fund | Kazia Therapeutics | C17 Council","highestDevelopmentStatusID":"7","companyTruncated":"Australian & New Zealand Children's Haematology\/Oncology Group \/ Children's Cancer Institute Australia | The Hospital for Sick Children | Medical Research Future Fund | Kazia Therapeutics | C17 Council"},{"orgOrder":0,"company":"Medical Research Council","sponsor":"Aarhus University Hospital | NCRI Clinical Studies Groups | European Cancer Organisation | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pictilisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical Research Council","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical Research Council \/ Aarhus University Hospital | NCRI Clinical Studies Groups | European Cancer Organisation | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medical Research Council \/ Aarhus University Hospital | NCRI Clinical Studies Groups | European Cancer Organisation | Merck & Co"},{"orgOrder":0,"company":"Cascadian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PX-866","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cascadian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascadian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cascadian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cascadian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PX-866","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cascadian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascadian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cascadian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SAR245408","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SAR245408","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SAR245408","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"SAR245408","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Genentech | EurocanPlatform | Rather","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Taselisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Genentech | EurocanPlatform | Rather","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Genentech | EurocanPlatform | Rather"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"XL147","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"XL147","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BGB-10188","moa":"PI3-kinase delta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZX-101A","moa":"PI3-kinase delta (PIK3CD)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZX-101A","moa":"PI3-kinase delta (PIK3CD)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZX-101A","moa":"PI3-kinase delta (PIK3CD)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Korean Cancer Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Korean Cancer Study Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korean Cancer Study Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korean Cancer Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ ImmunityBio"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Priyanka Sharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Priyanka Sharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priyanka Sharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Priyanka Sharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Criterium","sponsor":"Novartis Pharmaceuticals Corporation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Novartis Pharmaceuticals Corporation | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Novartis Pharmaceuticals Corporation | Pfizer Inc"},{"orgOrder":0,"company":"Petra Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Serabelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Petra Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petra Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Petra Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | National Institutes of Health | Merck & Co | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GSK2636771","moa":"PI3-kinase p110-beta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | National Institutes of Health | Merck & Co | GSK","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | National Institutes of Health | Merck & Co | GSK"},{"orgOrder":0,"company":"Chonnam National University Hospital","sponsor":"Bayer AG | Consortium for Improving Survival of Lymphoma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chonnam National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chonnam National University Hospital \/ Bayer AG | Consortium for Improving Survival of Lymphoma","highestDevelopmentStatusID":"7","companyTruncated":"Chonnam National University Hospital \/ Bayer AG | Consortium for Improving Survival of Lymphoma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VA Office of Research and Development \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"VA Office of Research and Development \/ Bayer AG"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Bayer AG | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bayer AG | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bayer AG | Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"SecuraBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SecuraBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SecuraBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SecuraBio \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tenalisib","moa":"||PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Medpace, Inc | Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Menarini \/ Medpace, Inc | Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Medpace, Inc | Theradex"},{"orgOrder":0,"company":"Menarini","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Menarini \/ Ryvu Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AIO-Studien-gGmbH \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Muenster","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Muenster","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Muenster \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Muenster \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Boehringer Ingelheim GmbH | University of Texas Health Science Center at San Antonio | South Plains Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH | University of Texas Health Science Center at San Antonio | South Plains Oncology Consortium","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH | University of Texas Health Science Center at San Antonio | South Plains Oncology Consortium"},{"orgOrder":0,"company":"Prof. Dr. med. Dirk Schadendorf","sponsor":"Boehringer Ingelheim GmbH | medac | Alcedis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prof. Dr. med. Dirk Schadendorf","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof. Dr. med. Dirk Schadendorf \/ Boehringer Ingelheim GmbH | medac | Alcedis","highestDevelopmentStatusID":"7","companyTruncated":"Prof. Dr. med. Dirk Schadendorf \/ Boehringer Ingelheim GmbH | medac | Alcedis"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Boehringer Ingelheim GmbH | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"angiogenesis inhibitors||Platelet-derived growth factor receptor | Fibroblast growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Bristol Myers Squibb"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Olaratumab","moa":"Platelet-derived growth factor receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Consorzio Oncotech","sponsor":"Clinical Research Technology | Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Consorzio Oncotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Consorzio Oncotech \/ Clinical Research Technology | Quercegen Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Consorzio Oncotech \/ Clinical Research Technology | Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Telparevir","moa":"PLK1||Polo-like kinase 1 (PLK1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Telparevir","moa":"PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"TKM-080301","moa":"PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbutus Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arbutus Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TKM-080301","moa":"PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbutus Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arbutus Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZD9574","moa":"Poly [ADP-ribose] polymerase (PARP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CEP-9722","moa":"Poly [ADP-ribose] polymerase (PARP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD5305","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZD5305","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Bayer AG"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"National Cancer Institute | BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ National Cancer Institute | BeOne Medicines"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Hutchmed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Myriad genetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Myriad genetics","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Myriad genetics"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamiparib","moa":"||Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pamiparib","moa":"||Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Senaparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Senaparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Senaparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"NSGO-CTU","sponsor":"European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | University of Utah | Massachusetts General Hospital | Myriad genetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NSGO-CTU","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NSGO-CTU \/ European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | University of Utah | Massachusetts General Hospital | Myriad genetics","highestDevelopmentStatusID":"7","companyTruncated":"NSGO-CTU \/ European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | University of Utah | Massachusetts General Hospital | Myriad genetics"},{"orgOrder":0,"company":"Institut Paoli-Calmettes","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Paoli-Calmettes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Paoli-Calmettes \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Institut Paoli-Calmettes \/ GSK"},{"orgOrder":0,"company":"Fundaci\u00f3n CRIS","sponsor":"Ipsen | GSK | Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3n CRIS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n CRIS \/ Ipsen | GSK | Apices Soluciones","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3n CRIS \/ Ipsen | GSK | Apices Soluciones"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Translational Breast Cancer Research Consortium | Tesaro | Susan G. Komen for the Cure | Breast Cancer Research Foundation of Alabama | V Foundation for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Translational Breast Cancer Research Consortium | Tesaro | Susan G. Komen for the Cure | Breast Cancer Research Foundation of Alabama | V Foundation for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Translational Breast Cancer Research Consortium | Tesaro | Susan G. Komen for the Cure | Breast Cancer Research Foundation of Alabama | V Foundation for Cancer Research"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Bristol Myers Squibb | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Bristol Myers Squibb | GSK","highestDevelopmentStatusID":"7","companyTruncated":"University of Pennsylvania \/ Bristol Myers Squibb | GSK"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Michelle S Ludwig","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Michelle S Ludwig","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michelle S Ludwig \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Michelle S Ludwig \/ GSK"},{"orgOrder":0,"company":"Joseph Caster","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joseph Caster","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Caster \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Joseph Caster \/ GSK"},{"orgOrder":0,"company":"Fondazione IRCCS Istituto Nazionale Tumori Milano","sponsor":"GSK | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CAS No 1613220-15-7","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fondazione IRCCS Istituto Nazionale Tumori Milano","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Istituto Nazionale Tumori Milano \/ GSK | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Fondazione IRCCS Istituto Nazionale Tumori Milano \/ GSK | Eli Lilly"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Talazoparib","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Pfizer Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Stenoparib","moa":"Poly [ADP-ribose] polymerase-1 | Tankyrase 1\/2 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fluzoparib","moa":"poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aminex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AMXT1501","moa":"Polyamine transport (Poly trans)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aminex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aminex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aminex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aminex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AMXT1501","moa":"Polyamine transport (Poly trans)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aminex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aminex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aminex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NanoCarrier Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"NC-6004","moa":"polymers; antineoplastics (platinum derivatives); PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoCarrier Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoCarrier Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanoCarrier Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Genoscience Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genoscience Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genoscience Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genoscience Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Genoscience Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genoscience Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genoscience Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genoscience Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Genfit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Undisclosed"},{"orgOrder":0,"company":"Genfit","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Genfit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BY101298","moa":"PRKDC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Baiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BY101298","moa":"PRKDC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Baiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Revolution Medicines"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"BCTG Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ BCTG Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ BCTG Acquisition Corp"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"WNT974","moa":"Probable protein-cysteine N-palmitoyltransferase porcupine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Allogeneic Mobilized Peripheral Blood Cell Transplantation","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellect Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Arno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Onapristone","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Geneplus-Beijing Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Geneplus-Beijing Co. Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ Geneplus-Beijing Co. Ltd."},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"AstraZeneca | European Organisation for Research and Treatment of Cancer | VIB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ AstraZeneca | European Organisation for Research and Treatment of Cancer | VIB","highestDevelopmentStatusID":"7","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ AstraZeneca | European Organisation for Research and Treatment of Cancer | VIB"},{"orgOrder":0,"company":"UNICANCER","sponsor":"National Cancer Institute, France | AstraZeneca | Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ National Cancer Institute, France | AstraZeneca | Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"UNICANCER \/ National Cancer Institute, France | AstraZeneca | Pierre Fabre"},{"orgOrder":0,"company":"Institut Claudius Regaud","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Claudius Regaud","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Claudius Regaud \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Institut Claudius Regaud \/ AstraZeneca"},{"orgOrder":0,"company":"Centre Georges Fran\u00e7ois Leclerc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Georges Fran\u00e7ois Leclerc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca"},{"orgOrder":0,"company":"ARCAGY GINECO GROUP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ARCAGY GINECO GROUP","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCAGY GINECO GROUP \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"ARCAGY GINECO GROUP \/ AstraZeneca"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Radboud University Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"Joachim Aerts","sponsor":"Aim ImmunoTech | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joachim Aerts","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joachim Aerts \/ Aim ImmunoTech | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Joachim Aerts \/ Aim ImmunoTech | AstraZeneca"},{"orgOrder":0,"company":"Instituto Portugues de Oncologia, Francisco Gentil, Porto","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"PORTUGAL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Instituto Portugues de Oncologia, Francisco Gentil, Porto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Instituto Portugues de Oncologia, Francisco Gentil, Porto \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Instituto Portugues de Oncologia, Francisco Gentil, Porto \/ AstraZeneca"},{"orgOrder":0,"company":"University College, London","sponsor":"AstraZeneca | Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University College, London \/ AstraZeneca | Shionogi","highestDevelopmentStatusID":"7","companyTruncated":"University College, London \/ AstraZeneca | Shionogi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Mayo Clinic | Indiana University | Gabrail Cancer Center Research | National Cancer Institute | George Mason University | Thomas Jefferson University | MedImmune | Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Mayo Clinic | Indiana University | Gabrail Cancer Center Research | National Cancer Institute | George Mason University | Thomas Jefferson University | MedImmune | Bavarian Nordic","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Mayo Clinic | Indiana University | Gabrail Cancer Center Research | National Cancer Institute | George Mason University | Thomas Jefferson University | MedImmune | Bavarian Nordic"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"AstraZeneca | University of Arizona | West Penn Allegheny Health System","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ AstraZeneca | University of Arizona | West Penn Allegheny Health System","highestDevelopmentStatusID":"7","companyTruncated":"University of Maryland, Baltimore \/ AstraZeneca | University of Arizona | West Penn Allegheny Health System"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Dracen Pharmaceuticals | Fibrolamellar Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Dracen Pharmaceuticals | Fibrolamellar Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Dracen Pharmaceuticals | Fibrolamellar Cancer Foundation"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"University of Nebraska \/ AstraZeneca"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | AstraZeneca"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ AstraZeneca"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"AstraZeneca | Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca | Cedars-Sinai","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca | Cedars-Sinai"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"MedImmune | Bristol Myers Squibb | Cancer Research Institute, New York City","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ludwig Institute for Cancer Research \/ MedImmune | Bristol Myers Squibb | Cancer Research Institute, New York City","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ MedImmune | Bristol Myers Squibb | Cancer Research Institute, New York City"},{"orgOrder":0,"company":"Noah Hahn, M.D.","sponsor":"AstraZeneca | Hoosier Cancer Research Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noah Hahn, M.D.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noah Hahn, M.D. \/ AstraZeneca | Hoosier Cancer Research Network","highestDevelopmentStatusID":"7","companyTruncated":"Noah Hahn, M.D. \/ AstraZeneca | Hoosier Cancer Research Network"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"MedImmune | Cancer Research Institute, New York City","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ MedImmune | Cancer Research Institute, New York City","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ MedImmune | Cancer Research Institute, New York City"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ AstraZeneca"},{"orgOrder":0,"company":"Monika Joshi, MD","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monika Joshi, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monika Joshi, MD \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Monika Joshi, MD \/ AstraZeneca"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"Cancer Research Institute, New York City | Boehringer Ingelheim GmbH | MedImmune | CureVac | PharmaJet","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ Cancer Research Institute, New York City | Boehringer Ingelheim GmbH | MedImmune | CureVac | PharmaJet","highestDevelopmentStatusID":"7","companyTruncated":"Ludwig Institute for Cancer Research \/ Cancer Research Institute, New York City | Boehringer Ingelheim GmbH | MedImmune | CureVac | PharmaJet"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"Programmed cell death 1 ligand 1 (PD-L1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Agenus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"AGEN2034","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AK105","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK105","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Apollomics Inc | Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"APL-501","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Apollomics Inc | Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Apollomics Inc | Novotech"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sun Yat-sen University \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cetrelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Taizhou Hanzhong biomedical co. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HX008","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taizhou Hanzhong biomedical co. LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taizhou Hanzhong biomedical co. LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taizhou Hanzhong biomedical co. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"JNJ-63723283","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"JNJ-63723283","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Chest Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Adagene Suzhou Limited | Bristol Myers Squibb | Singapore Translational Cancer Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National University Hospital, Singapore \/ Adagene Suzhou Limited | Bristol Myers Squibb | Singapore Translational Cancer Consortium","highestDevelopmentStatusID":"7","companyTruncated":"National University Hospital, Singapore \/ Adagene Suzhou Limited | Bristol Myers Squibb | Singapore Translational Cancer Consortium"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"The N.1 Institute for Health | Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Hospital, Singapore \/ The N.1 Institute for Health | Natera","highestDevelopmentStatusID":"7","companyTruncated":"National University Hospital, Singapore \/ The N.1 Institute for Health | Natera"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Seoul National University Bundang Hospital | Korean Cancer Study Group | Eisai | Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Seoul National University Bundang Hospital | Korean Cancer Study Group | Eisai | Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Seoul National University Hospital \/ Seoul National University Bundang Hospital | Korean Cancer Study Group | Eisai | Ono Pharmaceutical"},{"orgOrder":0,"company":"University Hospital Hradec Kralove","sponsor":"Bristol Myers Squibb | GCP-Service International","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Hradec Kralove","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Hradec Kralove \/ Bristol Myers Squibb | GCP-Service International","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Hradec Kralove \/ Bristol Myers Squibb | GCP-Service International"},{"orgOrder":0,"company":"University Hospital, Strasbourg","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Strasbourg","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Strasbourg \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Strasbourg \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Institut Curie","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Curie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Curie \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Institut Curie \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Oslo University Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Oslo University Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Parker Institute for Cancer Immunotherapy","sponsor":"Bristol Myers Squibb | Pyxis Oncology | Cancer Research Institute, New York City","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parker Institute for Cancer Immunotherapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parker Institute for Cancer Immunotherapy \/ Bristol Myers Squibb | Pyxis Oncology | Cancer Research Institute, New York City","highestDevelopmentStatusID":"7","companyTruncated":"Parker Institute for Cancer Immunotherapy \/ Bristol Myers Squibb | Pyxis Oncology | Cancer Research Institute, New York City"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Colorado, Denver \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Bristol Myers Squibb | Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Bristol Myers Squibb | Advanced Accelerator Applications","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Bristol Myers Squibb | Advanced Accelerator Applications"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Hospital for Sick Children \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"The Hospital for Sick Children \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Ipsen | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Michigan Rogel Cancer Center \/ Ipsen | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Ipsen | Bristol Myers Squibb"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Earle A. Chiles Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Earle A. Chiles Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Providence Health & Services \/ Earle A. Chiles Research Institute"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"James and Esther King Research Program | Eli Lilly | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ James and Esther King Research Program | Eli Lilly | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ James and Esther King Research Program | Eli Lilly | Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Nektar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Nektar Therapeutics"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mark Stein","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mark Stein","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mark Stein \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Mark Stein \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Takayuki Yoshino","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takayuki Yoshino","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takayuki Yoshino \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takayuki Yoshino \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Salma Sabbour","sponsor":"BeyondSpring | Bristol Myers Squibb | Rutgers Cancer Institute of New Jersey","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salma Sabbour","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salma Sabbour \/ BeyondSpring | Bristol Myers Squibb | Rutgers Cancer Institute of New Jersey","highestDevelopmentStatusID":"7","companyTruncated":"Salma Sabbour \/ BeyondSpring | Bristol Myers Squibb | Rutgers Cancer Institute of New Jersey"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"TACL Consortium \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ravi Amaravadi, MD","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ravi Amaravadi, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ravi Amaravadi, MD \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Ravi Amaravadi, MD \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"John Kirkwood","sponsor":"Secura Bio | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"John Kirkwood","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"John Kirkwood \/ Secura Bio | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"John Kirkwood \/ Secura Bio | Bristol Myers Squibb"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"PDR001","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Asan Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"PF-06801591","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SHR-1210","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbin Medical University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Harbin Medical University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"National Cancer Institute, France | Fondation ARC | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spartalizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Bordeaux \/ National Cancer Institute, France | Fondation ARC | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Bordeaux \/ National Cancer Institute, France | Fondation ARC | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Spartalizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Spartalizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"BeOne Medicines | Huidu Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RenJi Hospital \/ BeOne Medicines | Huidu Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"RenJi Hospital \/ BeOne Medicines | Huidu Medical Sciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MEDI0680","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"MEDI0680","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK104","moa":"Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Akeso","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Akeso"},{"orgOrder":0,"company":"Akeso","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK104","moa":"Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Zhang Tao","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhang Tao","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhang Tao \/ Akeso","highestDevelopmentStatusID":"7","companyTruncated":"Zhang Tao \/ Akeso"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MGD013","moa":"Programmed cell death protein 1 | Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"Rottapharm Biotech","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CR6086","moa":"Prostanoid EP4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rottapharm Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rottapharm Biotech \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"Rottapharm Biotech \/ Agenus"},{"orgOrder":0,"company":"Arrys Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Grapiprant","moa":"Prostanoid EP4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arrys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrys Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Arrys Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-PSA","moa":"||Prostate specific antigen (KLK3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-PSA","moa":"||Prostate specific antigen (KLK3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"MTS Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ MTS Securities","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ MTS Securities"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"BPX-601","moa":"Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"GSK3326595","moa":"Protein arginine N-methyltransferase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK3326595","moa":"Protein arginine N-methyltransferase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"CAS 26833-87-4","moa":"Protein biosynthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UKRAINE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sotrastaurin","moa":"Protein kinase C (PKC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Tigilanol Tiglate","moa":"||Protein kinase C (PKC)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ QBiotics Group","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ QBiotics Group"},{"orgOrder":0,"company":"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MS-553","moa":"Protein kinase C beta (PRKCB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"MingSight Pharmaceuticals","sponsor":"Shenzhen MingSight Relin Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MS-553","moa":"Protein kinase C beta (PRKCB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MingSight Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MingSight Pharmaceuticals \/ Shenzhen MingSight Relin Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"MingSight Pharmaceuticals \/ Shenzhen MingSight Relin Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"MingSight Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MS-553","moa":"Protein kinase C beta (PRKCB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MingSight Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MingSight Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MingSight Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MingSight Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MS-553","moa":"Protein kinase C beta (PRKCB)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MingSight Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MingSight Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MingSight Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merete Haedersdal","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merete Haedersdal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merete Haedersdal \/ Leo Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merete Haedersdal \/ Leo Pharma"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Granzer Regulatory Consulting | FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Atu027","moa":"Protein kinase N3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Granzer Regulatory Consulting | FGK Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Silence Therapeutics \/ Granzer Regulatory Consulting | FGK Clinical Research"},{"orgOrder":0,"company":"Michael McHale","sponsor":"Verastem Oncology | Nine Girls Ask","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Michael McHale","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael McHale \/ Verastem Oncology | Nine Girls Ask","highestDevelopmentStatusID":"7","companyTruncated":"Michael McHale \/ Verastem Oncology | Nine Girls Ask"},{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | Cancer Research UK | Merck & Co | Verastem Oncology | University of Edinburgh | University of Southampton | University of Leicester | Queen's University, Belfast","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | Cancer Research UK | Merck & Co | Verastem Oncology | University of Edinburgh | University of Southampton | University of Leicester | Queen's University, Belfast","highestDevelopmentStatusID":"7","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | Cancer Research UK | Merck & Co | Verastem Oncology | University of Edinburgh | University of Southampton | University of Leicester | Queen's University, Belfast"},{"orgOrder":0,"company":"University of Utah","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Verastem Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Private Placement","leadProduct":"Defactinib","moa":"||Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ RA Capital Management"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JAB-3068","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"JAB-3068","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"JAB-3068","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"JAB-3068","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Jacobio","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Jacobio"},{"orgOrder":0,"company":"Allist Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JAB-3312","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allist Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allist Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Allist Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"JAB-3312","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Binimetinib","moa":"||Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CEP-18770","moa":"proteozome inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Cooperative Group for Digestive Tumours","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spanish Cooperative Group for Digestive Tumours","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Cooperative Group for Digestive Tumours \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spanish Cooperative Group for Digestive Tumours \/ Undisclosed"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandion Oncology \/ TFS Trial Form Support","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Quintiles Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Quintiles Inc"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"REGN5093","moa":"Proto-oncogene c-Met (MET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"TPX-0046","moa":"Proto-oncogene c-Ret (RET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"TPX-0046","moa":"Proto-oncogene c-Ret (RET)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ADXS31-142","moa":"PSA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"111-In FPI-1547","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Imaging Projects","sponsor":"University of Witwatersrand, South Africa | Postgraduate Institute of Medical and Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"177-lu DOTAGA-IAC","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced Imaging Projects","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Imaging Projects \/ University of Witwatersrand, South Africa | Postgraduate Institute of Medical and Research","highestDevelopmentStatusID":"7","companyTruncated":"Advanced Imaging Projects \/ University of Witwatersrand, South Africa | Postgraduate Institute of Medical and Research"},{"orgOrder":0,"company":"Bivision Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu JH020002","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bivision Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bivision Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bivision Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Norroy Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu NYM032","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Norroy Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Norroy Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Norroy Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Essen","sponsor":"Advanced Accelerator Applications | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PSMA-617","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Essen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Essen \/ Advanced Accelerator Applications | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Essen \/ Advanced Accelerator Applications | Bristol Myers Squibb"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ PSI CRO","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ PSI CRO"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu XT033","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu-rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"212-Pb VMT-alpha-NET","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Holding \/ Perspective Therapeutics"},{"orgOrder":0,"company":"Perspective Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"212-Pb VMT-alpha-NET","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Perspective Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perspective Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Perspective Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"US Department of Defense | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"225-Ac J591","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ US Department of Defense | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ US Department of Defense | Merck & Co"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"225-Ac PSMA-R2","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Series A Financing","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Convergent Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu PSMA-I&T","moa":"||PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Convergent Therapeutics \/ Ionetix","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Ionetix"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Convergent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Convergent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Expanded Collaboration","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"64-Cu LNTH-1363S","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Norroy Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"68-Ga NYM005","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Norroy Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Norroy Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Norroy Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Norroy Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"68-Ga NYM032","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Norroy Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Norroy Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Norroy Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"German Cancer Research Center","sponsor":"ABX CRO | FAU Erlangen-N\u00fcrnberg | University Hospital Freiburg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"68-Ga PSMA-11","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"German Cancer Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Cancer Research Center \/ ABX CRO | FAU Erlangen-N\u00fcrnberg | University Hospital Freiburg","highestDevelopmentStatusID":"7","companyTruncated":"German Cancer Research Center \/ ABX CRO | FAU Erlangen-N\u00fcrnberg | University Hospital Freiburg"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"68-Ga PSMA-R2","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"89-Zr Df-IAB2M","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ Undisclosed"},{"orgOrder":0,"company":"Five Eleven Pharma","sponsor":"Indiana University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ga-68 P16-093","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Five Eleven Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Five Eleven Pharma \/ Indiana University","highestDevelopmentStatusID":"7","companyTruncated":"Five Eleven Pharma \/ Indiana University"},{"orgOrder":0,"company":"Tceleron Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TmPSMA-02","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tceleron Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tceleron Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tceleron Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"LP-184","moa":"PTGR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"LP-184","moa":"PTGR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Revolution Medicines | Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"Protein-tyrosine phosphatase SHP-2 (PTPN11)||PTPN11","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Revolution Medicines | Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Revolution Medicines | Mirati Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"284490-13-7","moa":"Purine nucleoside phosphorylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PTX-200","moa":"RAC-alpha serine\/threonine-protein kinase (AKT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prescient Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RX-0201","moa":"RAC-alpha serine\/threonine-protein kinase (AKT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IPN01195","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"RAF serine\/threonine protein kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Day One Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"RAF serine\/threonine protein kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Day One Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AP-002","moa":"RANKL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Altum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai JMT-Bio Inc.","sponsor":"CSPC ZhongQi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"JMT103","moa":"RANKL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai JMT-Bio Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai JMT-Bio Inc. \/ CSPC ZhongQi","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai JMT-Bio Inc. \/ CSPC ZhongQi"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"REC-1245","moa":"RBM39","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recursion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"REC-1245","moa":"RBM39","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recursion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"REC-1245","moa":"RBM39","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recursion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"N-803","moa":"receptor molecules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"AstraZeneca | Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Netherlands Cancer Institute \/ AstraZeneca | Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ AstraZeneca | Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity","highestDevelopmentStatusID":"7","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Boehringer Ingelheim GmbH | Cancer Research UK | University of Cambridge | The Brain Tumour Charity"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Instituto Oncol\u00f3gico Dr. Rosell","sponsor":"Bioven Europe | MFAR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Instituto Oncol\u00f3gico Dr. Rosell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Oncol\u00f3gico Dr. Rosell \/ Bioven Europe | MFAR","highestDevelopmentStatusID":"7","companyTruncated":"Instituto Oncol\u00f3gico Dr. Rosell \/ Bioven Europe | MFAR"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Alphamab Oncology"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Institut Curie","sponsor":"F. Hoffmann-La Roche | Centre L\u00e9on B\u00e9rard | Groupe Hospitalier Pitie-Salpetriere | Centre Oscar Lambret | Centre Fran\u00e7ois Baclesse | Institut Bergoni\u00e9 | University Hospital, Toulouse | Institut du Cancer de Montpellier | University Hospital, Grenoble","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Curie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Curie \/ F. Hoffmann-La Roche | Centre L\u00e9on B\u00e9rard | Groupe Hospitalier Pitie-Salpetriere | Centre Oscar Lambret | Centre Fran\u00e7ois Baclesse | Institut Bergoni\u00e9 | University Hospital, Toulouse | Institut du Cancer de Montpellier | University Hospital, Grenoble","highestDevelopmentStatusID":"7","companyTruncated":"Institut Curie \/ F. Hoffmann-La Roche | Centre L\u00e9on B\u00e9rard | Groupe Hospitalier Pitie-Salpetriere | Centre Oscar Lambret | Centre Fran\u00e7ois Baclesse | Institut Bergoni\u00e9 | University Hospital, Toulouse | Institut du Cancer de Montpellier | University Hospital, Grenoble"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Pfizer Inc | Cascadian Therapeutics | Criterium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Pfizer Inc | Cascadian Therapeutics | Criterium","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Pfizer Inc | Cascadian Therapeutics | Criterium"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Providence Health & Services \/ Pfizer Inc"},{"orgOrder":0,"company":"Reva Basho","sponsor":"Merck & Co | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Reva Basho","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reva Basho \/ Merck & Co | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Reva Basho \/ Merck & Co | Pfizer Inc"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ ALX Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Jazz Pharmaceuticals \/ ALX Oncology"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"IKF Nordwest","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IKF Nordwest","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IKF Nordwest \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"IKF Nordwest \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tesevatinib","moa":"Receptor protein-tyrosine kinase erbB-2 | Epidermal growth factor receptor erbB1 | Ephrin type-B receptor 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"NSABP Foundation","sponsor":"Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NSABP Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NSABP Foundation \/ Puma Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"NSABP Foundation \/ Puma Biotechnology"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Celcuity | Novartis Pharmaceuticals Corporation | Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MD Anderson Cancer Center \/ Celcuity | Novartis Pharmaceuticals Corporation | Puma Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Celcuity | Novartis Pharmaceuticals Corporation | Puma Biotechnology"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Puma Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Virginia Commonwealth University \/ Puma Biotechnology"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Puma Biotechnology | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Puma Biotechnology | GSK","highestDevelopmentStatusID":"7","companyTruncated":"Virginia Commonwealth University \/ Puma Biotechnology | GSK"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"LJM716","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"U3-1287","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"U3-1287","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"Receptor tyrosine-protein kinase erbB-3 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"University of Florida","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CA-4948","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Merck & Co"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Kelun-Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Kelun-Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Kelun-Biotech"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HM06","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TAS0953","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Nova Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nova Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Nova Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nova Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MK-4621","moa":"Retinoic acid-inducible gene-1 (RIG-1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MK-4621","moa":"Retinoic acid-inducible gene-1 (RIG-1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Maria Liljefors","sponsor":"Karolinska University Hospital | Karolinska Institutet | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maria Liljefors","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Maria Liljefors \/ Karolinska University Hospital | Karolinska Institutet | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Maria Liljefors \/ Karolinska University Hospital | Karolinska Institutet | Bristol Myers Squibb"},{"orgOrder":0,"company":"Changhai Hospital","sponsor":"ImmunoGene Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Changhai Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changhai Hospital \/ ImmunoGene Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Changhai Hospital \/ ImmunoGene Biotechnology"},{"orgOrder":0,"company":"Shenzhen Hornetcorn Bio-technology Company, LTD","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Hornetcorn Bio-technology Company, LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hornetcorn Bio-technology Company, LTD \/ Affiliated Cancer Hospital & Institute of Guangzhou Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Hornetcorn Bio-technology Company, LTD \/ Affiliated Cancer Hospital & Institute of Guangzhou Medical University"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Novartis Pharmaceuticals Corporation | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Novartis Pharmaceuticals Corporation | Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Novartis Pharmaceuticals Corporation | Celgene Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Compass Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Compass Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Compass Therapeutics"},{"orgOrder":0,"company":"University of Vermont","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Vermont","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Vermont \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Vermont \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PharmaBio Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ PharmaBio Development","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ PharmaBio Development"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Nelum","sponsor":"Apices Soluciones | Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nelum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nelum \/ Apices Soluciones | Agenus","highestDevelopmentStatusID":"7","companyTruncated":"Nelum \/ Apices Soluciones | Agenus"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Sanofi"},{"orgOrder":0,"company":"University Hospital Southampton NHS Foundation Trust","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Southampton NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Southampton NHS Foundation Trust \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Southampton NHS Foundation Trust \/ Sanofi"},{"orgOrder":0,"company":"Phoenix Molecular Designs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PMD-026","moa":"Ribosomal protein S6 kinase beta-2 (RPS6KB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phoenix Molecular Designs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Molecular Designs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phoenix Molecular Designs \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix Molecular Designs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Ribosomal protein S6 kinase beta-2 (RPS6KB2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phoenix Molecular Designs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Molecular Designs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Phoenix Molecular Designs \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Homoharringtonine","moa":"Ribosome A (hRA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Oncodesign Precision Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"OPM-101","moa":"RIPK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncodesign Precision Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncodesign Precision Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncodesign Precision Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Cancer Institute | Boehringer Ingelheim GmbH | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Cancer Institute | Boehringer Ingelheim GmbH | National Comprehensive Cancer Network","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Cancer Institute | Boehringer Ingelheim GmbH | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Puma Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Puma Biotechnology"},{"orgOrder":0,"company":"John Strickler","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"John Strickler","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"John Strickler \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"John Strickler \/ Sanofi"},{"orgOrder":0,"company":"Japan Clinical Cancer Research Organization","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Japan Clinical Cancer Research Organization","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japan Clinical Cancer Research Organization \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Japan Clinical Cancer Research Organization \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Medigen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBI-825","moa":"RNR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Undisclosed"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBI-825","moa":"RNR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boundless Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Undisclosed"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABT-101","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"National Health Research Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABT-101","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ National Health Research Institutes","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ National Health Research Institutes"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"CDIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"ABT-101","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ CDIB","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ CDIB"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CAB-ROR2-ADC","moa":"ROR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1||ROS1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Icon Plc | CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BXQ-350","moa":"S1P receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Icon Plc | CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Icon Plc | CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1P receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Saposin C","moa":"||S1P receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Subasumstat","moa":"SAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Subasumstat","moa":"SAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Subasumstat","moa":"SAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Subasumstat","moa":"SAE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Merck & Co"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Merck & Co"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"VX15\/2503","moa":"Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccinex \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Peposertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Pangea Biomed","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Rigosertib","moa":"||serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pangea Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pangea Biomed \/ Onconova Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pangea Biomed \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bristol Myers Squibb | Traws Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb | Traws Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb | Traws Pharma"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rigosertib","moa":"serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"LB-100","moa":"Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"LB-100","moa":"Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Alliance Global Partners"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"LB-100","moa":"Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LB-100","moa":"Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Velindre NHS Trust","sponsor":"AstraZeneca | Cenduit | Covance | Cardiff and Vale University Health Board","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Velindre NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Velindre NHS Trust \/ AstraZeneca | Cenduit | Covance | Cardiff and Vale University Health Board","highestDevelopmentStatusID":"7","companyTruncated":"Velindre NHS Trust \/ AstraZeneca | Cenduit | Covance | Cardiff and Vale University Health Board"},{"orgOrder":0,"company":"University Hospital Southampton NHS Foundation Trust","sponsor":"AstraZeneca | Cancer Research UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital Southampton NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Southampton NHS Foundation Trust \/ AstraZeneca | Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital Southampton NHS Foundation Trust \/ AstraZeneca | Cancer Research UK"},{"orgOrder":0,"company":"Accenture","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"GSK2110183","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accenture","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accenture \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accenture \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ipatasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Institute of Cancer Research, United Kingdom \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Triciribine","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prescient Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Fox Chase Cancer Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Fox Chase Cancer Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Chiauranib","moa":"Serine\/threonine-protein kinase Aurora-B | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chiauranib","moa":"Serine\/threonine-protein kinase Aurora-B | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chiauranib","moa":"Serine\/threonine-protein kinase Aurora-B | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Melanoma Institute Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia","highestDevelopmentStatusID":"7","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Jason J. Luke","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jason J. Luke","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jason J. Luke \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Jason J. Luke \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lifirafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lifirafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lifirafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lifirafenib","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Plixorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Plexxikon \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Novellus"},{"orgOrder":0,"company":"Tempus","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Plixorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempus \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Tempus \/ Novellus"},{"orgOrder":0,"company":"Novellus","sponsor":"Pontifax Medison Debt Financing","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series C Financing","leadProduct":"Plixorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novellus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Pontifax Medison Debt Financing","highestDevelopmentStatusID":"7","companyTruncated":"Novellus \/ Pontifax Medison Debt Financing"},{"orgOrder":0,"company":"National Cancer Center Hospital East","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Center Hospital East","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center Hospital East \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Center Hospital East \/ Bayer AG"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Bayer AG | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ Bayer AG | Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Institut Bergoni\u00e9 \/ Bayer AG | Merck Group"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"UNICANCER \/ Bayer AG"},{"orgOrder":0,"company":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica \/ Apices Soluciones","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica \/ Apices Soluciones"},{"orgOrder":0,"company":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","sponsor":"Qilu Pharmaceutical | Shanghai Junshi Biomedical Technology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial gr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center \/ Qilu Pharmaceutical | Shanghai Junshi Biomedical Technology Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center \/ Qilu Pharmaceutical | Shanghai Junshi Biomedical Technology Co., Ltd"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ATG-008","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kathy Miller","sponsor":"Takeda Pharmaceutical | Big Ten Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kathy Miller","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kathy Miller \/ Takeda Pharmaceutical | Big Ten Cancer Research Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Kathy Miller \/ Takeda Pharmaceutical | Big Ten Cancer Research Consortium"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Cancer Research UK | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vistusertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ Cancer Research UK | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Queen Mary University of London \/ Cancer Research UK | AstraZeneca"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Aadi Bioscience \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Aadi Bioscience \/ National Cancer Institute"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Charles Ryan","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charles Ryan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Charles Ryan \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Charles Ryan \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Florida","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Florida \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Pfizer Inc"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Bayer AG"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Kari Wisinski","sponsor":"Pfizer Inc | Celcuity","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kari Wisinski","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kari Wisinski \/ Pfizer Inc | Celcuity","highestDevelopmentStatusID":"7","companyTruncated":"Kari Wisinski \/ Pfizer Inc | Celcuity"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"Serine\/threonine-protein kinase pim (PIM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"Serine\/threonine-protein kinase pim (PIM)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Undisclosed"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Cardiff Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Onvansertib","moa":"Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Cardiff Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Kansas Medical Center \/ Cardiff Oncology"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Onvansertib","moa":"Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Trovagene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trovagene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Trovagene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trovagene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Undisclosed"},{"orgOrder":0,"company":"Trovagene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trovagene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Antonio Giordano","sponsor":"Cardiff Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"Serine\/threonine-protein kinase PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antonio Giordano","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antonio Giordano \/ Cardiff Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Antonio Giordano \/ Cardiff Oncology"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CFI-400945","moa":"Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CFI-400945","moa":"||Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFI-400945","moa":"||Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Treadwell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"CFI-400945","moa":"||Serine\/threonine-protein kinase PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Treadwell Therapeutics \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PharmaBio Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Serine\/threonine-protein kinase RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ PharmaBio Development","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ PharmaBio Development"},{"orgOrder":0,"company":"Hamid Sayar","sponsor":"Takeda Pharmaceutical | Bayer AG | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Serine\/threonine-protein kinase RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hamid Sayar","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamid Sayar \/ Takeda Pharmaceutical | Bayer AG | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Hamid Sayar \/ Takeda Pharmaceutical | Bayer AG | Merck & Co"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-908662","moa":"Serine\/threonine-protein kinase RAF | Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adavosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azenosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Filipa Lynce","sponsor":"Merck & Co | Zentalis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azenosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Filipa Lynce","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Filipa Lynce \/ Merck & Co | Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Filipa Lynce \/ Merck & Co | Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"||Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986466","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Gopherwood Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BR790","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Gopherwood Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Gopherwood Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Gopherwood Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Gopherwood Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BR790","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Gopherwood Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Gopherwood Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Gopherwood Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Genhouse Bio Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GH21","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Genhouse Bio Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Genhouse Bio Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Genhouse Bio Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NC318","moa":"||Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NC318","moa":"Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NC318","moa":"Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"IMX-110","moa":"Signal transducer and activator of transcription 3 (STAT3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMX-110","moa":"Signal transducer and activator of transcription 3 (STAT3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeOne Medicines | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeOne Medicines | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"OPB-31121","moa":"Signal transducer and activator of transcription 3 (STAT3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"iOmx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"iOmx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"iOmx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"SIRPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":2.2200000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2.2599999999999998,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"SIRPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":2.2599999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2.2599999999999998,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"SIRPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Yale University \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ GSK"},{"orgOrder":0,"company":"Omar Nadeem, MD","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omar Nadeem, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omar Nadeem, MD \/ Bristol Myers Squibb | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Omar Nadeem, MD \/ Bristol Myers Squibb | Bristol Myers Squibb"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Patidegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Novartis Pharmaceuticals Corporation | Skip Viragh Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Novartis Pharmaceuticals Corporation | Skip Viragh Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Novartis Pharmaceuticals Corporation | Skip Viragh Foundation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"KSQ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KSQ-001EX","moa":"SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ KSQ Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ KSQ Therapeutics"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"CTMC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"KSQ-001EX","moa":"SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ CTMC","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ CTMC"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KSQ-001EX","moa":"SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KSQ-004EX","moa":"SOCS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tyme, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SM-88","moa":"Sodium channel alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyme, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tyme, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SM-88","moa":"Sodium channel alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyme, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":1,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Mersana Therapeutics"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Perspective Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"203-Pb PSV359","moa":"Somatostatin receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Perspective Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perspective Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Perspective Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Perspective Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"203-Pb VMT01","moa":"Somatostatin receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Perspective Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Perspective Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Perspective Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Perspective Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"203-Pb VMT01","moa":"Somatostatin receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Perspective Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perspective Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Perspective Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Merck & Co | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Merck & Co | Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Duke University \/ Merck & Co | Ipsen"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pasireotide","moa":"peptides: inhibition of growth hormone release||Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pasireotide","moa":"peptides: inhibition of growth hormone release||Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ US Department of Defense"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HYP-6589","moa":"SOS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MRTX0902","moa":"SOS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"LSU Health Sciences Center New Orleans | Apogee Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ LSU Health Sciences Center New Orleans | Apogee Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"RedHill Biopharma \/ LSU Health Sciences Center New Orleans | Apogee Biotechnology"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apogee Biotechnology | Duke University | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Apogee Biotechnology | Duke University | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"RedHill Biopharma \/ Apogee Biotechnology | Duke University | National Cancer Institute"},{"orgOrder":0,"company":"Cho Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CHO-A04","moa":"SSEA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cho Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cho Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cho Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CRN09682","moa":"SST2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crinetics Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Crinetics Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"225-Ac SSO110","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ariceum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"67-Cu MeCOSar-Tyr3-octreotate","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Cardinal Health"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"64-Cu MeCOSar-Tyr3-octreotate","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"RYZ101","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Undisclosed"},{"orgOrder":0,"company":"David Bushnell","sponsor":"National Institutes of Health | National Cancer Institute | Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"David Bushnell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Bushnell \/ National Institutes of Health | National Cancer Institute | Lantheus Holding","highestDevelopmentStatusID":"7","companyTruncated":"David Bushnell \/ National Institutes of Health | National Cancer Institute | Lantheus Holding"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"177-Lu DOTA-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sue O'Dorisio","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"177-Lu DOTA-tyr3-Octreotate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sue O'Dorisio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sue O'Dorisio \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"7","companyTruncated":"Sue O'Dorisio \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"64-Cu SARTATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medical University Innsbruck","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga DOTA-MGS5","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University Innsbruck","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University Innsbruck \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Medical University Innsbruck \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"INSERM | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2012","type":"Inapplicable","leadProduct":"68-Ga IMP-288","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ INSERM | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ INSERM | Gilead Sciences"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Takayuki Yoshino","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Napabucasin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takayuki Yoshino","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takayuki Yoshino \/ Sumitomo Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Takayuki Yoshino \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"OPB-111001","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Tvardi Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Tvardi Therapeutics"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Tvardi Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Tvardi Therapeutics"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Tvardi Therapeutics | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Tvardi Therapeutics | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Tvardi Therapeutics | National Institutes of Health"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"AZD9150","moa":"STAT-3 mRNA 3'UTR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ MedImmune"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"Danvatirsen","moa":"STAT-3 mRNA 3'UTR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Joanne Jeter","sponsor":"National Cancer Institute | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joanne Jeter","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joanne Jeter \/ National Cancer Institute | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Joanne Jeter \/ National Cancer Institute | Merck & Co"},{"orgOrder":0,"company":"Cardiff University","sponsor":"Leukaemia & Lymphoma Research Group | Experimental Cancer Medicine Centres","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Quizartinib","moa":"Stem cell growth factor receptor | Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor RET | Platelet-derived growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor RET | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff University \/ Leukaemia & Lymphoma Research Group | Experimental Cancer Medicine Centres","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff University \/ Leukaemia & Lymphoma Research Group | Experimental Cancer Medicine Centres"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"IMSA101","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMSA101","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"IMSA101","moa":"||Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TAK-500","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Tianhong Li","sponsor":"National Cancer Institute | LabyRx Immunologic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LabVax 3(22)-23","moa":"Streptococcus pneumoniae antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianhong Li","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianhong Li \/ National Cancer Institute | LabyRx Immunologic Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Tianhong Li \/ National Cancer Institute | LabyRx Immunologic Therapeutics"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"Stromal cell-derived factor 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"Stromal cell-derived factor 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Merck & Co"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"BioMimetix JV","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"BMX-001","moa":"Superoxide Radical","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ BioMimetix JV","highestDevelopmentStatusID":"7","companyTruncated":"University of Nebraska \/ BioMimetix JV"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"BMX-001","moa":"Superoxide Radical","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMimetix JV \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioMimetix JV \/ Undisclosed"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Duke Cancer Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"BMX-001","moa":"Superoxide Radical","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMimetix JV \/ Duke Cancer Institute | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"BioMimetix JV \/ Duke Cancer Institute | National Cancer Institute"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Duke Cancer Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"BMX-001","moa":"Superoxide Radical","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMimetix JV \/ Duke Cancer Institute | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"BioMimetix JV \/ Duke Cancer Institute | National Cancer Institute"},{"orgOrder":0,"company":"Queensland Institute of Medical Research","sponsor":"CUREator | Merck & Co | Newro Foundation | Royal Brisbane and Women's Hospital | Princess Alexandra Hospital, Brisbane | Austin Hospital, Melbourne Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Cytomegalovirus-Specific T Cell","moa":"T cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Queensland Institute of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queensland Institute of Medical Research \/ CUREator | Merck & Co | Newro Foundation | Royal Brisbane and Women's Hospital | Princess Alexandra Hospital, Brisbane | Austin Hospital, Melbourne Australia","highestDevelopmentStatusID":"7","companyTruncated":"Queensland Institute of Medical Research \/ CUREator | Merck & Co | Newro Foundation | Royal Brisbane and Women's Hospital | Princess Alexandra Hospital, Brisbane | Austin Hospital, Melbourne Australia"},{"orgOrder":0,"company":"Stichting Hemato-Oncologie voor Volwassenen Nederland","sponsor":"Nordic CLL Study Group | German CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stichting Hemato-Oncologie voor Volwassenen Nederland","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ Nordic CLL Study Group | German CLL Study Group","highestDevelopmentStatusID":"7","companyTruncated":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ Nordic CLL Study Group | German CLL Study Group"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":3.8999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.8999999999999999,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"Yazeed Sawalha","sponsor":"AbbVie Inc | Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yazeed Sawalha","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yazeed Sawalha \/ AbbVie Inc | Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Yazeed Sawalha \/ AbbVie Inc | Genmab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"City of Hope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"City of Hope \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Inhye Ahn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Inhye Ahn","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Inhye Ahn"},{"orgOrder":0,"company":"LintonPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"T cell surface glycoprotein CD3 | Epithelial cell adhesion molecule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LintonPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LintonPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LintonPharm \/ Undisclosed"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"T cell surface glycoprotein CD3 | Epithelial cell adhesion molecule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lindis Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lindis Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"T cell surface glycoprotein CD3 | Epithelial cell adhesion molecule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Lindis Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lindis Biotech \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"||T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Glycotope","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycotope","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Glycotope \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Glycotope \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"mRNA-2416","moa":"TAX transcriptionally-activated glycoprotein 1 (OX40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GIM-531","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Georgiamune \/ Undisclosed"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GIM-531","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Georgiamune \/ Undisclosed"},{"orgOrder":0,"company":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda","sponsor":"Medical Cannabis Bike Tour | Voices Against Brain Cancer | Tilray","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TN-TC11G","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda \/ Medical Cannabis Bike Tour | Voices Against Brain Cancer | Tilray","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda \/ Medical Cannabis Bike Tour | Voices Against Brain Cancer | Tilray"},{"orgOrder":0,"company":"Immatics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Undisclosed"},{"orgOrder":0,"company":"Immatics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Undisclosed"},{"orgOrder":0,"company":"Immatics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Undisclosed"},{"orgOrder":0,"company":"Immatics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Etigilimab","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Icon Plc"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ociperlimab","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Partnership","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BOXR1030","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"VGXI","sponsor":"Geneos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VGXI \/ Geneos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"VGXI \/ Geneos Therapeutics"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BPX-701","moa":"T-cell receptor (TCR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":1.5900000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5900000000000001,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Kings College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Kings College London","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Kings College London"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"STAR0602","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"STAR0602","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VT3989","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vivace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VT3989","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vivace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"F16IL2","moa":"Tenascin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"F16IL2","moa":"Tenascin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"F16IL2","moa":"Tenascin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ZGGS18","moa":"TGF-?\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"ZGGS18","moa":"TGF-?\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Accendatech","sponsor":"C3 Research Associates | Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACT001","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accendatech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Accendatech \/ C3 Research Associates | Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Accendatech \/ C3 Research Associates | Avance Clinical"},{"orgOrder":0,"company":"Oblato","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"OKN-007","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oblato","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oblato \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oblato \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Galunisertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"MedPacto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vactosertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MedPacto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MedPacto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MedPacto \/ Undisclosed"},{"orgOrder":0,"company":"MedPacto","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vactosertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MedPacto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedPacto \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"MedPacto \/ Merck & Co"},{"orgOrder":0,"company":"MedPacto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vactosertib","moa":"TGF-beta receptor type I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MedPacto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedPacto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MedPacto \/ Undisclosed"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY3200882","moa":"TGF-beta receptor type I (TGFBR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY3200882","moa":"TGF-beta receptor type I (TGFBR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Merck & Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"LY3200882","moa":"TGF-beta receptor type I (TGFBR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Avadomide","moa":"thalidomide derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Avadomide","moa":"thalidomide derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Avadomide","moa":"thalidomide derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kathleen Dorritie","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mezigdomide","moa":"thalidomide derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kathleen Dorritie","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kathleen Dorritie \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Kathleen Dorritie \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"SDK Therapeutics","sponsor":"University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SDK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SDK Therapeutics \/ University of Hong Kong","highestDevelopmentStatusID":"7","companyTruncated":"SDK Therapeutics \/ University of Hong Kong"},{"orgOrder":0,"company":"University of Ulm","sponsor":"GSK | German CLL Study Group | WiSP Wissenschaftlicher Service Pharma GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ GSK | German CLL Study Group | WiSP Wissenschaftlicher Service Pharma GmbH","highestDevelopmentStatusID":"7","companyTruncated":"University of Ulm \/ GSK | German CLL Study Group | WiSP Wissenschaftlicher Service Pharma GmbH"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vastra Gotaland Region","sponsor":"Isofol Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vastra Gotaland Region","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vastra Gotaland Region \/ Isofol Medical","highestDevelopmentStatusID":"7","companyTruncated":"Vastra Gotaland Region \/ Isofol Medical"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Isofol Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Isofol Medical \/ Undisclosed"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isofol Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Isofol Medical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics | BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics | BioLineRx","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics | BioLineRx"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Arcus Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Arcus Biosciences"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Bristol Myers Squibb | Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Bristol Myers Squibb | Novocure","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Bristol Myers Squibb | Novocure"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Syneos Health"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK127","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK127","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK127","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK127","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BMS-986207","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Medpace, Inc | Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CHS-006","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Medpace, Inc | Shanghai Junshi Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Biosciences \/ Medpace, Inc | Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CHS-006","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK | iTeos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EOS-448","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK | iTeos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ GSK | iTeos Therapeutics"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"||TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IOV-4001","moa":"TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IOV-4001","moa":"TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Cellectis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BMS-986258","moa":"TIM3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AB-201","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BNT411","moa":"TLR7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DSP-0509","moa":"TLR7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sumitomo Pharma America \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Syneos Health"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Merger","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ MedTech"},{"orgOrder":0,"company":"Umar Farooq","sponsor":"Checkmate Pharmaceuticals | Merck & Co | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9||Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Umar Farooq","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umar Farooq \/ Checkmate Pharmaceuticals | Merck & Co | University of Iowa","highestDevelopmentStatusID":"7","companyTruncated":"Umar Farooq \/ Checkmate Pharmaceuticals | Merck & Co | University of Iowa"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"University of Iowa Holden Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SLN124","moa":"TMPRSS6 messenger RNA (TMPRSS6 mRNA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI-1910","moa":"TNF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAT1306","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent | Merck & Co"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"EIC Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2025","type":"Series B Financing","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TILT Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"TILT Biotherapeutics \/ EIC Fund","highestDevelopmentStatusID":"7","companyTruncated":"TILT Biotherapeutics \/ EIC Fund"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TILT Biotherapeutics \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"TILT Biotherapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TILT Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TILT Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"TILT-123","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TILT Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"TILT Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BSG-001","moa":"Toll-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BioSyngen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioSyngen \/ Undisclosed"},{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital"},{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Opsona Therapeutics Ltd \/ MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"Robert Edwards","sponsor":"Aim ImmunoTech | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Robert Edwards","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Robert Edwards \/ Aim ImmunoTech | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Robert Edwards \/ Aim ImmunoTech | Merck & Co"},{"orgOrder":0,"company":"Oncovir","sponsor":"Chevy Chase Regional Cancer Care | Mount Sinai School of Medicine, New York | Bay Hematology Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Poly-ICLC","moa":"Toll-like receptor 3 (TLR3)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncovir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncovir \/ Chevy Chase Regional Cancer Care | Mount Sinai School of Medicine, New York | Bay Hematology Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Oncovir \/ Chevy Chase Regional Cancer Care | Mount Sinai School of Medicine, New York | Bay Hematology Oncology"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"G100","moa":"Toll-like receptor 4 (TLR4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKTR-262","moa":"Toll-like receptor 7 (TLR7)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"VTX-2337","moa":"Toll-like receptor 8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Stanford University","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Stanford University"},{"orgOrder":0,"company":"Spirig Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spirig Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Spirig Healthcare \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spirig Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SURGE Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SURGE Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"7","companyTruncated":"SURGE Therapeutics \/ Bioluminescence Ventures"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Leonard Appleman","sponsor":"PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leonard Appleman","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leonard Appleman \/ PROMETHEUS LABS","highestDevelopmentStatusID":"7","companyTruncated":"Leonard Appleman \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dynavax Technologies \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Merck & Co"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Undisclosed"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Cl\u00ednica Universidad de Navarra","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cl\u00ednica Universidad de Navarra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cl\u00ednica Universidad de Navarra \/ Highlight Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cl\u00ednica Universidad de Navarra \/ Highlight Therapeutics"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Translational Drug Development"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Private Placement","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STM-416","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURGE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SURGE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Imbotolimod","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Nivolumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"Toll-like-9\/CD22 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"Toll-like-9\/CD22 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series A Financing","leadProduct":"TAC-001","moa":"Toll-like-9\/CD22 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Venbio Partners","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Venbio Partners"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"Toll-like-9\/CD22 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"Toll-like-9\/CD22 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-253","moa":"Top I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Multitude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Multitude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Polish National Center for Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"||TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"WPD Pharmaceuticals \/ Polish National Center for Research and Development","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Polish National Center for Research and Development"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Moleculin Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WPD Pharmaceuticals \/ Moleculin Biotech","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Moleculin Biotech"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Genesiscare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Genesiscare","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Genesiscare"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ HighCape Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ HighCape Capital"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Cybrexa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IBI354","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"David S Shulman","sponsor":"PEEL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PEEL-224","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"David S Shulman","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"David S Shulman \/ PEEL Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"David S Shulman \/ PEEL Therapeutics"},{"orgOrder":0,"company":"Theodore Laetsch","sponsor":"PEEL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PEEL-224","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theodore Laetsch","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theodore Laetsch \/ PEEL Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Theodore Laetsch \/ PEEL Therapeutics"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"TLC388","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Rezatapopt","moa":"||TP53*","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ PMV Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ PMV Pharma"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"GEN1029","moa":"TRAIL receptor 2 (TRAIL-R2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Mapatumumab","moa":"TRAIL receptor-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Center Groningen \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Mapatumumab","moa":"TRAIL receptor-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"BBB-Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"2B3-101","moa":"Transferrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BBB-Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BBB-Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BBB-Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Maximilian Diehn","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Fresolimumab","moa":"Transforming growth factor beta-1 | Transforming growth factor beta-3 | Transforming growth factor beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maximilian Diehn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maximilian Diehn \/ Varian Medical Systems","highestDevelopmentStatusID":"7","companyTruncated":"Maximilian Diehn \/ Varian Medical Systems"},{"orgOrder":0,"company":"PrECOG","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Glembatumumab Vedotin","moa":"Transmembrane glycoprotein NMB | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PrECOG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrECOG \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"PrECOG \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Undisclosed"},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tafamidis","moa":"Transthyretin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SignPath Pharma \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"SignPath Pharma \/ Avance Clinical"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"AUTO4","moa":"TRBC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AUTO4","moa":"||TRBC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PBI-200","moa":"TRK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyramid Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Undisclosed"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"PBI-200","moa":"TRK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyramid Bio \/ Caris Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Caris Life Sciences"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PBI-200","moa":"TRK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyramid Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8008","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8008","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8008","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Levena Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Escugen Biotechnology \/ Levena Biopharma"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"BostonGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LegoChem Biosciences \/ BostonGene","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ BostonGene"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":1.7,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Infusion","sponsorNew":"LegoChem Biosciences \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ Janssen Biotech"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"AntibodyChem Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LCB84","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ AntibodyChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Ligachem Biosciences \/ AntibodyChem Biosciences"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MHB036C","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MHB036C","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MHB036C","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"OBI-902","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"OBI-902","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Biosion","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Biosion"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"IBI130","moa":"Trop-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ST101","moa":"||T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Funding","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Maxim Group","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Maxim Group"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"BiOneCure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BIO-106","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BiOneCure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiOneCure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BiOneCure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BiOneCure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BIO-106","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BiOneCure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiOneCure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BiOneCure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Peregrine Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medical University of South Carolina \/ Peregrine Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of South Carolina \/ Peregrine Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Guarionex J. Decastro","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guarionex J. Decastro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Guarionex J. Decastro \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Guarionex J. Decastro \/ Sanofi"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CKD-516 free base","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Asan Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Chong Kun Dang Pharm \/ Asan Medical Center"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Cascadian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cascadian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascadian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cascadian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ US Biotest, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ US Biotest, Inc."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"Melissa Burgess, MD","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Melissa Burgess, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melissa Burgess, MD \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Melissa Burgess, MD \/ Merck & Co"},{"orgOrder":0,"company":"Erin Bertino","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erin Bertino","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erin Bertino \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Erin Bertino \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Rahul Aggarwal","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel-PNP","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rahul Aggarwal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rahul Aggarwal \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Rahul Aggarwal \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Francisco \/ Eisai Inc"},{"orgOrder":0,"company":"Vector Oncology","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vector Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vector Oncology \/ Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vector Oncology \/ Eisai Inc"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Indibulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alaunos Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Susan G. Komen for the Cure | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Susan G. Komen for the Cure | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Susan G. Komen for the Cure | Amgen Inc"},{"orgOrder":0,"company":"Repos Pharma","sponsor":"Uppsala University | Uppsala University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repos Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Repos Pharma \/ Uppsala University | Uppsala University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Repos Pharma \/ Uppsala University | Uppsala University Hospital"},{"orgOrder":0,"company":"Julie Krystal","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Julie Krystal","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Julie Krystal \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Julie Krystal \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Celgene Corporation"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Bristol Myers Squibb | Cancer Research UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Bristol Myers Squibb | Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"University of Oxford \/ Bristol Myers Squibb | Cancer Research UK"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"CarThera | Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northwestern University \/ CarThera | Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ CarThera | Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Novocure","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ Novocure"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NovoTTF-100L","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Boryung Pharmaceutical Co., Ltd | B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seoul National University Bundang Hospital \/ Boryung Pharmaceutical Co., Ltd | B. Braun Medical","highestDevelopmentStatusID":"7","companyTruncated":"Seoul National University Bundang Hospital \/ Boryung Pharmaceutical Co., Ltd | B. Braun Medical"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jules Bordet Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Jules Bordet Institute \/ AstraZeneca"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Merck & Co | Centre L\u00e9on B\u00e9rard","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NETRIS Pharma \/ Merck & Co | Centre L\u00e9on B\u00e9rard","highestDevelopmentStatusID":"7","companyTruncated":"NETRIS Pharma \/ Merck & Co | Centre L\u00e9on B\u00e9rard"},{"orgOrder":0,"company":"King Faisal Specialist Hospital & Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SAUDI ARABIA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"King Faisal Specialist Hospital & Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King Faisal Specialist Hospital & Research Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"King Faisal Specialist Hospital & Research Center \/ AstraZeneca"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ US Biotest, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ US Biotest, Inc."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Imunon","sponsor":"Breakthrough Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imunon \/ Breakthrough Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Breakthrough Cancer Research"},{"orgOrder":0,"company":"Jungsil Ro","sponsor":"Pfizer Inc | HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jungsil Ro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jungsil Ro \/ Pfizer Inc | HK inno.N","highestDevelopmentStatusID":"7","companyTruncated":"Jungsil Ro \/ Pfizer Inc | HK inno.N"},{"orgOrder":0,"company":"Jungsil Ro","sponsor":"GSK | HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jungsil Ro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jungsil Ro \/ GSK | HK inno.N","highestDevelopmentStatusID":"7","companyTruncated":"Jungsil Ro \/ GSK | HK inno.N"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TLC178","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Centre Oscar Lambret","sponsor":"Anticancer Fund, Belgium | Bristol Myers Squibb | CTD-CNO | ECS-Progastrin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vinblastine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Oscar Lambret","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Oscar Lambret \/ Anticancer Fund, Belgium | Bristol Myers Squibb | CTD-CNO | ECS-Progastrin","highestDevelopmentStatusID":"7","companyTruncated":"Centre Oscar Lambret \/ Anticancer Fund, Belgium | Bristol Myers Squibb | CTD-CNO | ECS-Progastrin"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Ligartis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinflunine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ligartis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ligartis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ligartis \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Miami \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"University of Miami \/ Genentech"},{"orgOrder":0,"company":"Auricula Biosciences Inc.","sponsor":"Simbec-Orion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"WEF-001","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Auricula Biosciences Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Auricula Biosciences Inc. \/ Simbec-Orion","highestDevelopmentStatusID":"7","companyTruncated":"Auricula Biosciences Inc. \/ Simbec-Orion"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Pinatuzumab Vedotin","moa":"Tubulin | CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enapotamab Vedotin","moa":"Tubulin | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Enapotamab Vedotin","moa":"Tubulin | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"||Tubulin | Zinc transporter ZIP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":1,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Ladiratuzumab Vedotin","moa":"Tubulin | Zinc transporter ZIP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Merck & Co"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"OXi4503","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MRG004A","moa":"\nTubulin\/tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Klus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"SKB264","moa":"Tumor associated calcium signal transducer 2 (TACSTD2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Klus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klus Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Klus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Craig L Slingluff, Jr","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"6MHP","moa":"Tumor cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Craig L Slingluff, Jr","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig L Slingluff, Jr \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Craig L Slingluff, Jr \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Craig L Slingluff, Jr","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"6MHP","moa":"Tumor cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Craig L Slingluff, Jr","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig L Slingluff, Jr \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Craig L Slingluff, Jr \/ Celldex Therapeutics"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PEP503","moa":"Tumor cell killer","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"PEP503","moa":"Tumor cell killer","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"NEOGAP Therapeutics","sponsor":"CTC Clinical Trial Consultants | Karolinska University Hospital | Region V\u00e4stmanland | Vecura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Personal Tumour-Trained Lymphocytes","moa":"Tumor cell killer","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NEOGAP Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEOGAP Therapeutics \/ CTC Clinical Trial Consultants | Karolinska University Hospital | Region V\u00e4stmanland | Vecura","highestDevelopmentStatusID":"7","companyTruncated":"NEOGAP Therapeutics \/ CTC Clinical Trial Consultants | Karolinska University Hospital | Region V\u00e4stmanland | Vecura"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Enadenotucirev","moa":"Tumor cells","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akamis Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akamis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Peter MacCallum Cancer Centre | Amgen Inc | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Peter MacCallum Cancer Centre | Amgen Inc | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Peter MacCallum Cancer Centre | Amgen Inc | Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Elranatamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Hellenic Society of Hematology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Society of Hematology \/ GSK"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Hellenic Society of Hematology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Society of Hematology \/ GSK"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Hellenic Society of Hematology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Society of Hematology \/ GSK"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Hellenic Society of Hematology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Society of Hematology \/ GSK"},{"orgOrder":0,"company":"Canadian Myeloma Research Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"GSK2857916","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canadian Myeloma Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Myeloma Research Group \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Canadian Myeloma Research Group \/ GSK"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"INCAGN01876","moa":"Tumor necrosis factor receptor superfamily member 18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"INCAGN01876","moa":"Tumor necrosis factor receptor superfamily member 18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"INCAGN01876","moa":"Tumor necrosis factor receptor superfamily member 18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MEDI6469","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Tumor necrosis factor receptor superfamily member 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"PF-04518600","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pyxis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pyxis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pyxis Oncology"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pyxis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Thai Lymphoma Study Group","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"THAILAND","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Thai Lymphoma Study Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thai Lymphoma Study Group \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Thai Lymphoma Study Group \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Mundipharma","highestDevelopmentStatusID":"7","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Mundipharma"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ Pfizer Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Anderson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | Pfizer Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc | National Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Urelumab","moa":"Tumor necrosis factor receptor superfamily member 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Urelumab","moa":"Tumor necrosis factor receptor superfamily member 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Urelumab","moa":"Tumor necrosis factor receptor superfamily member 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Xilio Development, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Development, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Development, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Development, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series C Financing","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Rock Springs Capital"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Tumor suppressor candidate 2 (TUSC2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Geneva","sponsor":"Immatics | Oncovir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IMA 950","moa":"Tumor-associated antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Geneva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Geneva \/ Immatics | Oncovir","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Geneva \/ Immatics | Oncovir"},{"orgOrder":0,"company":"National Cancer Institute, Naples","sponsor":"Immatics | CureVac | European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IMA970A","moa":"Tumor-associated antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute, Naples","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute, Naples \/ Immatics | CureVac | European Commission","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute, Naples \/ Immatics | CureVac | European Commission"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MGN1601","moa":"Tumor-associated antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"IKF Nordwest","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IKF Nordwest","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IKF Nordwest \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"IKF Nordwest \/ Gilead Sciences"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Immunomedics"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"HDM201","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"HDM201","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idasanutlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Idasanutlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Idasanutlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Idasanutlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kartos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kartos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kartos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kartos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kartos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kartos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kartos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kartos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kartos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kartos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Siremadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Siremadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TYK-00540","moa":"TYK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TYK-00540","moa":"TYK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-986482","moa":"TYK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APL-101","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Apollomics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Chemical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Chemical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Chemical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Chemical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fisogatinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Blueprint Medicines","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pharmaceuticals \/ Blueprint Medicines"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fisogatinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Ping An Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series C Financing","leadProduct":"Vebreltinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Ping An Capital","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Ping An Capital"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Maxpro Capital Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Vebreltinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Maxpro Capital Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Maxpro Capital Acquisition Corp."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Asciminib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Duke University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rebastinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rebastinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vodobatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Spanish Breast Cancer Research Group","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spanish Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Breast Cancer Research Group \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Spanish Breast Cancer Research Group \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Chul Kim","sponsor":"AstraZeneca | Bristol Myers Squibb | Walter Reed National Military Medical Center | Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chul Kim","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chul Kim \/ AstraZeneca | Bristol Myers Squibb | Walter Reed National Military Medical Center | Hackensack Meridian Health","highestDevelopmentStatusID":"7","companyTruncated":"Chul Kim \/ AstraZeneca | Bristol Myers Squibb | Walter Reed National Military Medical Center | Hackensack Meridian Health"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"University of Washington","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ AstraZeneca"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Austin I Kim","sponsor":"Genentech | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Austin I Kim","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin I Kim \/ Genentech | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Austin I Kim \/ Genentech | AstraZeneca"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Johnson & Johnson Innovative Medicine | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Johnson & Johnson Innovative Medicine | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ Johnson & Johnson Innovative Medicine | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Davis \/ Pharmacyclics"},{"orgOrder":0,"company":"Georgetown University","sponsor":"AbbVie Inc | Pharmacyclics | Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ AbbVie Inc | Pharmacyclics | Hackensack Meridian Health","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ AbbVie Inc | Pharmacyclics | Hackensack Meridian Health"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pharmacyclics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pharmacyclics | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pharmacyclics | National Cancer Institute"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pharmacyclics | JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pharmacyclics | JANSSEN BIOTECH","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pharmacyclics | JANSSEN BIOTECH"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Prof. Dr. Clemens Schmitt","sponsor":"Charite University, Berlin, Germany | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prof. Dr. Clemens Schmitt","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof. Dr. Clemens Schmitt \/ Charite University, Berlin, Germany | Janssen-Cilag","highestDevelopmentStatusID":"7","companyTruncated":"Prof. Dr. Clemens Schmitt \/ Charite University, Berlin, Germany | Janssen-Cilag"},{"orgOrder":0,"company":"Joshua Brody","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joshua Brody","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joshua Brody \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Joshua Brody \/ Merck & Co"},{"orgOrder":0,"company":"Robert Lowsky","sponsor":"Johnson & Johnson Innovative Medicine | National Cancer Institute | Leukemia and Lymphoma Society | Rising Tide Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Robert Lowsky","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Robert Lowsky \/ Johnson & Johnson Innovative Medicine | National Cancer Institute | Leukemia and Lymphoma Society | Rising Tide Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Robert Lowsky \/ Johnson & Johnson Innovative Medicine | National Cancer Institute | Leukemia and Lymphoma Society | Rising Tide Foundation"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Undisclosed"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SNS-062","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vecabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alvaro Alencar","sponsor":"BeOne Medicines | Incyte Corporation | MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alvaro Alencar","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alvaro Alencar \/ BeOne Medicines | Incyte Corporation | MorphoSys","highestDevelopmentStatusID":"7","companyTruncated":"Alvaro Alencar \/ BeOne Medicines | Incyte Corporation | MorphoSys"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"||Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ AstraZeneca"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Dawn L. Hershman","sponsor":"Incyte Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dawn L. Hershman","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dawn L. Hershman \/ Incyte Corporation | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Dawn L. Hershman \/ Incyte Corporation | National Cancer Institute"},{"orgOrder":0,"company":"Veronika Bachanova","sponsor":"Incyte Corporation | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Veronika Bachanova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veronika Bachanova \/ Incyte Corporation | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Veronika Bachanova \/ Incyte Corporation | Bristol Myers Squibb"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-911543","moa":"Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ONO-7475","moa":"Tyrosine-protein kinase Mer (MERTK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Akinion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AKN-028","moa":"Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akinion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akinion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akinion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Synimmune GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Flysyn","moa":"Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synimmune GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synimmune GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Synimmune GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Synimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Flysyn","moa":"Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenScript ProBio \/ Synimmune","highestDevelopmentStatusID":"7","companyTruncated":"GenScript ProBio \/ Synimmune"},{"orgOrder":0,"company":"Douglas Tremblay","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Douglas Tremblay","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Douglas Tremblay \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"7","companyTruncated":"Douglas Tremblay \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Adastra Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zotiraciclib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2 | Cyclin-dependent kinase 7 | Cyclin-dependent kinase 9 | Cyclin-dependent kinase 2 | Cyclin-dependent kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adastra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adastra Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adastra Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Joshua Palmer","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joshua Palmer","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joshua Palmer \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Joshua Palmer \/ Genentech"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ BerGenBio ASA","highestDevelopmentStatusID":"7","companyTruncated":"Haukeland University Hospital \/ BerGenBio ASA"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ Undisclosed"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ University Of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ University Of Alabama"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Triligent International | Translational Genomics Research Institute | BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Triligent International | Translational Genomics Research Institute | BerGenBio ASA","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Triligent International | Translational Genomics Research Institute | BerGenBio ASA"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ GSK"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica","sponsor":"Pfizer Inc | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica \/ Pfizer Inc | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica \/ Pfizer Inc | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"H Scott Boswell","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H Scott Boswell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H Scott Boswell \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"H Scott Boswell \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Jason J. Luke","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ARRY-614","moa":"Tyrosine-protein kinase TIE-2 | MAP kinase p38 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jason J. Luke","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jason J. Luke \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jason J. Luke \/ Pfizer Inc"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cerdulatinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase SYK | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Inlexisertib","moa":"ULK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Inlexisertib","moa":"ULK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DCC-3116","moa":"||ULK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Abnoba","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Abnoba Viscum Fraxini","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abnoba","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Abnoba \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abnoba \/ Undisclosed"},{"orgOrder":0,"company":"GeneMedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GM103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeneMedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneMedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GeneMedicine \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IPG1094","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanjing Immunophage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Seqker Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Personalized Neoantigen Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seqker Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqker Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Seqker Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Seqker Biosciences","sponsor":"Bumrungrad International Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Personalized Neoantigen Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seqker Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqker Biosciences \/ Bumrungrad International Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Seqker Biosciences \/ Bumrungrad International Hospital"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"Beijing 302 Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"GPC3 CART Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai GeneChem \/ Beijing 302 Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai GeneChem \/ Beijing 302 Hospital"},{"orgOrder":0,"company":"Shanghai Kanda Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KD6001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Kanda Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kanda Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Kanda Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kanda Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KD6001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Kanda Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kanda Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Kanda Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MRG007","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Shine-On BioMedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SOA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shine-On BioMedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shine-On BioMedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shine-On BioMedical \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCTB14","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SCTB39-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SCTB39G","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCTB41","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"SkinJect","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"A4368","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SkinJect","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SkinJect \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SkinJect \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CM4307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZG005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZG005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZG005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZG006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZG006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG19018","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZG2001 Tosilate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"T-ACE Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"T-Ace Oil","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-ACE Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oil","sponsorNew":"T-ACE Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"T-ACE Medical \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Leader Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LEAC-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiwan Leader Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiwan Leader Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiwan Leader Biotech \/ Undisclosed"},{"orgOrder":0,"company":"TCM Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PTX-9908","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCM Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TCM Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TCM Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Therapex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TRX-221","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Therapex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Therapex \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TJ1133","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TJ Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TJ Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TJ Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TY-1091","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TY-302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan YZY Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"M701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan YZY Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan YZY Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan YZY Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan YZY Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Y101D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan YZY Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan YZY Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan YZY Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Xynomic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XP-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xynomic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xynomic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xynomic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group | EMD Serono | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Merck Group | EMD Serono | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Merck Group | EMD Serono | Pfizer Inc"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Merck & Co"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Merck Group"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Everfront Biotech","sponsor":"DOIT, Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"(Z)-N-Butylidenephthalide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everfront Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Everfront Biotech \/ DOIT, Taiwan","highestDevelopmentStatusID":"7","companyTruncated":"Everfront Biotech \/ DOIT, Taiwan"},{"orgOrder":0,"company":"Biomedical Radiation Sciences","sponsor":"Swedish Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"111-In ABY-025","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biomedical Radiation Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedical Radiation Sciences \/ Swedish Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Biomedical Radiation Sciences \/ Swedish Cancer Society"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"177-Lu DPI-4452","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Undisclosed"},{"orgOrder":0,"company":"Rhine Pharma","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Demerger","leadProduct":"188-Re PSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhine Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhine Pharma \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Rhine Pharma \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Chimagen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"1A46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chimagen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chimagen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"3H Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"3HP-2827","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3H Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3H Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"3H Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"3H Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"3HP-2827","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3H Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3H Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"3H Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"451238","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Merck Group"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-BBN","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Financing","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cellbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"68-Ga NGUL","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellbion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellbion \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellbion \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"6MW3211","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"6MW3211","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"6MW3511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"89-Zr DFO-REGN3767","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Center Groningen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Olivia Newton-John Cancer Research Institute","sponsor":"Merck Group | Austin Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"89-Zr M7824","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olivia Newton-John Cancer Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olivia Newton-John Cancer Research Institute \/ Merck Group | Austin Health","highestDevelopmentStatusID":"7","companyTruncated":"Olivia Newton-John Cancer Research Institute \/ Merck Group | Austin Health"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"8MW2311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Gilead Sciences | Institut Cancerologie de l'Ouest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"90-Y DOTA-Epratuzumab IgG","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nantes University Hospital \/ Gilead Sciences | Institut Cancerologie de l'Ouest","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ Gilead Sciences | Institut Cancerologie de l'Ouest"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"A2B395","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2 Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AAA602","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ArsenalBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Undisclosed"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series C Financing","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"ArsenalBio \/ Arch Ventures","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Arch Ventures"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ArsenalBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-453","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-453","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Abogen Biosciences","sponsor":"Suzhou Abogen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABO2011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Abogen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Abogen Biosciences \/ Suzhou Abogen Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Abogen Biosciences \/ Suzhou Abogen Biosciences"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"Acerand Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ACE-86225106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerand Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acerand Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acerand Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Vaccines","sponsor":"Liverpool University Hospitals NHS FT | The Clatterbridge Cancer Centre NHS Foundation Trust | University of Liverpool | Cancer Research UK | National Institute for Health Research, UK | Cancer Vaccines Charitable Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ACIT-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cancer Vaccines \/ Liverpool University Hospitals NHS FT | The Clatterbridge Cancer Centre NHS Foundation Trust | University of Liverpool | Cancer Research UK | National Institute for Health Research, UK | Cancer Vaccines Charitable Trust","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Vaccines \/ Liverpool University Hospitals NHS FT | The Clatterbridge Cancer Centre NHS Foundation Trust | University of Liverpool | Cancer Research UK | National Institute for Health Research, UK | Cancer Vaccines Charitable Trust"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Ad\/PNP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AD1208","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Etubics Corporation","sponsor":"Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"AD5 CEA Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etubics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etubics Corporation \/ Duke University","highestDevelopmentStatusID":"7","companyTruncated":"Etubics Corporation \/ Duke University"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Adenovirus Loaded Purine Nucleoside Phosphorylase","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Angimmune","sponsor":"University of Louisville","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"A-dmDT390-bisFv","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angimmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angimmune \/ University of Louisville","highestDevelopmentStatusID":"7","companyTruncated":"Angimmune \/ University of Louisville"},{"orgOrder":0,"company":"Angimmune","sponsor":"James Graham Brown Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"A-dmDT390-bisFv","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angimmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angimmune \/ James Graham Brown Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Angimmune \/ James Graham Brown Cancer Center"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AFNT-211","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affini-T Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Affini-T Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Agenus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AGN1181","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agenus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"NH TherAguix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Aguix","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ NH TherAguix","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ NH TherAguix"},{"orgOrder":0,"company":"OncoC4","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AI-011","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ Undisclosed"},{"orgOrder":0,"company":"OncoC4","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AI-081","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AL2846","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AL2846","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AL2846","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Orca Bio | Florida Department of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Cell Graft","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Orca Bio | Florida Department of Health","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Orca Bio | Florida Department of Health"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"PapiVax Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Hpv-Specific T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ PapiVax Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ PapiVax Biotech"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Adienne | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Allogeneic Stem Cell Transplant","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Adienne | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Adienne | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Mirror Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allostim","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirror Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirror Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mirror Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Michael Har-Noy","sponsor":"Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Allostim","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Michael Har-Noy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Michael Har-Noy \/ Hadassah Medical Organization","highestDevelopmentStatusID":"7","companyTruncated":"Michael Har-Noy \/ Hadassah Medical Organization"},{"orgOrder":0,"company":"Hamlet Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Alpha1H","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hamlet Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamlet Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hamlet Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Immunochina Medical Science & Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMT-116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Immunochina Medical Science & Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Immunochina Medical Science & Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Immunochina Medical Science & Technology \/ Undisclosed"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMT-116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Multitude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMT-116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Multitude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AtlasMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMXI-5001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AtlasMedx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AtlasMedx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AtlasMedx \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AP203","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aveta Biomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APG-157","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveta Biomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aveta Biomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aveta Biomics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AP-L1898","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AP-L1898","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"APL-4098","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Apollo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"APL-5125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Apollo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anaeropharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"APS001F","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaeropharma Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaeropharma Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anaeropharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ART6043","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Antelope Surgical Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AS1986NS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antelope Surgical Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antelope Surgical Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antelope Surgical Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Valerio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Asidna","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Valerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valerio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Valerio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ASN-3186","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ASP0739","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Multiple Myeloma Research Consortium | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ASP7487","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Multiple Myeloma Research Consortium | Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Multiple Myeloma Research Consortium | Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ASP7517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ASP7517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ASP9521","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PhytoHealth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Astragulus Root Etract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PhytoHealth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhytoHealth Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PhytoHealth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Alyssum Therapeutics","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AT-1965","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alyssum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alyssum Therapeutics \/ CBCC Global","highestDevelopmentStatusID":"7","companyTruncated":"Alyssum Therapeutics \/ CBCC Global"},{"orgOrder":0,"company":"Accession Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"ATTR-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accession Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accession Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Accession Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Peking University Cancer Hospital & Institute | Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Peking University Cancer Hospital & Institute | Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Peking University Cancer Hospital & Institute | Fudan University"},{"orgOrder":0,"company":"Uppsala University","sponsor":"Uppsala University Hospital | Karolinska University Hospital | AFA Insurance | Swedish Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous CD19 3rd Gen CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uppsala University \/ Uppsala University Hospital | Karolinska University Hospital | AFA Insurance | Swedish Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Uppsala University \/ Uppsala University Hospital | Karolinska University Hospital | AFA Insurance | Swedish Cancer Society"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"The Second Hospital of Hebei Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Autologous CD19-targeting CAR T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ The Second Hospital of Hebei Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Hebei Senlang Biotechnology \/ The Second Hospital of Hebei Medical University"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"CTTQ Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Autologous Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Cancer Hospital \/ CTTQ Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Henan Cancer Hospital \/ CTTQ Pharma"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Autologous Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"IN8bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Genetically Modified Gamma-Delta T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Undisclosed"},{"orgOrder":0,"company":"Lion TCR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Hbv-Tcr T Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lion TCR \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Undisclosed"},{"orgOrder":0,"company":"Lion TCR","sponsor":"Beijing GoBroad Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Autologous Hbv-Tcr T Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lion TCR \/ Beijing GoBroad Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Beijing GoBroad Hospital"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Immune Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai AbelZeta Ltd. \/ Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ Fudan University"},{"orgOrder":0,"company":"HRYZ Biotech","sponsor":"Nanfang Hospital, Southern Medical University | Third Affiliated Hospital, Sun Yat-sen University | Sun Yat-sen University | Beijing 302 Hospital | Fujian Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Autologous Immune Cytotoxic Of T-Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HRYZ Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HRYZ Biotech \/ Nanfang Hospital, Southern Medical University | Third Affiliated Hospital, Sun Yat-sen University | Sun Yat-sen University | Beijing 302 Hospital | Fujian Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"HRYZ Biotech \/ Nanfang Hospital, Southern Medical University | Third Affiliated Hospital, Sun Yat-sen University | Sun Yat-sen University | Beijing 302 Hospital | Fujian Cancer Hospital"},{"orgOrder":0,"company":"T-knife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous MAGE-A1 CD8+ T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-knife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Undisclosed"},{"orgOrder":0,"company":"Xiangyang No.1 People\u2019s Hospital","sponsor":"Qingdao Haier Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xiangyang No.1 People\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiangyang No.1 People\u2019s Hospital \/ Qingdao Haier Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Xiangyang No.1 People\u2019s Hospital \/ Qingdao Haier Biotechnology"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Autologous T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics"},{"orgOrder":0,"company":"Cell Medica","sponsor":"University College, London | Cell Therapy Catapult","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous WT1 TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cell Medica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cell Medica \/ University College, London | Cell Therapy Catapult","highestDevelopmentStatusID":"7","companyTruncated":"Cell Medica \/ University College, London | Cell Therapy Catapult"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD0022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD0305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD0486","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD0486","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD0754","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD2962","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD3470","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD3470","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD4360","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD5335","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD5492","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD5851","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD5863","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD8421","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ImaginAb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AZD8853","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ ImaginAb","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ ImaginAb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD9793","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AZD9829","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"China Medical University Hospital","sponsor":"Heron Neutron Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"B10 L-BPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"China Medical University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Medical University Hospital \/ Heron Neutron Medical","highestDevelopmentStatusID":"7","companyTruncated":"China Medical University Hospital \/ Heron Neutron Medical"},{"orgOrder":0,"company":"Heron Neutron Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B10 L-BPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heron Neutron Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Neutron Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heron Neutron Medical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BBT369","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BC1 Cell Line","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BDC-4182","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BEAM-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beam Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BEAM-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BG1805","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BG1805","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Beihai Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BH011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhuhai Beihai Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Zhuhai Beihai Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhuhai Beihai Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BHV-1510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BHV-1510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen BinDeBio Ltd.","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BinD19","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen BinDeBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shenzhen BinDeBio Ltd. \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen BinDeBio Ltd. \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Shenzhen BinDeBio Ltd.","sponsor":"Children's Hospital of Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BinD19","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen BinDeBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shenzhen BinDeBio Ltd. \/ Children's Hospital of Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen BinDeBio Ltd. \/ Children's Hospital of Fudan University"},{"orgOrder":0,"company":"BioLite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLEX404","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"BioLite \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioLite \/ Undisclosed"},{"orgOrder":0,"company":"Rgene Corporation","sponsor":"American BriVision","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BLEX404","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Rgene Corporation \/ American BriVision","highestDevelopmentStatusID":"7","companyTruncated":"Rgene Corporation \/ American BriVision"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M02D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BL-M07D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BMS-986178","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BMS-986179","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BMS-986183","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BMS-986277","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMS-986490","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"University of Southampton","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"BNT113","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Southampton","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southampton \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"University of Southampton \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics | Biotheus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BNT323","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Duality Biologics | Biotheus","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics | Biotheus"},{"orgOrder":0,"company":"BioNTech","sponsor":"Biotheus | Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BNT324","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Biotheus | Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Biotheus | Duality Biologics"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BNT325","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BPB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bracco \/ Undisclosed"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"7","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Byondis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BYON5667","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byondis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Byondis \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Haixi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C019199","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fujian Haixi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Haixi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fujian Haixi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Canwell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CAN1012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canwell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Canwell Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Canwell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Canwell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CAN1012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canwell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Canwell Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Canwell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kara Yakhteh Tajhiz Azma Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CAR T-Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kara Yakhteh Tajhiz Azma Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kara Yakhteh Tajhiz Azma Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kara Yakhteh Tajhiz Azma Company \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CART-19 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Coherent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CBP-1019","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coherent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai PerHum Therapeutics Co., Ltd.","sponsor":"Shanghai Public Health Clinical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CCT301-59","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai PerHum Therapeutics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai PerHum Therapeutics Co., Ltd. \/ Shanghai Public Health Clinical Center","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai PerHum Therapeutics Co., Ltd. \/ Shanghai Public Health Clinical Center"},{"orgOrder":0,"company":"advesya","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CCTx-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"advesya","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"advesya \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"advesya \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD146\/HER2 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology | Zhujiang Hospital | Jingzhou Central Hospital | Shiyan People's Hospital | Xiangyang Central Hospital | Yichang Central People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 BiCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology | Zhujiang Hospital | Jingzhou Central Hospital | Shiyan People's Hospital | Xiangyang Central Hospital | Yichang Central People\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology | Zhujiang Hospital | Jingzhou Central Hospital | Shiyan People's Hospital | Xiangyang Central Hospital | Yichang Central People\u2019s Hospital"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 BiCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19 Prime CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Cancer Foundation | Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CD19-directed CAR T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Cancer Foundation | Canadian Cancer Trials Group","highestDevelopmentStatusID":"7","companyTruncated":"University of Alberta \/ Alberta Cancer Foundation | Canadian Cancer Trials Group"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CD40HVac","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax \/ Gustave Roussy"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"CD40HVac","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax \/ Gustave Roussy"},{"orgOrder":0,"company":"Maria Liljefors","sponsor":"Karolinska Institutet | Swedish Institute for Infectious Disease Control | Cyto Pulse Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Cea DNA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maria Liljefors","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maria Liljefors \/ Karolinska Institutet | Swedish Institute for Infectious Disease Control | Cyto Pulse Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Maria Liljefors \/ Karolinska Institutet | Swedish Institute for Infectious Disease Control | Cyto Pulse Sciences"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CGT4859","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vietlife Healthcare Corporation","sponsor":"Vietnam National Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CH1701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vietlife Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vietlife Healthcare Corporation \/ Vietnam National Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Vietlife Healthcare Corporation \/ Vietnam National Cancer Hospital"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"ChAdOx1-MVA 5T4 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Oxford \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1-PCAQ","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Barinthus Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ChAdOx1-PCAQ","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Barinthus Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kecellitics Biotech","sponsor":"Hebei Yanda Ludaopei Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Chimeric Antigen Receptor Modified T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kecellitics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kecellitics Biotech \/ Hebei Yanda Ludaopei Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Kecellitics Biotech \/ Hebei Yanda Ludaopei Hospital"},{"orgOrder":0,"company":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chlorogenic Acid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM-2101 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeric Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chimeric Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cho Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CHO-H01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cho Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cho Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cho Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Cholesterol-TUSC2 Liposome Complex","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"CJ Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CJRB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CJ Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CJ Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Calidi Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Jackson Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Jackson Investment Group","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Jackson Investment Group"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CM350","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curon Biopharmaceutical \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Novotech"},{"orgOrder":0,"company":"Jacinto Convit World Organization","sponsor":"Fundaci\u00f3n Jacinto Convit | Instituto Oncol\u00f3gico Luis Razetti","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Convitvax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacinto Convit World Organization","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jacinto Convit World Organization \/ Fundaci\u00f3n Jacinto Convit | Instituto Oncol\u00f3gico Luis Razetti","highestDevelopmentStatusID":"7","companyTruncated":"Jacinto Convit World Organization \/ Fundaci\u00f3n Jacinto Convit | Instituto Oncol\u00f3gico Luis Razetti"},{"orgOrder":0,"company":"Tasca Therapeutics","sponsor":"Regeneron Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"CAS 77168-63-9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tasca Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tasca Therapeutics \/ Regeneron Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Tasca Therapeutics \/ Regeneron Ventures"},{"orgOrder":0,"company":"Tasca Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CAS 77168-63-9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tasca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tasca Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tasca Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ CSPC Zhongnuo Pharmaceutical Shijiazhuang Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ CSPC Zhongnuo Pharmaceutical Shijiazhuang Co., Ltd"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Curocell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CRC01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curocell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curocell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curocell \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Centaurus Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CT-1530","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centaurus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centaurus Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Centaurus Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crossignal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CT3001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Crossignal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Crossignal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Crossignal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytosinLab Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTS2190","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytosinLab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytosinLab Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytosinLab Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytosinLab Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CTS3497","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytosinLab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytosinLab Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytosinLab Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Celularity \/ YA II PN","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ YA II PN"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Innopharmax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"D07001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innopharmax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Innopharmax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innopharmax \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-4505","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Careseng Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Dammarane Sapogenins","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Careseng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Careseng Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Careseng Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"California Institute for Regenerative Medicine (CIRM) | Denovo Biopharma | Anova Enterprises","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DB107-RRV","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ California Institute for Regenerative Medicine (CIRM) | Denovo Biopharma | Anova Enterprises","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Francisco \/ California Institute for Regenerative Medicine (CIRM) | Denovo Biopharma | Anova Enterprises"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DB-1305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DB-1311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DB-1419","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Heronova Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DC05F01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heronova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heronova Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heronova Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Heronova Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DC05F01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heronova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heronova Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heronova Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Chung Mei Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DCB-BO1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chung Mei Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chung Mei Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chung Mei Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DCC-3009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DCC-3084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Debio 1562M","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Forbion"},{"orgOrder":0,"company":"enGene","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Deep Track Capital"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Adage Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Adage Capital Partners"},{"orgOrder":0,"company":"enGene","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Hercules Capital"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Divesiran","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DR-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dren Bio \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Dren Bio \/ Novotech"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DR30206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DS-3939a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Domain Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DT-7012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Domain Therapeutics \/ Domain Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Domain Therapeutics \/ Domain Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DYP-688","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Christian Hinrichs","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"E7 TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Christian Hinrichs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Christian Hinrichs \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Christian Hinrichs \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ECI-830","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","sponsor":"ExCellThera | Centre C3i","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al \/ ExCellThera | Centre C3i","highestDevelopmentStatusID":"7","companyTruncated":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al \/ ExCellThera | Centre C3i"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ExCellThera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ExCellThera \/ Undisclosed"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ExCellThera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ExCellThera \/ Undisclosed"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ECT-001-CB","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"ExCellThera \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Everfront Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EF-009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everfront Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Everfront Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Everfront Biotech \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"EG-70","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"enGene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Undisclosed"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EGL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Egle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"EGL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Egle Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Egle Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Egle Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EGL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Egle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"EIK1004-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eikon Therapeutics \/ IMPACT Therapeutics, Inc"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Elicio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Angion Biomedica \/ Elicio Therapeutics"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GKCC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ GKCC","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ GKCC"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ENV-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endeavor Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Endeavor Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"EO2401","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Covance"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Labcorp Drug Development","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Enterome","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"EO2401","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Prana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Epidiferphane","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Florida \/ Prana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Prana Therapeutics"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ES101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ETBX-011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ETBX-011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"CM&D Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Eviendep","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CM&D Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CM&D Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CM&D Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM14","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Novotech"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Excelmab Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EX103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangzhou Excelmab Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Excelmab Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Guangzhou Excelmab Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Exeliom Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EXL01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital, Lille \/ Exeliom Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Lille \/ Exeliom Biosciences"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FB-1603","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ National Taiwan University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"1ST Biotherapeutics, Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FB849","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"1ST Biotherapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"1ST Biotherapeutics, Inc \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"1ST Biotherapeutics, Inc \/ Merck & Co"},{"orgOrder":0,"company":"FindCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FC084CSA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FindCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FindCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FindCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"FindCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FC084CSA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FindCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FindCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FindCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Femmed Breast Health Formula","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nutrasource \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FH-006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FH-006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Yongchang Zhang","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FHND-9041","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yongchang Zhang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yongchang Zhang \/ Jiangsu Chia Tai Fenghai Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Yongchang Zhang \/ Jiangsu Chia Tai Fenghai Pharmaceutical"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibromun","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Fibromun","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Suzhou Forlong Biotechnology Co.,Ltd,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FL115","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Forlong Biotechnology Co.,Ltd,","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Forlong Biotechnology Co.,Ltd,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FL115","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Forlong Biotechnology Co.,Ltd,","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Forlong Biotechnology Co.,Ltd,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FL115","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Forlong Biotechnology Co.,Ltd,","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Forlong Biotechnology Co.,Ltd,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FL115","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Forlong Biotechnology Co.,Ltd,","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Forlong Biotechnology Co.,Ltd, \/ Undisclosed"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"KAIMRC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"FLASH-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Flashpoint Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Flashpoint Therapeutics \/ KAIMRC","highestDevelopmentStatusID":"7","companyTruncated":"Flashpoint Therapeutics \/ KAIMRC"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Flonoltinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Flonoltinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Oryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"FSP Peptide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryx \/ Undisclosed"},{"orgOrder":0,"company":"Forward Pharma","sponsor":"WuXi Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FWD1509","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forward Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forward Pharma \/ WuXi Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Forward Pharma \/ WuXi Clinical"},{"orgOrder":0,"company":"Forward Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FWD1802","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forward Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forward Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Forward Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Forward Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FWD1802","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forward Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forward Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Forward Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GAd20-209-FSP","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nouscom AG \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Merck & Co"},{"orgOrder":0,"company":"Kyushu University","sponsor":"GAIA BioMedicine | Toho University Omori Medical Center | Jichi Medical University | Kindai University Hospital | Teikyo University Hospital | Kansai Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GAIA-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyushu University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyushu University \/ GAIA BioMedicine | Toho University Omori Medical Center | Jichi Medical University | Kindai University Hospital | Teikyo University Hospital | Kansai Medical University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Kyushu University \/ GAIA BioMedicine | Toho University Omori Medical Center | Jichi Medical University | Kindai University Hospital | Teikyo University Hospital | Kansai Medical University Hospital"},{"orgOrder":0,"company":"GAIA BioMedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GAIA-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GAIA BioMedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GAIA BioMedicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GAIA BioMedicine \/ Undisclosed"},{"orgOrder":0,"company":"GAIA BioMedicine","sponsor":"TreeFrog Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"GAIA-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GAIA BioMedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GAIA BioMedicine \/ TreeFrog Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"GAIA BioMedicine \/ TreeFrog Therapeutics"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GB5121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"GD Kongming Biotech","sponsor":"Jinan University Guangzhou","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GDKM-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GD Kongming Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GD Kongming Biotech \/ Jinan University Guangzhou","highestDevelopmentStatusID":"7","companyTruncated":"GD Kongming Biotech \/ Jinan University Guangzhou"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GDX012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gebasaxturev","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GEN1078","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEN1107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GEN1286","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEN3017","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Shanghai East Hospital | Zhejiang University | Fujian Tumor Hospital | Sir Run Run Shaw Hospital | The Affiliated Tumor Hospital of Harbin Medical University | Wuhan Union Hospital | Sixth Affiliated Hospital, Sun Yat-sen University | Tongji Hospital | Sh","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Gentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai East Hospital | Zhejiang University | Fujian Tumor Hospital | Sir Run Run Shaw Hospital | The Affiliated Tumor Hospital of Harbin Medical University | Wuhan Union Hospital | Sixth Affiliated Hospital, Sun Yat-sen University | Tongji Hospital | Sh","highestDevelopmentStatusID":"7","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai East Hospital | Zhejiang University | Fujian Tumor Hospital | Sir Run Run Shaw Hospital | The Affiliated Tumor Hospital of Harbin Medical University | Wuhan Union Hospital | Sixth Affiliated Hospital, Sun Yat-sen University | Tongji Hospital | Sh"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GFS101A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Genhouse Bio Co., Ltd.","sponsor":"Shanghai East Hospital | Shandong Tumor Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GH55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Genhouse Bio Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou Genhouse Bio Co., Ltd. \/ Shanghai East Hospital | Shandong Tumor Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Genhouse Bio Co., Ltd. \/ Shanghai East Hospital | Shandong Tumor Hospital"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"GI-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Innovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Merck & Co"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"GI-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Innovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Merck & Co"},{"orgOrder":0,"company":"GI Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GIC-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GI Cell \/ Undisclosed"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GIM122","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Georgiamune \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GLS-012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GLS-012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GNC-035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GNC-035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune | Baili-Bio (Chengdu) Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune | Baili-Bio (Chengdu) Pharmaceutical"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"SystImmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GNC-038","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baili Pharmaceutical \/ SystImmune","highestDevelopmentStatusID":"7","companyTruncated":"Baili Pharmaceutical \/ SystImmune"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GNR-084","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"Cure&Sure Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"gp96 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese PLA General Hospital \/ Cure&Sure Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ Cure&Sure Biotech"},{"orgOrder":0,"company":"Cure&Sure Biotech","sponsor":"Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"gp96 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cure&Sure Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure&Sure Biotech \/ Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Cure&Sure Biotech \/ Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GPC3 CD146 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Lin BioScience","sponsor":"Lin BioScience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Granaticin B","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lin BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lin BioScience \/ Lin BioScience","highestDevelopmentStatusID":"7","companyTruncated":"Lin BioScience \/ Lin BioScience"},{"orgOrder":0,"company":"Lin BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Granaticin B","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lin BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lin BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lin BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Charles Drew University of Medicine and Science","sponsor":"National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charles Drew University of Medicine and Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Wilmington Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Public Offering","leadProduct":"Grifola Frondosa Maitake Mushroom Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABVC BioPharma \/ Wilmington Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ Wilmington Capital Securities"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"GRT-C901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C901","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GSK4524101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GSK5458514","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GSK5733584","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GT719","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Ganzhou City People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GT719","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Ganzhou City People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"GRIT Biotechnology \/ Ganzhou City People's Hospital"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GV20 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GV20 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GV20 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GV20 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HB0028","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Gabrail Cancer Center Research | Dana-Farber Cancer Institute | MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HB0045","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Gabrail Cancer Center Research | Dana-Farber Cancer Institute | MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Gabrail Cancer Center Research | Dana-Farber Cancer Institute | MD Anderson Cancer Center"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hookipa Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HEC169096","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","sponsor":"Tampere University | University of Jyvaskyla","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Tampere University | University of Jyvaskyla","highestDevelopmentStatusID":"7","companyTruncated":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Tampere University | University of Jyvaskyla"},{"orgOrder":0,"company":"Ever Supreme Bio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Hla-G-Car.Bite Allogeneic T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ever Supreme Bio Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Supreme Bio Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ever Supreme Bio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HLD-0915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Halda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"HLD-0915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halda Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Halda Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Halda Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HLD-0915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Halda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HP568","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"LinKinVax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HPVDC Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gustave Roussy \/ LinKinVax","highestDevelopmentStatusID":"7","companyTruncated":"Gustave Roussy \/ LinKinVax"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-1738","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-2189","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS2398","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HRS2398","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-4357","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fudan University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-4642","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Fudan University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-4642","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-4642","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HRS-4642","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-5041","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-5041","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-5041","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-6209","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-6209","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-6213","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-6719","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-6768","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRX215","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HepaRegeniX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HepaRegeniX \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HepaRegeniX \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10365","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10370","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10370","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10375","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-20105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"HS-410","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heat Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"HSC835","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hamlet Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Human Alpha-Lactalbumin Made Lethal To Tumor Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hamlet Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Hamlet Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hamlet Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Leiden University Medical Center | ISA Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Human Papillomavirus 16 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Leiden University Medical Center | ISA Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Leiden University Medical Center | ISA Pharmaceuticals"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"PersonGen BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Humanized CD7 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ PersonGen BioTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Soochow University \/ PersonGen BioTherapeutics"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Crown Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Crown Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Crown Bioscience"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IBB0979","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IBB0979","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Bellicum Pharmaceuticals | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"iC9-CAR19 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"7","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"iC9-CAR19 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IDP-023","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Series A Financing","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IDP Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"IDP Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"HCA International | Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immodulon Therapeutics \/ HCA International | Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Immodulon Therapeutics \/ HCA International | Theradex"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Immodulon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immodulon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Immodulon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immodulon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmPACT Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Undisclosed"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmPACT Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Undisclosed"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"IN8bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Undisclosed"},{"orgOrder":0,"company":"IN8bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Undisclosed"},{"orgOrder":0,"company":"IN8bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Undisclosed"},{"orgOrder":0,"company":"IN8bio","sponsor":"B. Riley Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ B. Riley Securities","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ B. Riley Securities"},{"orgOrder":0,"company":"IN8bio","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"INB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Barclays","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Barclays"},{"orgOrder":0,"company":"IN8bio","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ University Of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ University Of Alabama"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"INCB047986","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"INCB052793","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"INCB053914","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"INCB059872","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"INCB177054","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Private Placement","leadProduct":"INDP020","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Private Placement","leadProduct":"INDP020","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Neoantigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"iNeo-Vac-P01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Neoantigen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Neoantigen Therapeutics"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Neoantigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"iNeo-Vac-R01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Neoantigen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Neoantigen Therapeutics"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Neoantigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"iNeo-Vac-R01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Neoantigen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Neoantigen Therapeutics"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Neoantigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"iNeo-Vac-R01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Neoantigen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Zhejiang University \/ Neoantigen Therapeutics"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Inkmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Inkmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"INO-3112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"INR102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yunhe Pharmaceutical (Tianjin) Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yunhe Pharmaceutical (Tianjin) Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"INXN-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iovance Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"IOV-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Iovance Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Center, China","sponsor":"Qilu Pharmaceutical | Affiliated Cancer Hospital of Zhengzhou University | Beijing Chest Hospital, Capital Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Shaanxi Provincial Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Iparomlimab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Center, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center, China \/ Qilu Pharmaceutical | Affiliated Cancer Hospital of Zhengzhou University | Beijing Chest Hospital, Capital Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Shaanxi Provincial Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Center, China \/ Qilu Pharmaceutical | Affiliated Cancer Hospital of Zhengzhou University | Beijing Chest Hospital, Capital Medical University | The Affiliated Hospital of Inner Mongolia Medical University | Shaanxi Provincial Cancer Hospital"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"IFLI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ IFLI","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ IFLI"},{"orgOrder":0,"company":"Elro Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IPP204106N","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elro Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elro Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elro Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PsiVac Ltd","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Ixovex-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PsiVac Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PsiVac Ltd \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"PsiVac Ltd \/ IQVIA"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JK08","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JNJ-90014496","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JS015","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JS015","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Risen Suzhou Pharma Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JS105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Risen Suzhou Pharma Tech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Risen Suzhou Pharma Tech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Risen Suzhou Pharma Tech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JS109","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Alphamab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Undisclosed"},{"orgOrder":0,"company":"JOYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JYP0015","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JOYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JOYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"JOYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Primocure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KAT-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Primocure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primocure Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Primocure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Konruns Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KC1036","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Konruns Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Konruns Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Konruns Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Filamon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Kesonotide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Filamon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filamon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Filamon \/ Undisclosed"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KiroVAX 002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kiromic BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KiroVAX 002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kiromic BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"KiroVAX 002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kiromic BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"KiroVAX 002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kiromic BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KL590586","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Kelun Pharmaceutical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sichuan Kelun Pharmaceutical Research Institute \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Kelun Pharmaceutical Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"NCC-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KN510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NCC-Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NCC-Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NCC-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Shanxi Province Cancer Hospital","sponsor":"Immune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KQ-2003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanxi Province Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanxi Province Cancer Hospital \/ Immune Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Shanxi Province Cancer Hospital \/ Immune Therapeutics"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQ-2003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KY-0301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latticon Antibody Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LAT010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Latticon Antibody Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latticon Antibody Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Latticon Antibody Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"L&L Biopharma","sponsor":"Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LB1410","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"L&L Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L&L Biopharma \/ Shanghai East Hospital","highestDevelopmentStatusID":"7","companyTruncated":"L&L Biopharma \/ Shanghai East Hospital"},{"orgOrder":0,"company":"L&L Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LB1410","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"L&L Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L&L Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"L&L Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LBL-015","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute | Henan Cancer Hospital | Hunan Cancer Hospital | The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LBL-019","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Theravectys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Lenti-HPV-07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theravectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theravectys \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theravectys \/ Undisclosed"},{"orgOrder":0,"company":"Theravectys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Lenti-HPV-07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theravectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravectys \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theravectys \/ Undisclosed"},{"orgOrder":0,"company":"Lion TCR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"LioCyx-M004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lion TCR \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Undisclosed"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LIS1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LM101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LM-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Shanghai Zhongshan Hospital | First Affiliated Hospital of Harbin Medical University | First Affiliated Hospital of Zhejiang University | Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LM-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LM-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LM-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LM-2417","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LM-24C5","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ AstraZeneca"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LM-305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Integro Theranostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LS301-IT","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Integro Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Integro Theranostics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Integro Theranostics \/ Undisclosed"},{"orgOrder":0,"company":"Letolab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LTC004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Letolab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Letolab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Letolab \/ Undisclosed"},{"orgOrder":0,"company":"Letolab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LTC004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Letolab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Letolab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Letolab \/ Undisclosed"},{"orgOrder":0,"company":"NaviFUS","sponsor":"NaviFUS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NaviFUS \/ NaviFUS","highestDevelopmentStatusID":"7","companyTruncated":"NaviFUS \/ NaviFUS"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lumbar Puncture","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Luzitin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LUZ11","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Luzitin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luzitin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Luzitin \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY010616","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"M9140","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MaaT011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunocore","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"MAGE-A4","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ General Atlantic"},{"orgOrder":0,"company":"The First People's Hospital of Lianyungang","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Masct-I","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First People's Hospital of Lianyungang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mavrostobart","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ BeOne Medicines"},{"orgOrder":0,"company":"Maxinovel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MAX-40279","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maxinovel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maxinovel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maxinovel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Maxinovel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MAX-40279-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maxinovel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maxinovel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maxinovel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Maxinovel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MAX-40279-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maxinovel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maxinovel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Maxinovel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MBRC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MBrace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MBS303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBS314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG1011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MDX2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ModeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ModeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MDX2004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ModeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ModeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Mesothelin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Cancer Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Mesothelin Specific Car-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ningbo Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ningbo Cancer Hospital \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ningbo Cancer Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Provincial Cancer Hospital","sponsor":"Anhui Kecheng intelligent health technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"METR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anhui Provincial Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anhui Provincial Cancer Hospital \/ Anhui Kecheng intelligent health technology","highestDevelopmentStatusID":"7","companyTruncated":"Anhui Provincial Cancer Hospital \/ Anhui Kecheng intelligent health technology"},{"orgOrder":0,"company":"Anhui Provincial Cancer Hospital","sponsor":"Anhui Kecheng intelligent health technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"METR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anhui Provincial Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Provincial Cancer Hospital \/ Anhui Kecheng intelligent health technology","highestDevelopmentStatusID":"7","companyTruncated":"Anhui Provincial Cancer Hospital \/ Anhui Kecheng intelligent health technology"},{"orgOrder":0,"company":"Ectin Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MFA-370","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ectin Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ectin Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ectin Research \/ Undisclosed"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Ottawa Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MG1MA3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Ottawa Hospital Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Canadian Cancer Trials Group \/ Ottawa Hospital Research Institute"},{"orgOrder":0,"company":"Xijing Hospital","sponsor":"Shanghai GeneChem Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"MG7-CART Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xijing Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xijing Hospital \/ Shanghai GeneChem Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Xijing Hospital \/ Shanghai GeneChem Co., Ltd."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MHB046C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Dutch Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"MiHA-loaded PD-L1\/L2-Silenced Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radboud University Medical Center \/ ZonMw | Dutch Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Radboud University Medical Center \/ ZonMw | Dutch Cancer Society"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-1045","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-1088","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-1200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-3120","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MLM-CAR44.1 T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AGC Biologics \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ European Commission"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Mobilized Peripheral Blood Cell Graft","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Scancell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Modi-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scancell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/ Undisclosed"},{"orgOrder":0,"company":"Scancell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Modi-1 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scancell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MPB-1734","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"The Canadian Collaborative for Childhood Cannabinoid Therapeutics | Canadian Cancer Society | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MPL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Manitoba \/ The Canadian Collaborative for Childhood Cannabinoid Therapeutics | Canadian Cancer Society | Canadian Institutes of Health Research","highestDevelopmentStatusID":"7","companyTruncated":"University of Manitoba \/ The Canadian Collaborative for Childhood Cannabinoid Therapeutics | Canadian Cancer Society | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"mRNA-2808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-4359","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4359","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hitachi Chemical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MSC_apceth_101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hitachi Chemical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Chemical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MT-4561","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"NanoPass Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ NanoPass Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ NanoPass Technologies"},{"orgOrder":0,"company":"Optimal Health Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Optimal Health Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optimal Health Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Optimal Health Research \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Hebei Taihe Chunyu Biotechnology | Huazhong University of Science and Technology Union Shenzhen Hospital | The Seventh Affiliated Hospital of Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Nanobody-Based Biepitope Car-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology | Huazhong University of Science and Technology Union Shenzhen Hospital | The Seventh Affiliated Hospital of Sun Yat-sen University","highestDevelopmentStatusID":"7","companyTruncated":"Wuhan Union Hospital \/ Hebei Taihe Chunyu Biotechnology | Huazhong University of Science and Technology Union Shenzhen Hospital | The Seventh Affiliated Hospital of Sun Yat-sen University"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Hebei Senlang Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Nanobody-Based CD19\/CD22 Tandem Dual CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking University People's Hospital \/ Hebei Senlang Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Hebei Senlang Biotechnology"},{"orgOrder":0,"company":"NantPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NANT-008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NantPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NantPharma \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NBP615","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"The First People's Hospital of Lianyungang","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Neoantigen Multiple Target Antigen Stimulating Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First People's Hospital of Lianyungang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Neoantigen specific TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immune System Key","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nerofe","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune System Key","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune System Key \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immune System Key \/ Undisclosed"},{"orgOrder":0,"company":"NexImmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NEXI-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NexImmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Undisclosed"},{"orgOrder":0,"company":"NexImmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NexImmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Undisclosed"},{"orgOrder":0,"company":"NexImmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NexImmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Undisclosed"},{"orgOrder":0,"company":"NexImmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NEXI-002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NexImmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Undisclosed"},{"orgOrder":0,"company":"NexImmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NEXI-002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NexImmune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Nivolimumab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKR-2 CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ IQVIA"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKR-2 CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NKR-2 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Undisclosed"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Undisclosed"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Undisclosed"},{"orgOrder":0,"company":"Xennials Therapeutics Australia Pty Ltd","sponsor":"PINOTBIO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTX-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xennials Therapeutics Australia Pty Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xennials Therapeutics Australia Pty Ltd \/ PINOTBIO","highestDevelopmentStatusID":"7","companyTruncated":"Xennials Therapeutics Australia Pty Ltd \/ PINOTBIO"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"NUC-7738","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3 Cl\u00ednic Barcelona","sponsor":"SOLTI Breast Cancer Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NUMARZU-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3 Cl\u00ednic Barcelona","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fundaci\u00f3 Cl\u00ednic Barcelona \/ SOLTI Breast Cancer Research Group","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3 Cl\u00ednic Barcelona \/ SOLTI Breast Cancer Research Group"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nusivertib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"NovalGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NovalGen \/ Undisclosed"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Maxim Group LLC"},{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Demerger","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ INVO Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"NAYA Therapeutics \/ INVO Bioscience"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Syena","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Replay Bio \/ Syena","highestDevelopmentStatusID":"7","companyTruncated":"Replay Bio \/ Syena"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"NY-ESO-1(c259) T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adaptimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"NY-ESO-1(c259) T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adaptimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"NY-ESO-1c259-Modified T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adaptimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ocellaris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"OC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ocellaris Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocellaris Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ocellaris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ODM-212","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Genelux","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Newsoara Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Newsoara Biopharma","sponsor":"Shanghai Chest Hospital | Zhejiang Provincial People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Newsoara Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newsoara Biopharma \/ Shanghai Chest Hospital | Zhejiang Provincial People\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Newsoara Biopharma \/ Shanghai Chest Hospital | Zhejiang Provincial People\u2019s Hospital"},{"orgOrder":0,"company":"Darell Bigner","sponsor":"Istari Oncology | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Oncolytic Polio-Rhinovirus Recombinant","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Darell Bigner","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Darell Bigner \/ Istari Oncology | Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Darell Bigner \/ Istari Oncology | Genentech"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Medac","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Medac"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Karolinska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"Oncorena","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Linc AB","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Linc AB"},{"orgOrder":0,"company":"Oncorena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncorena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ori-C101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Series B Financing","leadProduct":"Ori-C101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OriCAR-017","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OriCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oshadi Drug Administration","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SRI LANKA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Oshadi D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oshadi Drug Administration","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oshadi Drug Administration \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oshadi Drug Administration \/ Undisclosed"},{"orgOrder":0,"company":"CAS Lamvac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"P.Vivax Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CAS Lamvac Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAS Lamvac Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CAS Lamvac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CAS Lamvac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"P.Vivax Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CAS Lamvac Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAS Lamvac Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CAS Lamvac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Precision Biotechnology","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PB103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision Biotechnology \/ Tri-Service General Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biotechnology \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"P-BCMA-101 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"7","companyTruncated":"Poseida Therapeutics, Inc \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"The First Affiliated Hospital of Guangdong Pharmaceutical University","sponsor":"Anjie Biomedical Technology | University of Technology, Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"PD-1 Knockout T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Guangdong Pharmaceutical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology | University of Technology, Sydney","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology | University of Technology, Sydney"},{"orgOrder":0,"company":"Biosuccess Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PD-616","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biosuccess Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosuccess Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biosuccess Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PDC*lung01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDC*line Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HyaMab Biotech Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PE0116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai HyaMab Biotech Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai HyaMab Biotech Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai HyaMab Biotech Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HyaMab Biotech Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PE0116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai HyaMab Biotech Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai HyaMab Biotech Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai HyaMab Biotech Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Shanghai HyaMab Biotech Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PE0116","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Shanghai HyaMab Biotech Co.,Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Shanghai HyaMab Biotech Co.,Ltd."},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Deutsches Konsortium f\u00fcrTranslationale Krebsforschung | Cooperative Ewing Sarkom Studiengruppe | Cooperative Weichteilsarkom Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Peptide Vaccine IPX","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Deutsches Konsortium f\u00fcrTranslationale Krebsforschung | Cooperative Ewing Sarkom Studiengruppe | Cooperative Weichteilsarkom Study Group","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital T\u00fcbingen \/ Deutsches Konsortium f\u00fcrTranslationale Krebsforschung | Cooperative Ewing Sarkom Studiengruppe | Cooperative Weichteilsarkom Study Group"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PH009-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Puhe Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Puhe Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Valerio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Plasmid Amep","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Valerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valerio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Valerio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Valerio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Plasmid Amep","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Valerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valerio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Valerio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Conjupro Biotherapeutics","sponsor":"CSPC ZhongQi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PLM60","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Conjupro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Conjupro Biotherapeutics \/ CSPC ZhongQi","highestDevelopmentStatusID":"7","companyTruncated":"Conjupro Biotherapeutics \/ CSPC ZhongQi"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PM1003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PM1022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"Biotheus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PM1032","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotheus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"The V Foundation for Cancer Research | National Pediatric Cancer Foundation | Alex's Lemonade Stand Foundation | The Osteosarcoma Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"pp65 RNA LP","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ The V Foundation for Cancer Research | National Pediatric Cancer Foundation | Alex's Lemonade Stand Foundation | The Osteosarcoma Institute | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ The V Foundation for Cancer Research | National Pediatric Cancer Foundation | Alex's Lemonade Stand Foundation | The Osteosarcoma Institute | National Cancer Institute"},{"orgOrder":0,"company":"Shanghai International Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Precision Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai International Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai International Medical Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai International Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Cancer Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Precision Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ningbo Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ningbo Cancer Hospital \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ningbo Cancer Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Prizloncabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai AbelZeta Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellular Biomedicine Group","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Cellular Biomedicine Group \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Cellular Biomedicine Group \/ Janssen Biotech"},{"orgOrder":0,"company":"Zhuhai Yufan Biotechnologies Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PRJ1-3024","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhuhai Yufan Biotechnologies Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Yufan Biotechnologies Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRJ1-3024","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhuhai Yufan Biotechnologies Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Yufan Biotechnologies Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PRJ1-3024","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zhuhai Yufan Biotechnologies Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zhuhai Yufan Biotechnologies Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PRO1107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PRO1160","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"Pyrotech Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PTT-936","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyrotech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyrotech Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pyrotech Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Shengjing Hospital | Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Henan Cancer Hospital | Gansu Provincial Maternal and Child Health Care Hospital |","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"QL1706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking Union Medical College Hospital \/ Shengjing Hospital | Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Henan Cancer Hospital | Gansu Provincial Maternal and Child Health Care Hospital |","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ Shengjing Hospital | Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Henan Cancer Hospital | Gansu Provincial Maternal and Child Health Care Hospital |"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"QL1706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"QL1706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLC1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLF31907","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QLF31907","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLH12016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLH12016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLP2117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLP2117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"R906289 Monosodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rapa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Rapamycin Resistant T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rapa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Hackensack Meridian Health | Georgetown University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Rapamycin-resistant, Th1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Hackensack Meridian Health | Georgetown University","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Hackensack Meridian Health | Georgetown University"},{"orgOrder":0,"company":"Ruishun Biotech","sponsor":"Anhui Provincial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RC1012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ruishun Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ruishun Biotech \/ Anhui Provincial Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Ruishun Biotech \/ Anhui Provincial Hospital"},{"orgOrder":0,"company":"Ruishun Biotech","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RC1012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ruishun Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ruishun Biotech \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"7","companyTruncated":"Ruishun Biotech \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RC148","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RC278","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Joshua Brody","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human Flt3 Ligand","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Joshua Brody","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joshua Brody \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Joshua Brody \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human IL12\/15-PDL1B Oncolytic HSV-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virogin Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virogin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Human IL-7-hyFc","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ NeoImmuneTech | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ NeoImmuneTech | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Mycobacterium BCG Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN10597","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN7945","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aptorum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Undisclosed"},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aptorum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Undisclosed"},{"orgOrder":0,"company":"Aptorum","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptorum","sponsor":"Aenco Technologies Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Aenco Technologies Limited","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Aenco Technologies Limited"},{"orgOrder":0,"company":"Aptorum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Undisclosed"},{"orgOrder":0,"company":"Aptorum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Undisclosed"},{"orgOrder":0,"company":"Coordination Pharmaceuticals","sponsor":"University of Illinois, Chicago","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RiMO-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coordination Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coordination Pharmaceuticals \/ University of Illinois, Chicago","highestDevelopmentStatusID":"7","companyTruncated":"Coordination Pharmaceuticals \/ University of Illinois, Chicago"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RO7247669","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"RO7247669","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RO7247669","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Asclepius Technology Company Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ROBO1 CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asclepius Technology Company Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asclepius Technology Company Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asclepius Technology Company Group \/ Undisclosed"},{"orgOrder":0,"company":"Asclepius Technology Company Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ROBO1 CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asclepius Technology Company Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asclepius Technology Company Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asclepius Technology Company Group \/ Undisclosed"},{"orgOrder":0,"company":"Asclepius Technology Company Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ROBO1 CAR-NK\/T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asclepius Technology Company Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asclepius Technology Company Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asclepius Technology Company Group \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EIR Biotherapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RR001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EIR Biotherapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EIR Biotherapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EIR Biotherapies \/ Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"S 64315","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S 64315","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S095018","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Merck & Co | Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S095029","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Merck & Co | Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Merck & Co | Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S095033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"S095035","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Kansai Hepatobiliary Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"S-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kansai Hepatobiliary Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansai Hepatobiliary Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kansai Hepatobiliary Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"S227928","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"S410914","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"S-531011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Shionogi \/ Merck & Co"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"S65487","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"S65487","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S81694","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lamassu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lamassu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SAF-189s","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR445514","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SBT6290","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silverback Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Silverback Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SC0191","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SC0245","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RAND Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SC-43","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RAND Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RAND Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RAND Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG142","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCG Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Sinogen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SGN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinogen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinogen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinogen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sinogen Pharmaceutical","sponsor":"Pharmaron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SGN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sinogen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinogen Pharmaceutical \/ Pharmaron","highestDevelopmentStatusID":"7","companyTruncated":"Sinogen Pharmaceutical \/ Pharmaron"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-1681","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-1826","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-1826","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-3276","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-4375","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-7787","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-9803","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-9839","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-9839","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-A1811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-A1811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-A1811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Atridia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR-A1811","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Atridia","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Atridia"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-A1904","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-A1912","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-A1912","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-A1921","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-A1921","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-A1921","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-A2009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-A2009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-A2009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-A2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-A2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-A2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-A2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SKL27969","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Life Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SK Life Science \/ Undisclosed"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SL-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemline Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SignalChem Lifesciences Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SLC-391","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SignalChem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SignalChem Lifesciences Corporation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"SignalChem Lifesciences Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Seqens","sponsor":"Smart Immune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqens \/ Smart Immune","highestDevelopmentStatusID":"7","companyTruncated":"Seqens \/ Smart Immune"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Smart Immune","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ European Innovation Council","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ European Innovation Council"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SMP3124LP","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Senesco Technologies, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SNS01-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senesco Technologies, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senesco Technologies, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Senesco Technologies, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"THERAPIM PTY LTD","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Deoxycholate","moa":"Cell membrane||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"THERAPIM PTY LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"THERAPIM PTY LTD \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"THERAPIM PTY LTD \/ Novotech"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Spevatamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SPH4336","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SPH4336","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"Peking University | EdiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SPPL3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ Peking University | EdiGene","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ Peking University | EdiGene"},{"orgOrder":0,"company":"Beijing Scitech-Mq Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ST-1898","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Scitech-Mq Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Scitech-Mq Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Scitech-Mq Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Scitech-Mq Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ST-1898","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Scitech-Mq Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Scitech-Mq Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Scitech-Mq Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Angelor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Angelor","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Angelor"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"French Blood Establishment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ French Blood Establishment","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ French Blood Establishment"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Super Dc Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Super DC Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Won & Partners"},{"orgOrder":0,"company":"Shouyao Holdings (Beijing) Co. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SY-5933","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shouyao Holdings (Beijing) Co. LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Shouyao Holdings (Beijing) Co. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SY-5933","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shouyao Holdings (Beijing) Co. LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SyB L-0501RI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SYHA1813","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","sponsor":"Jilin Provincial Tumor Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SYHA1815","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Jilin Provincial Tumor Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Runshi Pharmaceutical Technology Co., Ltd \/ Jilin Provincial Tumor Hospital"},{"orgOrder":0,"company":"CSPC Megalith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SYS6010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC Megalith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Megalith \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC Megalith \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Megalith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SYS6045","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC Megalith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Megalith \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC Megalith \/ Undisclosed"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"T3P-Y058-739","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T3 Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T3 Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"T3 Pharma \/ Undisclosed"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"T3P-Y058-739","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T3 Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"T3 Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series A Financing","leadProduct":"TAC01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Triumvira Immunologics \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Bayer AG"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TAK-853","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAS3351","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Twinpig Biolab, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TB511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Twinpig Biolab, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Twinpig Biolab, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Twinpig Biolab, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"TBI-1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takara Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takara Bio \/ Undisclosed"},{"orgOrder":0,"company":"Taiga Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TBX-3400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiga Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiga Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiga Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TCC1727","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Tide Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Tide Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TCRCure Biopharma","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TC-E202 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCRCure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCRCure Biopharma \/ Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"TCRCure Biopharma \/ Fudan University"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TER-2013","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Terremoto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Terremoto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Terremoto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"INSERM | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"TF2-68Ga-IMP-288","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ INSERM | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ INSERM | Gilead Sciences"},{"orgOrder":0,"company":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TFX05-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TFX06","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-814","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Undisclosed"},{"orgOrder":0,"company":"Theolytics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Undisclosed"},{"orgOrder":0,"company":"Theolytics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Financing","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Sound Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Sound Bioventures"},{"orgOrder":0,"company":"Cliniques Universitaires Saint-Luc","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Theravac Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cliniques Universitaires Saint-Luc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cliniques Universitaires Saint-Luc \/ Institut Pasteur","highestDevelopmentStatusID":"7","companyTruncated":"Cliniques Universitaires Saint-Luc \/ Institut Pasteur"},{"orgOrder":0,"company":"T-knife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-knife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Undisclosed"},{"orgOrder":0,"company":"T-knife","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"T-knife \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"T-knife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-knife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Junde Biotechnology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TL117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junde Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou Junde Biotechnology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junde Biotechnology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Elios Therapeutics","sponsor":"LumaBridge","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Tlpldc Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elios Therapeutics \/ LumaBridge","highestDevelopmentStatusID":"7","companyTruncated":"Elios Therapeutics \/ LumaBridge"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TNG456","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Centre Antoine Lacassagne","sponsor":"GORTEC | GERCOR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TPF2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Centre Antoine Lacassagne","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Antoine Lacassagne \/ GORTEC | GERCOR","highestDevelopmentStatusID":"7","companyTruncated":"Centre Antoine Lacassagne \/ GORTEC | GERCOR"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Cortice Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TPI 287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Cortice Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Cortice Biosciences"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Cortice Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TPI 287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Cortice Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Cortice Biosciences"},{"orgOrder":0,"company":"Giselle Sholler","sponsor":"Cortice Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TPI 287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Giselle Sholler","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giselle Sholler \/ Cortice Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Giselle Sholler \/ Cortice Biosciences"},{"orgOrder":0,"company":"Giselle Sholler","sponsor":"Cortice Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"TPI 287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Giselle Sholler","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giselle Sholler \/ Cortice Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Giselle Sholler \/ Cortice Biosciences"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TQ-A3334","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQ-A3334","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TQB2303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TQB2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQB2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQB2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQB2858","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQB2858","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQB2858","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB2922","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQB3454","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TQ-B3525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQ-B3525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQ-B3525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB3728","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQB3823","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB3909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB3909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQB3909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQB3909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQB3912","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lightspeed Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series D Financing","leadProduct":"TRGFT-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Lightspeed Venture","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/ Lightspeed Venture"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"TesoRx Pharma, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TSD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ TesoRx Pharma, LLC","highestDevelopmentStatusID":"7","companyTruncated":"LIPAC Oncology \/ TesoRx Pharma, LLC"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN1611","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TSN1611","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TSN222","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tyligand Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Tubulis \/ EQT Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ EQT Life Sciences"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nantes University Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nantes University Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CAR-T Cell Biotechnology","sponsor":"Eastern Hepatobiliary Surgery Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Tumor Infiltrating Lymphocyte","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CAR-T Cell Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CAR-T Cell Biotechnology \/ Eastern Hepatobiliary Surgery Hospital","highestDevelopmentStatusID":"7","companyTruncated":"CAR-T Cell Biotechnology \/ Eastern Hepatobiliary Surgery Hospital"},{"orgOrder":0,"company":"Tayu Huaxia Biotech Medical Group Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TY101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tayu Huaxia Biotech Medical Group Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tayu Huaxia Biotech Medical Group Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tayu Huaxia Biotech Medical Group Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"U16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"U32 CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UCB4594","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cancer Research UK \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Umbilical Cord-Derived Ex Vivo Expanded Stem And Progenitor Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord-Derived Ex Vivo Expanded Stem And Progenitor Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"UV1 synthetic peptide vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultimovacs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs \/ Undisclosed"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"UV1 synthetic peptide vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs \/ Oslo University Hospital"},{"orgOrder":0,"company":"Immunitor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"V3-X","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Immunitor \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunitor \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","sponsor":"Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VB15010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd \/ Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"Valerio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VIO-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Valerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Valerio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Valerio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Vivomixx","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Perrigo Company plc","highestDevelopmentStatusID":"7","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Perrigo Company plc"},{"orgOrder":0,"company":"Vironexis Biotherapeutics Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VNX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vironexis Biotherapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vironexis Biotherapeutics Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vironexis Biotherapeutics Inc. \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Undisclosed"},{"orgOrder":0,"company":"Guangdong Provincial People's Hospital","sponsor":"Virotech Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VRT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Guangdong Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangdong Provincial People's Hospital \/ Virotech Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Guangdong Provincial People's Hospital \/ Virotech Pharmaceutical"},{"orgOrder":0,"company":"Xiangya Hospital, Central South University","sponsor":"Virotech Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VRT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xiangya Hospital, Central South University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiangya Hospital, Central South University \/ Virotech Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Xiangya Hospital, Central South University \/ Virotech Pharmaceutical"},{"orgOrder":0,"company":"Virotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VRT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vestan, Inc.","sponsor":"MD Anderson Cancer Center | Huntsman Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"VST-1001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vestan, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vestan, Inc. \/ MD Anderson Cancer Center | Huntsman Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Vestan, Inc. \/ MD Anderson Cancer Center | Huntsman Cancer Institute"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"W0101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"WJ05129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Suzhou Junjing BioSciences Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"WJ13404","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Junjing BioSciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Junjing BioSciences Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"WJB001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wigen Biomedicine Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wigen Biomedicine Technology \/ Sponsor GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Wigen Biomedicine Technology \/ Sponsor GmbH"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"WJB001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wigen Biomedicine Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wigen Biomedicine Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wigen Biomedicine Technology \/ Undisclosed"},{"orgOrder":0,"company":"Cell Medica","sponsor":"University College, London | Cell Therapy Catapult","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"WT1 TCR-Transduced T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cell Medica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Medica \/ University College, London | Cell Therapy Catapult","highestDevelopmentStatusID":"7","companyTruncated":"Cell Medica \/ University College, London | Cell Therapy Catapult"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XNW28012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"XON7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"Nova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XS-03","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nova \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"XZP-3287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-5955","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xuanzhu Biopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xuanzhu Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ BankM AG"},{"orgOrder":0,"company":"Y Biologics Inc.","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"YBL-006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y Biologics Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y Biologics Inc. \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Y Biologics Inc. \/ Novotech"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"YH32367","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YH42946","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Excyte Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YK012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Excyte Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Excyte Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Excyte Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Shanghai Yingli Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"YL-15293","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Shanghai Yingli Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Shanghai Yingli Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"YL-15293","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"YL201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"YL201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"YL201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YL205","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Z650","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ Zai Lab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10516","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10516","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10516","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Virttu Biologics Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HSV1716","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virttu Biologics Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virttu Biologics Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Virttu Biologics Limited \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HTMC0435","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HY004","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HY004","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IAE0972","moa":"Unknown","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HSK39775","moa":"USP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"USP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Undisclosed"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ GSK"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"SCRI Development Innovations, LLC \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can"},{"orgOrder":0,"company":"Hawaii Pacific Health","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hawaii Pacific Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hawaii Pacific Health \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Hawaii Pacific Health \/ Genentech"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"The Netherlands Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Chinese PLA General Hospital \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ BeOne Medicines"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Fudan University"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PharmaBio Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ PharmaBio Development","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ PharmaBio Development"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Quintiles Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Quintiles Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Roswell Park Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc | National Cancer Institute"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aveo Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aveo Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aveo Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AIV001","moa":"Vascular endothelial growth factor receptor (VEGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Bristol Myers Squibb | European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lucitanib","moa":"Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Bristol Myers Squibb | European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Bristol Myers Squibb | European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Peking University Cancer Hospital & Institute","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University Cancer Hospital & Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University Cancer Hospital & Institute \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Peking University Cancer Hospital & Institute \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"The First People's Hospital of Lianyungang","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First People's Hospital of Lianyungang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"The First People's Hospital of Lianyungang \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Bukwang Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Bukwang Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Elevar Therapeutics \/ Bukwang Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Colorado, Denver \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Merck & Co"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Exelixis"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Undisclosed"},{"orgOrder":0,"company":"Exelixis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Undisclosed"},{"orgOrder":0,"company":"Exelixis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Undisclosed"},{"orgOrder":0,"company":"Exelixis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Undisclosed"},{"orgOrder":0,"company":"John Rieth","sponsor":"Exelixis | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"John Rieth","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"John Rieth \/ Exelixis | University of Iowa","highestDevelopmentStatusID":"7","companyTruncated":"John Rieth \/ Exelixis | University of Iowa"},{"orgOrder":0,"company":"Anwaar Saeed","sponsor":"AstraZeneca | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anwaar Saeed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anwaar Saeed \/ AstraZeneca | Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Anwaar Saeed \/ AstraZeneca | Exelixis"},{"orgOrder":0,"company":"Korean Cancer Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Korean Cancer Study Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korean Cancer Study Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korean Cancer Study Group \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Center, Japan","sponsor":"Ono Pharmaceutical | Fiverings","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Center, Japan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center, Japan \/ Ono Pharmaceutical | Fiverings","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Center, Japan \/ Ono Pharmaceutical | Fiverings"},{"orgOrder":0,"company":"Hellenic Cooperative Oncology Group","sponsor":"Eli Lilly | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Cooperative Oncology Group \/ Eli Lilly | Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Cooperative Oncology Group \/ Eli Lilly | Celgene Corporation"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Pharm-Olam","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Pharm-Olam","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Pharm-Olam"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Theradex"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Theradex"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Exelixis"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PharmaBio Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Golvatinib","moa":"Vascular endothelial growth factor receptor 2 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ PharmaBio Development","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ PharmaBio Development"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Golvatinib","moa":"Vascular endothelial growth factor receptor 2 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Quintiles Inc","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Quintiles Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Golvatinib","moa":"Vascular endothelial growth factor receptor 2 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"Jubilant Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"JI-101","moa":"Vascular endothelial growth factor receptor 2 | Platelet-derived growth factor receptor beta | Ephrin type-B receptor 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Jubilant Innovation","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Jubilant Innovation"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Peking University Shougang Hospital | Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Famitinib","moa":"Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor 3 | Vascular endothelial growth factor receptor 1 | Stem cell growth factor receptor | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Peking University Shougang Hospital | Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Peking University Shougang Hospital | Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AAVAnc80-antiVEGF","moa":"VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK109","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK109","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK109","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Cancer Hospital","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Cancer Hospital \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Cancer Hospital \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sarcoma Oncology Research Center","sponsor":"Advenchen Laboratories, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Oncology Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Oncology Research Center \/ Advenchen Laboratories, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Oncology Research Center \/ Advenchen Laboratories, LLC"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Drebuxelimab","moa":"||VEGFA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"VEGFA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Anderson Cancer Center \/ Summit Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Summit Therapeutics"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TU2218","moa":"VEGFR1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Tiumbio \/ Merck & Co"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TU2218","moa":"VEGFR1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tiumbio \/ Undisclosed"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||VEGFR1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tiumbio \/ Undisclosed"},{"orgOrder":0,"company":"Indiana University","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Indiana University \/ Exelixis"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group | Pfizer Inc"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXM01","moa":"||VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegavivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iterion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegavivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iterion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegavivint","moa":"||vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iterion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iterion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintara Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Merger","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Yumanity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Merck & Co"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Merck & Co"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Prolexys Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PRLX 93936","moa":"Voltage-dependent anion-selective channel protein 2; Voltage-dependent anion-selective channel protein 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prolexys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolexys Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prolexys Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deuterium Oxide","moa":"Water","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Pharmacyclics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Debiopharm | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"MEDSIR \/ Debiopharm | Gilead Sciences"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"DSP-7888","moa":"Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"DSP-7888","moa":"Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"DSP-7888","moa":"Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Merck & Co"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Merck & Co"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ombipepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"GSK","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GSK4418959","moa":"WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Ideaya Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NDI-219216","moa":"WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Wadjet","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NDI-219216","moa":"WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Wadjet","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Wadjet \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Wadjet \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"INO-5401","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"INO-5401","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"WT1\/PRAME","moa":"WT1\/PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis protein||XIAP messenger RNA (XIAP mRNA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis protein||XIAP messenger RNA (XIAP mRNA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ATG-010","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATG-016","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATG-016","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"ZG16B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MGB Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Zinc Tetra-Ascorbo-Camphorate","moa":"Zinc","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MGB Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGB Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MGB Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vector Vitale LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Zinc-64 Aspartate","moa":"Zinc","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vector Vitale LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vector Vitale LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vector Vitale LLC \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai GeneChem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai GeneChem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai GeneChem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai GeneChem \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second People's Hospital of Huai'an | PersonGen BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second People's Hospital of Huai'an | PersonGen BioTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Soochow University \/ The First Affiliated Hospital with Nanjing Medical University | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | The Second People's Hospital of Huai'an | PersonGen BioTherapeutics"},{"orgOrder":0,"company":"The First Affiliated Hospital of Guangdong Pharmaceutical University","sponsor":"Anjie Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital of Guangdong Pharmaceutical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital of Guangdong Pharmaceutical University \/ Anjie Biomedical Technology"},{"orgOrder":0,"company":"Xinqiao Hospital, Chongqing","sponsor":"TCRCure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xinqiao Hospital, Chongqing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Xinqiao Hospital, Chongqing \/ TCRCure Biopharma"},{"orgOrder":0,"company":"NKMax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKMax \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Undisclosed"},{"orgOrder":0,"company":"AbClon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbClon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbClon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbClon \/ Undisclosed"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First People's Hospital of Hefei | Hefei Binhu Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital","highestDevelopmentStatusID":"7","companyTruncated":"PersonGen BioTherapeutics \/ The First People's Hospital of Hefei | Hefei Binhu Hospital"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CellPoint","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellPoint","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"CellPoint \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"CellPoint \/ Galapagos"},{"orgOrder":0,"company":"Onxeo","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Gustave Roussy"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Etherna","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Etherna \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ European Commission"},{"orgOrder":0,"company":"Etherna","sponsor":"Vub","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Etherna \/ Vub","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ Vub"},{"orgOrder":0,"company":"Adcendo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Ori Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Therapeutics \/ Ori Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Ori Biotech"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Therapeutics \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Adcendo","sponsor":"Dawn Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Dawn Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Dawn Biopharma"},{"orgOrder":0,"company":"Adcendo","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcendo","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Pontifax Venture Capital","highestDevelopmentStatusID":"7","companyTruncated":"Adcendo \/ Pontifax Venture Capital"},{"orgOrder":0,"company":"IGEA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TURKEY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGEA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"IGEA \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IGEA \/ Undisclosed"},{"orgOrder":0,"company":"Immunicom Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunicom Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunicom Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunicom Inc \/ Undisclosed"},{"orgOrder":0,"company":"Southern Illinois University","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Southern Illinois University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Southern Illinois University \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Southern Illinois University \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intima Bioscience \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bioscience \/ MaxCyte"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abound Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abound Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Abound Bio \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"Abound Bio \/ Galapagos"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alaunos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Yongchang Zhang","sponsor":"Shanghai Houchao Biotechnology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yongchang Zhang","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yongchang Zhang \/ Shanghai Houchao Biotechnology Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Yongchang Zhang \/ Shanghai Houchao Biotechnology Co., Ltd"},{"orgOrder":0,"company":"Novatim Immune Therapeutics","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-601","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novatim Immune Therapeutics","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Novatim Immune Therapeutics \/ Radiance Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Novatim Immune Therapeutics \/ Radiance Biopharma"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Socazolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ZKAB001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"225-Ac Dotatate RYZ101","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Undisclosed"},{"orgOrder":0,"company":"One-carbon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TH9619","moa":"MTHFD1L | MTHFD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"One-carbon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"One-carbon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"One-carbon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"University Hospital Freiburg | Technical University of Munich | National Center for Tumor Diseases, Heidelberg | Wuerzburg University Hospital | Berlin Institute of Health | Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD318-CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital T\u00fcbingen \/ University Hospital Freiburg | Technical University of Munich | National Center for Tumor Diseases, Heidelberg | Wuerzburg University Hospital | Berlin Institute of Health | Miltenyi Biotec","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital T\u00fcbingen \/ University Hospital Freiburg | Technical University of Munich | National Center for Tumor Diseases, Heidelberg | Wuerzburg University Hospital | Berlin Institute of Health | Miltenyi Biotec"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Biosplice","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK|DYRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Biosplice","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Biosplice"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AZD3632","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Xerient Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amifostine","moa":"TNSALP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xerient Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xerient Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xerient Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CVL006","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABL103","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BMS-986517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Nagoya University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nagoya University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nagoya University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Nagoya University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ALE.P03","moa":"CLDN1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"YL202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"IMM2510","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneOnco \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"TQB3201","moa":"AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"GI-108","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GI Innovation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"QLC1401","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IDE849","moa":"DLL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"AstraZeneca | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ AstraZeneca | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ AstraZeneca | AbbVie Inc"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Fresubin Supportan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"PAREXEL International Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AZD0516","moa":"STEAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ PAREXEL International Corporation","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BNT329","moa":"CA19-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu BetaBart","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radiopharm Theranostics \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Radiopharm Theranostics \/ Medpace, Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MHB042C","moa":"Top I|c-Met","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"MHB048C","moa":"PSMA|Top I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vironexis Biotherapeutics Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"VNX-202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vironexis Biotherapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vironexis Biotherapeutics Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vironexis Biotherapeutics Inc. \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6621","moa":"STEAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-103","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"YL242","moa":"Top1 | VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"MediLink Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediLink Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GFH276","moa":"RAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"QLC5508","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Atebimetinib","moa":"||MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Leerink Partners"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Atebimetinib","moa":"||MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Sanofi"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"XenoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Masofaniten","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Essa Pharma \/ XenoTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ XenoTherapeutics"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Alnodesertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"CXCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"}]

    Find Oncology Drugs in Phase I/II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-453

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With ...

                            Details : ABBV-453 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2025

                            Lead Product(s) : ABBV-453

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etentamig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myel...

                            Details : Etentamig is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 24, 2025

                            Lead Product(s) : Etentamig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telisotuzumab Adizutecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizuteca...

                            Details : Telisotuzumab Adizutecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Telisotuzumab Adizutecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orion Corporation

                            Finland
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ODM-212

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours

                            Details : ODM-212 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : ODM-212

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seqens

                            France
                            CPhI WW Frankfurt
                            Booth #11.0C76
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Smart Immune

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Smart Immune & CELLforCURE by SEQENS Partner for SMART101 Clinical Manufacturing

                            Details : The partnership aims to advance the clinical development of SMART101 an innovative therapy for patients with acute leukemia or primary immunodeficiencies (PID), in the EU and the US.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : SMART101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Smart Immune

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Seqens Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : AMX-818,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vir Biotech Closes Global License Deal with Sanofi For T-Cell Engagers

                            Details : Through the license agreement, Vir Biotechnology will gain the rights of three clinical-stage masked TCEs, which include SAR446309 (AMX-818) for the treatment of HER2-mutated Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : AMX-818,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : AMX-818,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vir Biotechnology Expands with Worldwide License Agreement with Sanofi for T-cell Engagers

                            Details : Through the license agreement, Vir Biotechnology will gain the rights of three clinical-stage masked TCEs, which include SAR446309 (AMX-818) for the treatment of HER2-mutated Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : AMX-818,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR443579

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hema...

                            Details : SAR443579 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : SAR443579

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AGC Pharma Chemicals Europe

                            Spain
                            CPhI WW Frankfurt
                            Booth #6.0B44
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothYour reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ability Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AGC Pharma and AbilityPharma to Produce Innovative Treatment for Pancreatic Cancer

                            Details : The collaboration aims for the development of an API for the treatment of pancreatic cancer, ABTL0812 (ibrilatazar), currently in clinical trials.

                            Product Name : ABTL0812

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ability Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-400

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Th...

                            Details : ABBV-400 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : ABBV-400

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth